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 Swine with severe combined immunodeficiency (SCID) are an emerging large animal 
model for biomedical research. There have been several SCID pig models described since 
our first discovery of naturally occurring SCID with mutations in Artemis (DCLRE1C) in 2012. 
SCID animals are particularly useful in biomedical research due to their lack of T, B, and 
sometimes NK cells. Absence of the adaptive immune system allows for human cell and 
tissue xenotransplantation into these SCID animals. The works described within this 
dissertation are categorized under four main goals: (1) further characterization of the 
immune system of Art-/- SCID pigs, (2) development of a method for in utero injection of 
human stem cells, (3) in utero injection of human stem cells for the study of human immune 
cell engraftment within Art-/- IL2RG-/Y SCID pigs, and (4) development of an ovarian 
carcinoma model in SCID pigs.  
 Characterization of the SCID pig immune system is important so that researchers can 
understand how components of the system could impact their research model within the 
pigs. This dissertation describes the characterization of porcine monocytes and their 
interaction with human cells, as well as “leaky” T cell development in SCID pigs. Firstly, we 
show that porcine SIRPA, which is expressed on myeloid cells, binds to the “self” protein, 
CD47, on human cells. Binding between porcine SIRPA and human CD47 prevents 
phagocytosis of human cells by porcine myeloid cells. Binding compatibility of these two 
proteins suggests that porcine monocyte phagocytosis of human cells would not be a 
barrier to human immune cell engraftment within SCID pigs. In addition, this dissertation 




functional, these T cells could negatively impact the ability of human cells to engraft within 
the pigs. I describe that there are small populations of leaky T cells within the blood and 
lymph nodes of Art-/- SCID pigs. 
 Another major goal described within this dissertation is the development of in-house 
laparotomy surgical protocols to be utilized for the in utero injection of SCID pig fetuses 
with human hematopoietic stem cells. We performed two practice laparotomies on non-
SCID litters and attempted to inject fetuses within the fetal liver or intraperitoneal space 
with saline and wire. We showed that our procedures were safe and successful, as we did 
not have incidence of abortion and 5 of 6 wire-injected piglets were liveborn. We were able 
to radiographically detect injected wire within the intraperitoneal space, and in one case, in 
the liver.   
 After developing the laparotomy procedures, we were able to utilize the surgery 
techniques to introduce human hematopoietic stem cells into fetal SCID pigs. Art-/- IL2RG-/Y 
pigs were generated from an Art-/- fetal fibroblast cell line via CRISPR/Cas9 mutagenesis. 
These Art-/- IL2RG-/Y SCID pigs have a T- B- NK- cellular phenotype, which is optimal for 
humanization studies, based on previous SCID mouse literature. SCID fetuses were injected 
with human hematopoietic stem cells utilizing developed laparotomy procedures. We 
detected human leukocytes cells within the blood, thymus, spleen, liver, and bone marrow 
of the injected Art-/- IL2RG-/Y pigs. More specifically, we detected human CD3ε+ cells within 
the blood, spleen, and thymus of these animals. These findings warrant further 




 Lastly, I describe the beginning stages of a model of ovarian cancer in SCID pigs. 
Human ovarian serous papillary carcinoma (OSPC)-ARK1 cells were injected into the ear and 
neck muscles to answer if this carcinoma could develop in an ectopic site within the SCID 
pig. We found that 3 out of 4 injected SCID pigs developed carcinomas in at least one 
injection site. OSPC-ARK1 tumors from SCID pigs, SCID mice, as well as the OSPC-ARK1 cell 
line and the original human tumor sample were stained with commonly used diagnostic 
markers: Claudin 3/4, Cytokeratin 7, p16, and EMA to assess if tumors that developed in 
SCID pigs resembled the human tumor. We found that expression of these proteins was 
highly similar between SCID pig and human carcinomas. The next step of this project is to 
develop an orthotopic model of ovarian cancer by injection of these cells into the ovary of 
SCID pigs. Development of such a model could be used for diagnostic imaging research. 
 In all, this work describes further characterization and development of biomedical 
models in SCID pigs with a focus on humanization and cancer modeling. The findings 









 A total of six manuscripts were composed for publication and are included as 
Chapters in this dissertation. As of the submission of this dissertation, four manuscripts are 
published, while two are near submission stage. I, Adeline Boettcher, was the major 
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hematopoietic stem cells the pigs via in utero procedures and analyzed tissues and blood 
from these animals. Christopher Tuggle and Jason Ross supervised the project presented in 
Chapter 5. We are combining these two major projects into one manuscript that is being 
prepared for submission to Nature Communications as of March 2019. Yunsheng Li and I will 





 Chapter 7 contains work that is being prepared for submission to Frontiers in 
Immunology as of March 2019.  
 Chapter 8 describes conclusions from all work presented throughout this dissertation 
























This chapter is derived from a hypothesis and theory review that was published in Frontiers 
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Abstract 
Within the last decade there have been several severe combined immunodeficient 
(SCID) pig models discovered or genetically engineered. The animals have mutations in 
Artemis (Art), IL2RG, or RAG1/2 genes, or combinations thereof, providing SCID pigs with NK 
cells, but deficient in T and B cells, or deficient in NK, T, and B cells for research studies. The 
immunophenotyping of these new animal models is important, as depending on the genetic 
background, leaky T or B cells may still develop.  Biocontainment facilities and positive 
pressure isolators are developed to limit pathogen exposure and prolong the life of SCID 




xenotransplantation of human cells. Ectopically injected human cancer cell lines develop into 
tumors in SCID pigs, thus providing a human-sized in vivo model for evaluating imaging 
methods to improve cancer detection and therapeutic research and development. 
Immunocompromised pigs have the potential to be immunologically humanized by 
xenotransplantation with human hematopoietic stem cells, peripheral blood leukocytes, or 
fetal tissue. These cells can be introduced through various routes including injection into 
fetal liver or the intraperitoneal (IP) space, or into piglets by intravenous, IP, and 
intraosseous administration. The development and maintenance of transplanted human 
immune cells would be initially (at least) dependent on immune signaling from swine cells. 
Compared to mice, swine share higher homology in immune related genes with humans. We 
hypothesize that the SCID pig may be able to support improved engraftment and 
differentiation of a wide range of human immune cells as compared to equivalent mouse 
models. Humanization of SCID pigs would thus provide a valuable model system for 
researchers to study interactions between human tumor and human immune cells. 
Additionally, as the SCID pig model is further developed, it may be possible to develop 
patient-derived xenograft models for individualized therapy and drug testing. We thus 
theorize that the individualized therapeutic approach would be significantly improved with a 
humanized SCID pig due to similarities in size, metabolism, and physiology. In all, porcine 
SCID models have significant potential as an excellent preclinical animal model for 







A new field of personalized medicine has been evolving over the last decade, 
especially with respect to advances in individualized cancer therapies, ranging from T cell 
and NK cell immunotherapies, targeted monoclonal antibody therapy, and newly developed 
small molecule drugs. As progress is made towards the development of cancer therapies, it 
will be critical that preclinical animal models can dependably represent human responses to 
drugs. Presently, mice are the most commonly used model for preclinical animal drug trials 
(1). However, many preclinical cancer drug trials that succeed in mice fail in humans due to 
vast differences in physiology, metabolic processes, and size (2,3). The drug development 
process is intensive; on average, 12 years of research and $1-2 billion is required to bring a 
new drug to market (4,5). To maximize the efficiency of preclinical drug and therapy testing, 
large animal models that better parallel human physiology are needed.  
Mice with severe combined immunodeficiency (SCID) are an extremely versatile 
animal model for the field of cancer biology, although they pose significant limitations. The 
ability to engraft SCID mice with a human immune and/or cancer cell lines has made them 
an invaluable model for research (6,7). Although mice are important for initial studies in 
different cancer fields, they are often not good models for specific aspects of human 
oncology (2,8). Limitations of mouse models of cancer include small size, difficulties in 
modeling human tumor heterogeneity (9) and metabolic differences to humans (10,11). 
Large animal models can be more costly than murine studies, thus murine studies 
remain valuable for first line screens. However, testing in larger animal models is warranted 




animal model. (12). Immunocompetent and SCID pigs are now being developed for human 
disease research purposes (13–18). Swine are more similar to humans with respect to size, 
anatomy, genetics, and immunology, therefore immunodeficient pigs may be a superior 
animal model for preclinical testing of cancer therapeutics (19–21). In addition, pigs are 
comparable in size to humans, have more similar metabolism to humans than mice (22,23), 
and can be transplanted with larger human tumors.  
Within the last decade there have been numerous SCID pig models created (16–
18,24–30) or discovered (31,32). One of the hurdles to working with SCID pigs is maintaining 
viability due to susceptibility to disease. The use of positive-pressure biocontainment 
facilities (33) and standard animal isolators (29) have improved SCID pig health and viability. 
The ability to house immunodeficient pigs in a controlled environment increases their 
lifespan, allowing them to be utilized for long-term biomedical research. In addition, cleaner 
biocontainment facilities appear to decrease the incidence of leaky T cell development in 
Art-/- SCID pigs, which could negatively impact the growth of human cells in the pigs. Raising 
clean pigs in these facilities increases their utility in biomedical research,  
 In this literature review we describe the different SCID pig models that have been 
reported in recent years, as well as published methods established to raise SCID pigs for use 
in long-term research trials of 6 months or more. We describe leaky T cell development in 
Art-/- SCID pigs and how these cells can impact the health of the animal, as well as impacts to 
xenograft studies. We describe the importance of human tumor and cancer cell 
xenotransplantation and how researchers can utilize immunodeficient pigs for translational 




potential to be engrafted with a human immune system, or “humanized”, just as numerous 
SCID mouse models have been humanized. While there is currently no published research on 
the development of a humanized SCID pig, substantial progress is being made towards this 
endeavor. We describe the different methods of humanization that could be used in SCID 
pigs, including fetal liver and intraperitoneal (IP) injections, as well as intravenous (IV), IP, 
and intraosseous (IO) injection in piglets. Despite the early developmental stage for 
humanized SCID pigs, the SCID pig has vast potential to be utilized for translational oncology. 
Our overarching hypothesis in this review is that porcine SCID models will be more 
translational than mouse models for oncology research in the future.  
Existing SCID pig models 
Previously described and generated SCID pigs 
 Within the last decade, numerous SCID pig models have been developed through 
mutagenesis or discovery of natural mutations. These SCID pig models are outlined in Table 
2.1.  Figure 2.1 shows the genetic and molecular mechanisms for the mutations described 
below that cause SCID, and Figure 2.2 shows the differentiation step blocked by each of 
these mutations.  
The first SCID pig was described in 2012 (13) after a serendipitous discovery in an 
infection study (31). To confirm the lack of a functional immune system, these SCID pigs 
were transplanted with human cancer cell lines. Injected cells were not rejected and 
developed into tumors in the SCID pigs (13). After further analysis, it was found that the 




the Artemis (DCLRE1C) gene, which leads to SCID either in the homozygous or compound 
heterozygous state (32).  
Artemis is required for DNA repair during T and B cell development. Specifically, 
during the process of VDJ recombination, after RAG1/2 nucleases cleave DNA at the RSS 
sequences flanking V, J (and sometimes D) segments (34), a hairpin loop then forms at the 
end of the double stranded break (DSB). Ku70/80 proteins are recruited to the area of the 
DSB along with Artemis protein, which is responsible for cleaving the hairpin loop so it can 
be ligated by Ligase IV (35). Without functional Artemis, these hairpins are not cleaved, and 
functional V, D, and J joins cannot be made. Lack of Artemis function leads to a cellular 
profile in which T and B cells are deficient, but NK cells develop (T- B- NK+) and are functional 
in vitro (31,32,36). Homozygous (Art12/12 or Art16/16) or compound heterozygous 
(Art12/16) pigs can be raised to 6 months of age in biocontainment facilities developed at 
Iowa State University (31, unpublished observation).  
 Another SCID pig was also described in 2012 with an engineered mutation within the 
IL2RG gene (16). In humans and mice, the IL2 receptor γ (IL2Rγ) subunit is required for IL-2, 
IL-4, IL-7, IL-9, IL-15, and IL-21 signaling (37). The IL2RG gene is on the X chromosome in 
mammals and the receptor is expressed on lymphoid cells, including lymphoid progenitors. 
The cytokines noted are required for proper lymphoid development, and thus deletion of 
the IL2Rγ subunit disrupts development of T and NK cells, and B cells to a variable extent 
(38,39). The cellular phenotype of these IL2RG knockout pigs was T- B+ NK-, similar to 
humans (38,39). B cells in IL2RG knockout SCID pigs were not able to secrete 




heterozygous IL2RG+/- females exhibited SCID-like phenotypes, which was attributed to 
aberrant X-inactivation. These females were raised to sexual maturity and crossed with WT 
males;  female IL2RG+/-  offspring from this cross phenotypically resembled WT animals (16). 
This finding emphasizes the importance of monitoring for SCID phenotype status in cloned 
piglets even if the expected outcome is a carrier animal. Other groups have also introduced 
mutations in the IL2RG gene by CRISPR/Cas9 (17) and zinc finger nuclease (18) methods, and 
the resulting pigs also displayed cellular phenotypes of T-B+NK-. Animals in these studies 
were raised in conventional settings and had lifespans that ranged from 12 days to 7 weeks 
(16–18). 
 The recombination activating genes, RAG1 and RAG2, have previously been mutated 
to create pig models. They code for subunits of a nuclease (RAG1/2), that is involved in VDJ 
recombination required for T and B cell receptor (TCR and BCR, respectively) generation (40). 
Without functional RAG1/2 nuclease, VDJ recombination does not initiate, and T and B cells 
do not develop (41,42). Homozygous or biallelic RAG1 or RAG2 SCID pigs lacked IgM+ B cells 
and CD3+ cells in peripheral blood (24,25,27). NK cells were present in these animals and 
were classified as either CD3- CD8α+ (24) or CD16+ CD8α+ (27). RAG knockout pigs were 
generated with either TALENs (24,26), gene targeting vectors (27), or CRISPR/Cas9 (28) 
mutagenesis methods. Previous RAG1 or RAG2 mutant SCID pigs have been raised to 29 days 
(24,26) to 12 weeks (27) of age in conventional housing.    
 Once single mutant pigs were established, research groups began to introduce 
mutations in both VDJ recombination pathway genes (RAG1/2 or Artemis) and IL2RG to 




pigs (28,30). Double-mutant pigs are an important animal model to develop, as rodent 
models of SCID mice lacking NK cells, as well as T and B cells, engraft human cells better than 
T-B- NK+ models (43). It is therefore of interest to generate a T- B- NK- SCID pig model for 
humanization studies. In 2016, RAG2/IL2RG knock out piglets were generated and used in 
pathogenesis study with human norovirus (28). RAG2/IL2RG SCID pigs lacked T and B cells, 
and there were decreased numbers of NK cells compared to controls. The presence of some 
NK cells was attributed to a hypomorphic mutation within IL2RG (28). Our group has recently 
engineered a complete IL2RG knockout that was introduced into an Artemis null genetic 
background resulting in SCID pigs that lack T, B, and NK cells (30) .  
Methods for SCID pig rearing 
 One of the difficulties to overcome when using SCID pigs in research is maintaining 
animal viability. SCID pigs raised in conventional settings typically succumb to disease 
between 6-12 weeks of age (unpublished observation, 17). Biocontainment facilities have 
been specifically designed to limit exposure of Iowa State University’s Art-/- SCID pigs to any 
micro-organisms (Figure 2.3A). These rooms have positive-pressure HEPA filtered air flow 
into a containment bubble and all water entering the bubble is UV irradiated and filtered 
through a 0.5 μm filter. Personnel entering the bubble wear appropriate garments to limit 
introduction or organisms into the room, including room dedicated protective suits, hair net, 
surgical mask, gloves and rubber boots (33). Piglets are derived either by snatch farrowing 
(caught in a sterile towel as they are delivered vaginally) or by cesarean section and are 
transferred immediately into a sterilized bubble. Piglets are immediately fed pasteurized 




days, and then transitioned to irradiated feed, which is continued throughout life (33). 
Specific pathogen-free (SPF) Art+/- carrier females have been raised to sexual maturity and 
are able to naturally farrow Art-/- SCID litters within the ISU bubble facilities (Figure 2.3B).  
Artemis mutant SCID pigs can be successfully reared to 6 months of age in these facilities 
(unpublished observation). 
 Survivability of previous IL2RG knock out pigs has varied from 2 to 7 weeks (16) and 
derivation of animals and available housing likely impacts outcome. Recently Hara et al. (29) 
used small isolators and developed piglet delivery protocols to help extend the lifespan of 
IL2RG knock out SCID pigs. To achieve this goal, excised uteruses were brought into isolators 
units, piglets were delivered, and reared within these isolators. One SCID piglet housed in 
the isolators was raised to a planned endpoint of 12 weeks of age without incidence of 
bacterial or fungal disease (29).  
Leaky T cell development in SCID and Artemis function 
 Humans or model animals with mutations in RAG1/2 or Artemis have the potential to 
develop “leaky” T cells with varying levels of function. These T cells can develop due to 
hypomorphic mutations within these genes, allowing them to retain residual VDJ 
recombination activity. There may also be unidentified mechanisms that explain the 
development of these cells in SCID patients and animals. Leaky T cells can cause problems 
such as cancer (45,46) and Omenn’s Syndrome (47,48). The Art-/- ISU SCID pig line comprises 
of two separate mutated Art alleles, termed Art12 and Art16 (32). The Art12 allele contains a 
nonsense mutation in exon 10 that leads to a premature stop codon. The Art16 allele 




We have previously reported the incidence of host derived T cell lymphoma development in 
two BMT SCID pigs (both Art16/16) (49). We have additionally documented two other 
suspected T cell lymphoma cases in non-BMT SCID pigs (in Art12/16 and Art12/12 pigs) 
(unpublished results), which led us to hypothesize that our two Art alleles may be 
hypomorphic. 
 The Artemis protein contains three domains: β-lactamase, β-CASP, and the C-
terminal domain (50). The Artemis protein possesses 5’ to 3’ exonuclease activity and, when 
complexed with DNA-PK, 5’ to 3’ endonuclease activity to cleave overhangs and open DNA 
hairpins (35). Mutagenesis experiments show that the catalytic core of Artemis in VDJ 
recombination is the β-Lact/β-CASP domains, while the C-terminal domain is required for 
DNA repair and potentially protein stabilization (50). Both the Art12 and Art16 allele 
mutations in the ISU SCID pig affect the β-Lact/β-CASP domains. All transcripts from 
Art16/16 fibroblasts lack the entire exon 8, while a majority of the transcripts from Art12/12 
fibroblasts are missing large portions of the gene transcript within all three domains (32). In 
humans, hypomorphic mutations in Artemis are reported for alleles in which there are small 
deletions in exon 14 (c-terminal domain), a missense mutation within the first codon (ATG to 
ACG), and G153R mutations (51). Further study of the SCID pig Art transcripts and encoded 
proteins are required to assess the VDJ recombination activity and their potential for 
generating functional VDJ TCR rearrangements.   
  There are currently a few SCID mouse models available to study leaky T cell 
development. One of these models is a mouse line containing an R229Q mutation within 




diagnosed with Omenn’s syndrome (52). T cells in secondary lymphoid organs from these 
animals showed a similar CD4+ and CD8+ T cells as compared to wildtype mice, however 
many of these cells had a memory phenotype (52).  Another mouse model was created to 
study hypomorphic Artemis protein activity; this mouse model contains an equivalent 
mutation as a human patient, termed P70 (named after the original patient), which is a 7 
nucleotide deletion at D451 of the human Artemis protein. (45). This mutation leads to 
increased thymocyte numbers compared to Art null mice. Additionally, mice homozygous for 
the Art P70 mutation were capable of producing functional VDJ recombination (53) SCID 
mouse models of hypomorphic activity are useful in studying the negative impacts of these 
mutations and may help answer questions pertinent to human patients afflicted with these 
diseases. Additionally, we can use methods developed for leaky T cell analysis within mice in 
our SCID pigs.  
 We have detected leaky CD3+ cells in all genotypes of the ISU SCID pig. We have also 
had one case where a SCID pig also displayed symptoms similar to Omenn’s syndrome. The 
pig presented with a rash, diarrhea, fever, and enlarged lymph nodes. CD3+ cells in SCID pigs 
appears to vary based on housing condition, age, and genotype. Researchers working with 
these animals need to be aware of the other ailments associated with mutations that cause 
SCID when working with SCID pigs.  
SCID pig cancer xenotransplantation studies 
Existing immortal cell lines develop into tumors in SCID pigs 
 Since the generation of SCID pigs is recent, there are only a few studies that have 




xenograft study involved the transplantation of human melanoma (A375SM) and pancreatic 
carcinoma cell (PANC-1) into the ear tissue of Art-/- SCID pigs (13). All SCID pigs receiving 
cancer cells developed tumors at the site of injection, thus establishing an orthotopic model 
of melanoma that could be studied further (13). Additionally, the ability of ovarian 
carcinoma cell line OSPC-ARK1 to develop tumors in Art-/- SCID pigs was explored. SCID pigs 
were injected in the ear and neck muscles with OSPC-ARK1 cells and subsequently 
monitored for tumor development. In 3 of the 4 SCID pigs injected, tumors developed within 
30 days, with a shortest time of 7 days to palpable tumors.  Biopsy samples revealed the 
ovarian tumors in SCID pigs expressed diagnostic markers commonly used in human cancer 
diagnoses, and tumors in SCID pigs resembled human tumors (54).  
 Pigs biallelic for RAG2 mutations can engraft human induced pluripotent stem cells 
(iPSCs). Injected iPSCs developed teratomas that represented endoderm, mesoderm and 
ectoderm tissues (26). Teratomas were grossly visible 12 days after cell inoculation for one 
recipient; and about 7.5 weeks in the other recipient. Histological analysis revealed CD34+ 
and CD45+ cells developed in the teratoma, (26), indicating that human immune lineage can 
survive and differentiate in RAG2 knockout pigs. This important finding indicates that SCID 
pigs can accept various types of human xenografts. In a follow-up study, PERFORIN and RAG2 
double knock out (Pfp/RAG2 dKO) mice and RAG2 knock out pigs were compared for their 
ability to engraft human iPSCs. The RAG2-/- pigs developed teratomas from injected iPSCs at 
a higher rate than the Pfp/RAG2 dKO mice. Human teratomas that developed in the RAG2 




than in SCID mice (55). Thus, the in vivo environment in pigs supports the growth and 
differentiation of human cells, and in some instances, is an improved system over SCID mice.  
Porcine immunological similarities to human 
 Several aspects of the pig immune system are more similar to humans than mice, 
providing another advantage of swine models for research (39). Humans and pigs have 
higher sequence orthology for immune-related genes (termed the ‘immunome’) than 
humans and mice (20). Immunome-specific gene family expansions, a measure of 
evolutionary divergence, have occurred in pig relative to human at half the rate detected in 
mouse or cow (20), and pigs have significantly fewer unique genes not found in humans 
when compared to unique gene abundance in cow or mouse (Figure 2.4). Additional 
analyses have further expanded human and pig similarities, although absence of two 
inflammasome gene families have also been found uniquely in the pig genome (57). As well 
as immunome structural similarities, immune responses are highly comparable between 
human and pig (reviewed in 41). For example, the transcriptomic response to 
lipopolysaccharide (LPS) of pig macrophages in vitro is more similar to human responses as 
compared to mice. Specifically, clusters of genes with IDO1 as hub were detected in human 
and pig macrophage responses, but not in mice, while a NOS2A-related gene cluster was 
only found in the mouse macrophage LPS response (59).   
 Human hematopoietic stem cell (HSC) development in swine for humanizing pigs will 
be dependent on swine cytokine signaling. Hence, it is important to determine the cross 
reactivity of porcine cytokines with human cells. Protein sequence analysis shows that swine 




2.5; Figure 2.S1), which suggests that certain human lineages may differentiate with greater 
success in SCID pigs than in SCID mouse models.  
Routes for humanization and applications 
 Given the high similarity of swine and human immune genes, we would anticipate 
that human HSCs transferred into SCID pigs would successfully engraft and differentiate into 
representative human immune cell types. Current building of swine SCID models relies 
heavily on translating methods used for mouse humanization to generate new humanized 
SCID pig models. To humanize the mouse, three different approaches are utilized (6,7). 
These methods include transfer of purified human CD34+ stem cells, peripheral blood 
leukocytes (PBLs), or transfer of fetal bone marrow, liver, spleen, and lymph node tissues. 
Just as in SCID mouse models, these same approaches and cell types can be investigated as 
methods to humanize SCID pigs. The pig immune signaling molecules that support 
engraftment are expected to be similar to humans, thus we expect successful development 
of human immune cells.  
 Currently the NOD-SCID-IL2Rγ (NSG) knockout mouse is the gold standard model for 
humanization. The Sirpa allele in the NOD background contains polymorphisms that allow 
the encoded Sirpa protein to bind to human CD47, which then sends a inhibitory signal that 
prevents phagocytosis of human cells (60,61). Swine SIRPA also binds to human CD47 (62), 
so we speculate that porcine SIRPA-dependent phagocytosis of human cells would not be a 
barrier to SCID pig humanization.  
 The following sections describe previous humanization methods performed in SCID 




SCID pigs. Figure 2.6 shows an overview of different human immune cell types and 
anatomical injection sites for SCID pig humanization. Past studies utilizing injection of human 
HSCs or human induced pluripotent stem cells into large animal models are presented in 
Table 2.2.  
CD34+ cell injection via fetal liver and intraperitoneal space 
 Successful humanization of SCID pigs will require that human HSC be injected into 
sites of hematopoiesis in the pig. During gestation the initial location of hematopoiesis is the 
yolk sac (63). As gestation continues, the fetal liver becomes the site of hematopoiesis, 
typically around the beginning of the second trimester (64–68). During swine gestation, 
hematopoiesis begins at day 30 in the fetal liver (67). Intrauterine injection of human 
hematopoietic cells during the fetal liver phase of hematopoiesis would provide a rich 
environment for human stem cells to engraft and differentiate (69), as supporting cells in the 
fetal liver niche express c-Kit, CD34, CXCL12, and NOTCH (64). Additionally cell subsets in the 
fetal liver can promote hematopoiesis, such as CD34lo CD133lo cells that have been described 
in human (70). Differentiated human cells that develop in the SCID pig liver may also migrate 
to the bone marrow around the same time as other developing swine immune cells, which 
may increase the ability of human immune progenitors to engraft within the SCID pig bone 
marrow. Fewer human cells would be required for the fetal liver injection strategy when 
compared to the number of cells required to engraft a fully developed piglet. Taken 
together, we hypothesize that fetal injection of human hematopoietic stem cells will likely 





 The first study involving in utero injection of human cells into a large animal was 
performed by Zanjani and colleagues (71). Human fetal liver cells were injected into the IP 
space of fetal sheep at days 48-54 gestation (145-day term) through the uterine wall. The 
recipient sheep were immunocompetent, but pre-immune at this stage of development. 
Two of the derived sheep were raised to 15 months of age, and human CD3+, CD16+, and 
CD20+ cells were still in circulation, albeit at very low frequencies (71). Other studies 
involving the transplantation of human CD34+ cells in the fetal liver of pre-immune sheep 
have resulted in similarly low levels of human cell engraftment and differentiation (72,73). 
 In addition to sheep, in utero injection of human CD34+ cells have been performed in 
pre-immunocompetent conventional pigs. The first was described in 2003 (74) with the 
injection of cord blood derived CD34+ cells into the IP space of pre-immune fetal piglets at 
approximately 40 days of gestation (114 day term). Populations of human CD3+ cells were 
detected in the thymus, CD19+ cells and myeloid cells also developed de novo in the pig, in as 
short as 40 days post-injection. Additionally, human CD34+ CD45+ cells were isolated from 
pig bone marrow 120 days after transplantation and were subsequently transplanted into 
SCID mice with successful engraftment of human cells observed. This result indicates that 
the pig bone marrow environment is able to support the development of functional human 
HSCs (74).  
Humanization of pigs could serve as a source of human T cells for immunotherapeutic 
use. Ogle et al. (75) depleted CD3+ cells from human bone marrow or cord blood and 
injected into the IP space of fetal piglets at 40-43 days of gestation. Human T, B, 




amplification of CD3, CD19, CD14, CD16, and CD56 transcripts, respectively. In order to 
determine if the human T cells had developed de novo, blood was analyzed for the presence 
of human T cell receptor excision circles (TREC). Human TRECs were observed at a level that 
suggested new human T cells had developed in the swine thymus (75). Similar studies were 
performed in which fetal swine were injected with human T cell depleted bone marrow (76) 
or T cell depleted cord blood (77), in which human cell engraftment was observed. In all, 
these studies show that human T cells can develop de novo when human HSC are injected 
into fetal swine.  
Successful engraftment of SCID pigs utilizing in utero injections requires 
consideration of timing and surgical procedures. We hypothesize that a humanized SCID pig 
could be developed via in utero injection of human CD34+ cells within the fetal liver or IP 
space at approximately 40 days of gestation. We have described detailed laparotomy 
protocols that can be followed for procedures involving stem cell injection into fetal IP space 
and livers (Boettcher et al., submitted 2018) (Figure 2.7). The level of human cell 
hematopoiesis in a SCID pig model has yet to be determined, however it is expected that 
engraftment would be comparable to that described for immunocompetent animals. Given 
the lack of pig immune cell development in pigs with SCID, the available niches for human 
progenitor cells to develop in the bone marrow and thymus would be increased.  
Peripheral blood leukocyte injection via intravenous or intraperitoneal routes 
 In 1988, the first humanized mouse models were generated in efforts to investigate 
the AIDS virus interaction with its human host. One of these models described the injection 




with 10-90 million human PBLs (termed hu-PBL SCID mice). IV injection was deemed 
ineffective in mice, likely due to the difficulty of proper IV administration in a mouse. Human 
cells injected IP in mice were able to migrate to the spleen, lymph nodes, and were also 
detected in peripheral blood; four weeks post IP injection, very few human PBL were 
detected in the peritoneal space.  Mice were vaccinated with tetanus toxoid, which PBL 
donors were known to be immune. Eight of ten animals injected with PBLs produced human 
immunoglobulin against tetanus toxoid which supported that human helper T cells and B 
cells were functional in the hu-PBL SCID mice. Human CD14+ monocytes were also present in 
the spleens of mice 8 weeks post transplantation (78). These hu-PBL SCID mice are utilized in 
a variety of different fields including HIV (79–81), cancer (82,83), basic immunology (84,85), 
and atopic dermatitis (86). 
 Hu-PBL-SCID pigs could be generated by IV or IP injection of human PBLs into SCID 
pigs. IV injection of human cells have been deemed ineffective for engraftment in mice. 
However, tail veins are typically used in mice, which are difficult to properly inject. Piglets 
have large and visible ear, cephalic, and saphenous veins that are easily accessible. A 
limitation of human PBL injections in pigs could be the amount of cells required relative to 
the number of cells injected into mice. Mice are typically 20 grams (0.02 kg), while a typical 
newborn piglet weighs about 1-2 kg. In previous studies, the minimum amount of human 
PBLs injected into mice is about 10 million cells, which scales up to 0.5-1 billion in a piglet. 
However, there are strategies to overcome the cell number limitation. One source for 
human PBLs could be leukoreduction system chambers (LRSCs), which are utilized by blood 




donor, approximately 2 billion PBLs can be obtained from LRSCs (87). Another approach is 
matching a human with a SCID pig and performing repeat PBL injections from the same 
human donor. Also, it is possible that the number of human PBLs required for successful 
engraftment of SCID pigs would not be as high as calculated from murine studies. Given that 
methods to obtain large numbers of PBLs are available, the number limitation is not 
expected to prevent development of a hu-PBL-SCID pig.  
 One consideration for using a SCID pig injected with human PBLs is that these animals 
will eventually develop graft versus host disease (GVHD). SCID mice injected with human 
PBLs develop GVHD approximately 3-11 weeks after injection (88) while it takes 14-16 weeks 
in SCID rats (89). It is currently unknown how long it would take SCID pigs to develop GVHD 
after human PBL cell transplantation, as well as how the cellular dose would impact the 
GVHD time frame. This is a question that will need to be addressed as this model is 
developed. Another important question that will need to be addressed in developing this 
model is the time period required for human PBL engraftment within the SCID pig. 
One benefit of the PBL model is that it could be used for short term studies in SCID 
pigs. SCID pigs raised in conventional settings can typically survive to 6 weeks of age. If 
piglets are injected with human PBLs shortly after birth (1-5 days), this would give 
researchers approximately a 6-week window to perform experiments. It may also be 
appropriate to administer immunosuppressive drugs during this period of time to reduce the 






CD34+ cell injection via intraosseous or intravenous routes 
 Another route for humanization is through the injection of purified human CD34+ 
HSCs into live-born piglets. We have previously performed bone marrow transplantations 
(BMT) on our SCID pigs through IV injection of unfractionated pig bone marrow cells (49). 
One hypothesis is that human HSC could be administered in the same way to generate a 
humanized SCID pig. Typically in pig to pig bone marrow transplants, it takes approximately 
10 weeks to observe  a moderate increase in the number of circulating porcine lymphocytes 
(49). We hypothesize that human engraftment and de novo development of human cells 
would require at least 10 weeks to observe human cells in circulation based on pig to pig 
BMT observations. It may be of value to compare cell dosages and engraftment rates of 
human and pig HSC in SCID pigs. IV injection of human HSC is much less invasive than fetal 
injections, however it may take longer to achieve engraftment and differentiation of human 
cells.  
 Another method of human HSC administration is through intraosseous (IO) injection. 
IO injection of stem cells and mesenchymal stem cells have previously been performed in 
SCID mice (90), dogs (91,92), and pigs (93). IO injection is also a method for bone marrow 
transplantation in humans (94). It is hypothesized that IO injections are preferable over IV 
injections due to stem cell trapping in pulmonary tissue, which is often observed in IV 
injections (95,96). In addition, IO administration introduces cells to the site within which 
they would differentiate. Protocols have also been developed for the delivery of various 




SCID pigs is therefore another potential route for studying engraftment and humanization 
models.  
Implantation of human fetal bone marrow, thymus, and liver tissues  
 Another potential method for humanization of SCID pigs is through the 
transplantation of human fetal liver, thymus, lymph node, and spleen tissue, as has been 
previously performed in mice (99). Such human lymphoid tissues can be transplanted into 
mice either by implantation under the kidney capsule or IV injection of a cellular suspension. 
Mice transplanted with human lymphoid tissues appear to have immunological protection, 
as the lifespan of transplanted mice can be extended to 17 months, compared to 4 months 
for non-transplanted mice. Mice injected with both human thymic and fetal liver cells 
developed human T and IgG secreting B cells (99). The chimeric mice with human bone 
marrow, liver and thymus (BLT) are used to study interactions between human immune cells 
and patient derived melanomas (100). 
 De novo development of human T cells within the pig requires that human T cells can 
differentiate within the swine thymus. Transplantation studies show that the porcine thymus 
supports human T cell development, as mature human T cells develop in athymic mice 
transplanted with porcine thymus and human HSCs (101,102). Human T cell development 
within the swine thymus is particularly important for long term studies because this would 
allow newly differentiated human T cells to develop tolerance to pig antigens. Human thymic 
tissue could also be transplanted into SCID pigs for human HLA restricted T cell 
development. Development of GVHD is observed in mice humanized with fetal bone 




development. Depending on the experimental question being addressed, transplantation of 
a human thymus may be a preferred method in humanizing SCID pigs.  
 One issue with generating BLT humanization models is the limited fetal tissue 
availability, as well as ethical implications. Smith and colleagues described a way to 
circumvent these issues by propagating and expanding BLT tissues in one mouse and then 
transplanting into 4-5 other mice (104). SCID pigs could be useful in this regard as human 
tissues would have the potential to grow to a large enough size that they could be 
transplanted again into a second set of animals.   
Future outlooks on the utilization of SCID pigs for cancer therapies and research 
Humanized SCID pigs for CAR-T and CAR-NK cell therapy research 
 Chimeric antigen receptor (CAR) T and NK cells have been developed in recent years 
as a cancer immunotherapy. CAR-T cells targeted against CD19 for patients with B cell 
lymphomas and leukemias (105) have been approved by the FDA for therapeutic use 
(106,107). One of the issues associated with CAR-T cells is that they can persist and be 
activated for long periods of time in the body, causing cytokine release syndrome (CRS). 
Symptoms of CRS manifest as fatigue, fever, nausea, cardiac failure, among other symptoms 
(108). CAR-NK therapies are being developed to overcome some of the issues associated 
with CAR-T cell therapy. Protocols have been developed to isolate NK cells from cord blood 
and expanded for use in patients. NK cells do not persist for long periods of time in vivo after 
infusion (109), do not cause GVHD, and can recognize tumor targets through intrinsic 
receptors (110). If SCID pigs can successfully develop human NK cells de novo, humanized 




approximately 85 kg (personal observation), and thus according to IACUC guidelines, up to 
1.2 L of blood could be collected for human NK cell isolation and used for CAR therapy 
research.  
We envision several applications for a hu-PBL SCID pig in testing cell-based 
immunotherapies. As more CAR therapy targets are generated, it may be possible to test 
their efficacy and safety in a humanized SCID pigs that are xenografted with human tumors. 
Other CAR therapies that are currently under development are CAR-T cells targeting CD20 
(111), CD30 (112), CD33 (113), CD7 (114) and CAR-NK cells targeting CD33 (115) and CD19 
(116).  In addition, as the field of precision medicine continues to grow, a patient’s tumor 
could be xenografted into a SCID pig and a therapy could be tested. Tumors in SCID pigs 
could be grown to a comparable size to those found in humans and would therefore be a 
more representative model compared to the limited size of tumors in mouse models. Similar 
studies have been performed in hu-PBL-mice, in which interactions between human thyroid 
tumors and PBLs were studied (117).  
Improving targeting imaging techniques 
  Pigs are an excellent animal model for surgical and clinical imaging research. Due to 
their larger size, techniques that are used for humans in the clinics (PET, MRI, CT, US) can 
also be readily adapted for use in swine. There are immunocompetent pig models of cancer 
that exist with inducible mutations in p53 (15,118,119) and KRAS (120). Pigs with inducible 
tumors have previously been imaged with CT and MRI, which is proof of concept that these 




 There are also practices that involve targeted imaging of tumors using small peptides 
and molecules. SCID mice have previously been used for such studies for ovarian (121), 
nasopharyngeal,  breast cancer (122), hepatic (123), lung cancer (124), and others. SCID mice 
are useful animal models for proof of concept studies that certain molecules and peptides 
can specifically bind to certain tumor types. After preliminary testing has been completed in 
mice, SCID pig models engrafted with human cells could then be used for testing these 
targeting techniques with respective imaging equipment that would be used in the clinics. As 
an example, human ovarian carcinomas expressing high levels of Claudin 3/4 expression will 
grow in SCID pigs (45; Boettcher et al., Comparative Med, In press). A Clostridium perfringens 
enterotoxin (CPE) peptide can specifically bind to Claudin 3/4 (121,125), and such a SCID pig 
ovarian cancer model can be used as an imaging and therapeutic target of the CPE peptide in 
targeting ovarian carcinomas in such a way that it is translatable to human patients.  
Development of Patient Derived Xenograft models in SCID pigs for personalized drug testing 
 Since SCID pigs have previously been shown to accept xenografts of human cancer 
cells (13), as well as pluripotent stem cells (26,55), it would be expected that they would also 
accept solid tumor tissues as well. Patient derived xenograft (PDX)  and cell derived 
xenograft models have previously been utilized in SCID mouse models for patient specific 
drug testing (126). SCID pig models can also be developed for these purposes. Due to higher 
similarity in metabolism between humans and pig (22) compared to mice, drug responses in 
the pig would likely lead to more directly comparable responses to those that would be 
found in humans (23). Additionally, the size of the pig would also allow representative drug 





Here we have described many of the novel uses of SCID pigs in oncology research 
involving the use of xenotransplantation of human tumor tissues, HSCs, and lymphoid 
tissues. The full potential of these animals will be realized when biocontainment facilities are 
more readily available and survivability of SCID pigs improved. Additionally, dissemination of 
handling protocols will be essential to prolonging the lives of these animals for long-term 
studies.  
Research groups generating SCID pigs are at the forefront of creating a new animal 
model that can be used for translational preclinical research. We have learned an incredible 
amount of information by use of small animal mouse models for cancer research. However, 
in order for therapies to be developed and tested thoroughly, they now need to be 
evaluated in a larger animal model that better represents human disease states and which 
can provide realistic opportunities for improved modeling of imaging and surgical 
approaches. As such, we believe that SCID pig models will provide a foundation for 
researchers to gain valuable and translational results to improve patient outcomes in a 
clinical setting.  
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Figure 2.1. Genetic and molecular mechanisms of RAG1/2, Artemis, and IL2Rγ in lymphoid 
development 
 
Previous SCID pig models have been generated or described with mutations in Artemis, 
RAG1, RAG2, or IL2RG. (A) RAG1 and 2 are subunits of an endonuclease that cleave 
recombination signal sequences (RSS) flanking V, D, and J gene segments. Cleavage of RSS 
sequences are required for the gene segments to be joined together. Non-functional RAG1 




and B cell receptors (BCRs) from forming. T cells and B cells cannot develop due to non-
functional TCR and BCR rearrangement.  (B) Artemis is an endonuclease that is responsible 
for the cleavage of hairpin loops that form after RAG1 and 2 cleaves RSS sequences. These 
hairpin loops must be cleaved in order for Ligase IV to ligate V, D, and J gene segments 
together. If Artemis is not functional, these hairpin loops cannot be cleaved, which prevents 
TCR and BCR rearrangement. (C) IL2Rγ is a subunit required in the receptors for IL-2, IL-15, 
IL-4, IL-7, IL-9, and IL-21. Without functional IL2Rγ, developing cells that require these 
cytokines for development (mainly T, B, and NK cells) are not receptive to cytokine signaling, 
which prevents proper differentiation of T, B, and NK cells. (D)  Pigs with mutations in both a 







































Figure 2.2. Lymphoid development and relevant SCID pig mutations 
 
Mutations in Artemis, RAG1/2, and IL2RG leads to SCID in pigs. Artemis and RAG1/2 are 
active in Pro-B and -T cells during differentiation. IL2Rγ is required at an earlier stage of 
development than RAG1/2 and Artemis. NK cells and T cells both require cytokine signaling 
through IL2Rγ early in differentiation. Mutations in IL2RG prevent differentiation of T and B 
cells. Mouse B cells appear to rely on IL2Rγ signaling more than human and pig B cells. B cells 
can still develop in humans and pigs with mutations in IL2RG, although they are mostly non-


















Figure 2.3. Biocontainment facilities for rearing SCID pigs 
 
(A) Biocontainment facilities for the rearing of Art-/- SCID pigs. (B) SPF female Art+/- carriers 
nursing three week old SCID and non-SCID piglets after naturally farrowing in 



























Figure 2.4. Swine have fewer unique immunological genes compared to humans than do 
mice 
 
A comparison of the number of unique immunological genes was compared between 
humans, mice, cows, and pigs. Pigs have 2 times less unique genes, while mice have 4.7 




















Figure 2.5. Amino acid sequence comparisons in hematopoietic cytokines for pig and 
mouse compared to humans 
 
Amino acid sequences for relevant hematopoietic cytokines and other ligands were acquired 
from Ensembl (https://useast.ensembl.org/index.html). The percentage of matching 
sequence between humans to pigs and mouse is shown above. Porcine shares higher 
sequence similarity to humans for a majority of hematopoietic cytokines compared to mice. 














Figure 2.6: Cell types and routes of injection for SCID pig immunological humanization  
 
Swine can be injected with human cells at two different developmental stages. During 
gestation, fetal piglets at approximately 40 days of gestation can be injected with human 
CD34+ stem cells within either the liver or intraperitoneal space via ultrasound guidance. 
Newborn piglets can also be injected with human CD34+ stem cells through either 
intravenous or intraosseous routes. PBLs can also be injected via intravenous injection. Fetal 
tissues including bone marrow, liver, thymus, or spleen can be transplanted within the 















Figure 2.7: In utero injection of fetal intraperitoneal space via laparotomy 
 
(A) Exteriorized uterus at 40 days gestation being ultra-sounded for fetuses. Water soluble 
marker can be used for marking fetuses. (B) Ultrasound image of fetal liver with which 


































IL2RG Zinc finger nuclease T- B+ NK- Cross bred Did not rear neonatal 18




RAG 1 Gene targeting T- B- Duroc Did not rear neonatal 25















RAG 2 IL2RG CRISPR/Cas9 T- B- NK- Yorkshire cross breed Gn Isolator 34 days 28












Table 2.2. Previously described human stem cell injection studies in swine and sheep
Large animal
Type of human cells 
injected
Number of cells 
injected
Age and injection 
site
Human cell type(s) that 
differentated
Reference
PI sheep Fetal liver cells 0.2-1 x 1010/kg
Fetal peritoneal 
cavity










T, B, NK, Myeloid 74
PI pig




















T cell depleted bone 









T, B, NK, myeloid 75
PI sheep ESC-derived CD34+ 0.5 x 106
Fetal peritoneal 
cavity
T, B, NK, Monocytes, 
neutrophils
72
SCID pig iPSCs 5-10 x 10
6 Piglet ear and 
lateral flank
CD34+, CD45+ 26
SCID pig iPSCs 10 x 10
6 Piglet ear and 
lateral flank
CD34+, CD45+ 55






Table 2.S1. Ensembl accession numbers used for amino acid comparisons
Protein Human Pig Mouse
SCF ENSG00000049130 ENSSSCG00000035495 ENSMUSG00000019966
TPO ENSG00000090534 ENSSSCG00000023909 ENSMUSG00000022847
Flt-3 ENSG00000122025 ENSSSCG00000009314 ENSMUSG00000042817
IL-11 ENSG00000095752 ENSSSCG00000040725 ENSMUSG00000004371
CXCL12 ENSG00000107562 ENSSSCG00000034973 ENSMUSG00000061353
EPO ENSG00000130427 ENSSSCG00000007673 ENSMUSG00000029711
IL-15 ENSG00000164136 ENSSSCG00000009051 ENSMUSG00000031712
IL-2 ENSG00000109471 ENSSSCG00000033267 ENSMUSG00000027720
IL-4 ENSG00000113520 ENSSSCG00000014282 ENSMUSG00000000869
IL-5 ENSG00000113525 ENSSSCG00000014278 ENSMUSG00000036117
IL-6 ENSG00000136244 ENSSSCG00000020970 ENSMUSG00000025746
IL-7 ENSG00000104432 ENSSSCG00000006161 ENSMUSG00000040329
M-CSF ENSG00000184371 ENSSSCG00000037449 ENSMUSG00000014599
GM-CSF ENSG00000164400 ENSSSCG00000023737 ENSMUSG00000018916
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 Severe combined immunodeficient (SCID) pigs are an emerging animal model being 
developed for biomedical and regenerative medicine research. SCID pigs can successfully 
engraft human induced pluripotent stem cells and cancer cell lines. The development of a 
humanized SCID pig through xenotransplantation of human hematopoietic stem cells (HSCs) 




 Xenotransplantation success with HSCs into non-obese diabetic (NOD)-derived SCID 
mice is dependent on the ability of NOD mouse signal regulatory protein alpha (SIRPA) to 
bind human CD47, inducing higher phagocytic tolerance than other mouse strains. 
Therefore, we investigated whether porcine SIRPA binds human CD47 in the context of 
developing a humanized SCID pig. 
Methods 
 Peripheral blood mononuclear cells (PBMCs) were collected from SCID and non-SCID 
pigs. Flow cytometry was used to assess if porcine monocytes could bind to human CD47. 
Porcine monocytes were isolated from PBMCs and were subjected to phagocytosis assays 
with pig, human, and mouse red blood cell (RBC) targets. Blocking phagocytosis assays were 
performed by incubating human RBCs with anti-human CD47 blocking antibody B6H12, non-
blocking antibody 2D3, and non-specific IgG1antibody and exposing to human or porcine 
monocytes. 
Results 
 We found that porcine SIRPA binds to human CD47 in vitro by flow cytometric assays. 
Additionally, phagocytosis assays were performed, and we found that porcine monocytes 
phagocytose human and porcine RBCs at significantly lower levels than mouse RBCs. When 
human RBCs were pre-incubated with CD47 antibodies B6H12 or 2D3, phagocytosis was 
induced only after B6H12 incubation, indicating the lower phagocytic activity of porcine 







 We have shown the first evidence that porcine monocytes can bind to human CD47 
and are phagocytically tolerant to human cells, suggesting that porcine SCID models have the 
potential to support engraftment of human HSCs.  
Introduction 
Mice are currently the most common animal model used in biomedical research. 
However, it has become apparent that results pertaining to human disease states and drug 
responses in mice may not be directly translatable to humans [1,2]. Therefore, progress is 
being made to develop larger animal models to provide a more accurate representation of 
human health. One such species that is increasing in research versatility is the domestic pig. 
Porcine models are advantageous over other rodent models due to their similarities in 
anatomy, physiology, immunology, and gene expression to humans [3,4,5,6,7]. Although 
primate models exist, pigs are preferable for biomedical research due to fewer ethical issues. 
Pigs also have a shorter gestation period and larger litter sizes than primates, which better 
facilitate experimental groups. Therefore, further development of porcine models is needed 
for translational biomedical research.  
 We have previously characterized naturally occurring T- B- NK+ severe combined 
immunodeficient (SCID) pigs with mutations within the Artemis gene [8].  Other SCID pig 
models that were  artificially created include IL2RG-/- [9,10], RAG2-/- [11], and RAG2-/- IL2RG-/- 
double knockouts [12]. One way to utilize and improve the SCID pig as a model is the 
humanization through efficient engraftment of human hematopoietic stem cells (HSCs).  




allowed researchers to study human immune cell function in the context of HIV, cancer, 
transplantation, and other important diseases[13,14].   
 The mouse strain used for the most efficient human cell engraftment is the non-
obese diabetic (NOD) SCID IL2RG (NSG) mouse, which has a T- B- NK- cellular phenotype. 
One mechanism for success of human cell engraftment within the NSG background is due to 
polymorphisms within the NOD signal regulatory protein alpha (SIRPA) gene [15], which 
allows it to intrinsically bind to human CD47  and signaling leads to phagocytic tolerance of 
human cells. SIRPA is expressed on the surface of monocytes, macrophages, and other 
immune cells and binds to the “self” protein CD47 [16]. SIRPA binding to CD47 results in an 
inhibitory “don’t eat me” signal within SIRPA expressing cells, resulting in the inhibition of 
phagocytosis [17,18]. Upon binding of CD47, intracellular tyrosine based inhibitory motifs on 
the intracellular domain of SIRPA are phosphorylated, leading to a dephosphorylation 
cascade mediated by SHP1, leading to phagocytic inhibition [19]. The SIRPA protein in 
C57BL/6 and BALB/c both have low affinity to human CD47 that is not sufficient for 
inhibitory signaling, which explains the lack of successful human cell engraftment in these 
mouse strains [20], and further demonstrates the importance of SIRPA-CD47 recognition for 
humanization of these rodent models [21].  Certain rats and mice of mixed 129/BALB/c 
background are genetically modified to express human SIRPA, making these animals 
candidates for humanization if crossed onto a SCID genetic background [22,23]. 
Interestingly, past studies have investigated the interaction between porcine CD47 and 
human SIRPA, the opposite interaction to that described here, in relation to transplantation 




able to bind to human SIRPA in vitro [24], while another showed that phagocytic inhibition 
was not induced between human macrophages and pig cells [25]. Expression of human CD47 
on porcine cells was required to inhibit phagocytosis by human macrophages [25,26]. 
Together, these studies show evidence that human SIRPA and pig CD47 can bind, although 
binding is not sufficient for phagocytic inhibition. However, the ability of swine SIRPA to bind 
to human CD47 has not been explored.  
 Humanized SCID pigs would be an excellent biomedical model for the study of human 
disease and cancer. To identify potential cellular barriers to humanization of SCID pigs 
related to SIRPA/CD47 interactions, we investigated if porcine SIRPA binds to human CD47 
and if binding is sufficient to inhibit phagocytosis of human cells. Flow cytometry assays with 
porcine cells and recombinant human CD47 showed that porcine SIRPA can bind to human 
CD47. Additionally, porcine monocytes phagocytosed pig and human cells at very low levels, 
while readily phagocytosing murine cells. Antibody blocking assays showed that the 
inhibition of phagocytosis of human cells by porcine monocytes was dependent on the 
SIRPA-CD47 interaction. The natural ability of porcine SIRPA to bind to human CD47 suggests 
that SCID pigs have the potential to be used for humanization and serve as a valuable 
biomedical model.  
Results 
Porcine SIRPA and CD47 share high degree of amino acid sequence homology with human  
 The extracellular IgV domain of SIRPA takes part in binding to the IgSF domain of 
CD47 [33]. CD47 IgSF amino acids from human, pig, and mouse were aligned (Figure 3.1A). In 




homology with porcine (53-62%) or human (53-63%) than is shared between porcine and 
human (72%). The higher degree of similarity between human and porcine CD47 suggests 
that human CD47 may be similar enough to porcine CD47 to be recognized by porcine SIRPA. 
 To clarify the level of amino acid conservation of SIRPA across human, pig and 
mouse, SIRPA IgV amino acids were aligned from human, pig, C57BL/6, BALB/C, and NOD 
mouse backgrounds (Figure 3.1B). Previously, mutagenesis experiments have identified 
critical residues in human SIRPA that are required for successful binding of human CD47, 
including Ala/Val 27 and Gln 37 [34,35,36]. Swine SIRPA contains Ala 27, suggesting that it 
could interact with human CD47 at this position. Additionally, porcine SIRPA contains 
residues present in NOD SIRPA that are shared with human, but not in C57BL/6 mice, 
including His 59, Val 63, Thr 64, and Thr 91. Importantly, NOD, pig, and human SIRPA all lack 
Ser 102 and Glu 103 present in the C57BL/6 and BALB/c derived protein; the re-insertion of 
these residues into NOD SIRPA in vitro dramatically decreased human CD47 binding [28]. Ser 
102 and Glu 103 are found on the surface of the binding interface of SIRPA and are near 
residues  shown to physically interact with CD47 including Ser 98 and Asp 100 (depicted as 
S101 and D106 in Figure 3.1B) [33]. Other critical residues, including Gln 8, Thr 26, Ser 66, 
and Arg 69 (depicted as R72 in Figure 3.1B) are conserved across human, pig, and mouse, 
indicating that these residues do not participate in the species-specific differences in the 
CD47-SIRPA interaction [34,35,36]. Taken together, porcine SIRPA shares specific amino acid 






Porcine monocytes bind to recombinant hCD47-Fc 
 Previous studies have utilized flow cytometry and recombinant human CD47 (hCD47-
Fc) to assess binding to mouse SIRPA [20], and thus we used a similar approach to determine 
if porcine SIRPA was capable of binding human CD47. PBMCs were isolated from human, 
SCID, and non-SCID pig blood and analyzed for surface expression of SIRPA and binding 
capability of hCD47-Fc. When staining with hCD47-Fc and anti-human SIRPA on human 
monocytes, we found that the anti-human SIRPA antibody we used inhibited binding of the 
hCD47-Fc protein. The anti-pig SIRPA antibody we used also appeared to block hCD47-Fc 
binding (Figure 3.S1).  Therefore, cells were stained with SIRPA antibodies and hCD47-Fc 
separately as to avoid the potential for SIRPA antibodies to block SIRPA-hCD47-Fc 
interactions. 
 Monocytes from SCID and non-SCID pigs both showed positive binding to hCD47-Fc 
(Figure 3.2A). The percent SIRPA+ positive monocytes in SCID and non-SCID pigs did not 
differ, nor did the percent of hCD47-Fc (Figure 3.2B). However, in cells from both types of 
pigs, as well as humans, there was variability in binding capability to hCD47-Fc (Figure 3.2B), 
with some binding at high levels (Figure 3.2A, top row), or low levels (Figure 3.2A, bottom 
row). Monocytes from all pigs were shown to bind hCD47-Fc at higher levels than 
fluorophore controls (Figure 3.2B). In summary, we interpreted these results to indicate that 
porcine SIRPA+ cells bound to human CD47-Fc in vitro.  
Porcine blood-derived monocytes phagocytose human RBCs at very low levels 
We next investigated if porcine monocytes phagocytose human cells in an in vitro 




failure to express CD47 on the surface of a RBCs results in immediate phagocytosis [39].  
Additionally, RBCs are an easily obtainable and comparable small cell type that can be 
collected from humans, pigs, and mice. Therefore, in this study, we utilized RBCs as a model 
to study the interaction between porcine SIRPA and human CD47.  
 In comparing CD47 amino acid sequences among species, mouse shares less 
homology with porcine CD47 than human (Figure 3.1A), indicating that mouse CD47 may not 
be recognized by porcine SIRPA. Based on sequence differences between pig and mouse 
CD47, we expected that porcine monocytes would phagocytose mouse RBCs due to lack of 
pig SIRPA- mouse CD47 binding. SCID and non-SCID pig SIRPA+ monocytes were incubated 
with fluorescently labeled human, pig, and mouse RBCs, and phagocytosis was assessed by 
the percentage of fluorescent monocytes, indicating phagocytosis of labeled RBCs. SCID and 
non-SCID pigs did not differ in their ability to phagocytose the RBC targets. As predicted, 
porcine monocytes phagocytosed mouse RBC at very high levels (Figure 3.3A), which 
indicates that the porcine monocytes have the potential to be phagocytic. Due to the high 
levels of mRBC phagocytosis, a slightly different gating strategy was used for mRBC 
phagocytosis since the phagocytic population had a higher fluorescence intensity than when 
incubated with hRBC or pRBC (Figure 3.3B). The brighter monocyte population (to the right 
of the gate) are indicated as the phagocytic populations.  The levels of phagocytosis of 
human and porcine RBCs by porcine monocytes were very similar, and significantly lower, 
than mouse RBCs (p < 0.001) (Figure 3.3A, B). Collectively, low levels of human RBC 
phagocytosis by porcine monocytes suggested that CD47 expressed on human RBCs bound 




Blocking Porcine SIRPA- human CD47 interaction induced phagocytosis 
To demonstrate that human RBCs were not phagocytosed by porcine monocytes due 
to inhibitory effects of porcine SIRPA-human CD47 binding, we utilized an antibody blocking 
assay used in a variety of cancer therapy studies [40,41,42,43,44]. The B6H12 clone of anti-
human CD47 antibody binds to an epitope of human CD47 that prevents it from binding to 
human SIRPA, while the 2D3 anti-human CD47 clone does not block the interaction. The 2D3 
antibody acts as an opsonization control in these experiments to show that it is the blocking 
activity of the B6H12 anti-CD47 clone, and not the presence of the antibody on the cellular 
surface, that allows for phagocytosis to be induced (not inhibited). In human studies, cancer 
cells that express high levels of CD47 that are incubated with B6H12 are phagocytosed at 
higher levels than those incubated with 2D3 or non-specific antibodies [40,41,42,43,44]. 
Thus, The B6H12 and 2D3 antibodies were used with human RBCs in an assay with porcine 
and human monocytes to interrogate if human CD47 binds to porcine SIRPA to inhibit 
phagocytosis 
 Since we have previously shown that SCID and non-SCID pigs do not differ in their 
ability to bind to human CD47 or phagocytose human RBC targets, they were analyzed as a 
single group. Human RBCs were incubated with B6H12, 2D3, and IgG control antibodies prior 
to incubation with either human or porcine monocytes. A schematic of cells and antibodies 
used are shown in Figure 3.4A.  Only pretreatment with B6H12 increased RBC phagocytosis 
for both human and pig monocytes (Figure 3.4B) (p < 0.001). Importantly, B6H12 and 2D3 
bound to human RBCs similarly (Figure 3.S2). On average, 80% of human monocytes 




monocytes as a proof of concept to show that blocking the interaction between SIRPA/CD47 
within the same species increases phagocytosis. Of porcine monocytes, 20% of monocytes 
phagocytosed B6H12 treated hRBC, compared to 5% for controls. One hypothesis for the 
difference in B6H12 phagocytosis induction between human and pig monocytes is that the 
protein interacting surface between human SIRPA-human CD47 and porcine SIRPA-human 
CD47 may slightly differ. The B6H12 antibody may not be as efficient at blocking the porcine 
SIRPA-human CD47 interaction, which would explain the lower levels of phagocytosis 
induction. While the increase in phagocytosis was not as high for porcine monocytes as 
human monocytes, a significant increase in the level of phagocytosis was induced upon 
blocking pig SIRPA-human CD47 binding. This result indicates that the SIRPA-CD47 
interaction between porcine monocytes and human RBCs is critical for limiting phagocytosis 
of human RBCs.  
Discussion 
We present the first evidence that porcine SIRPA can bind and recognize human 
CD47 to inhibit phagocytosis of human cells by porcine phagocytes in an in vitro system. 
Importantly, monocytes specifically from SCID pigs were capable of binding human CD47 to 
inhibit phagocytosis of human RBCs.  Specifically, porcine monocytes uniformly failed to 
phagocytose hRBC and blocking the porcine SIRPA-human CD47 axis induced phagocytosis of 
hRBC. Together, these results show that the porcine SIRPA-human CD47 binding interaction 
was sufficient to inhibit phagocytosis of human cells. Mouse and rat models have previously 
required genetic modification to express human SIRPA to allow engraftment of human cells 




believe that pigs would require introduction of the human SIRPA gene to allow for HSC 
engraftment. In moving forward with the development of a humanized SCID pig model, it is 
necessary to characterize interactions that are required for successful engraftment.  
 There are few studies that have investigated how porcine immune cells interact with 
human cells, particularly phagocytosis of human cells by pig myeloid lineage cells. Porcine 
liver sinusoidal endothelial cells phagocytose human platelets perfused through the liver 
[45]; however, the involvement of porcine SIRPA and human CD47 in the phagocytosis of 
human platelets was not assessed in this study.  A follow-up report suggests that differences 
in Galβ and βGlcNAc oligosaccharides on human and porcine platelets contributed to the 
phagocytosis of human platelets [46]. Previous reports in mouse models indicate NOD 
mouse macrophages phagocytose human RBC despite the ability of NOD SIRPA to bind to 
human CD47. The phagocytosis of human RBC by NOD macrophages is hypothesized to be 
attributed to either mouse complement [47] or xenoantigens on the human RBCs [48]. In our 
study we were able to show low levels of in vitro phagocytosis of human RBC by porcine 
monocytes; enhanced phagocytosis only occurred when the porcine SIRPA-human CD47 axis 
was blocked with the anti-human CD47 B6H12 antibody. One method that could be utilized 
in future studies would be generating a crystal structure of the human CD47- porcine SIRPA 
complex to study this interaction in more detail. Additionally, it would be insightful to 
determine if there are unidentified polymorphisms in the IgV domain of swine SIRPA that 
could contribute to different binding affinities to human CD47.   
 Porcine SCID models have already been utilized for different facets of biomedical 




human cancer cells lines [49] and human induced pluripotent stem cells [52] can survive and 
persist in SCID pigs.  The ability of these cell types to survive within SCID pigs suggests that 
other human cell types, including HSCs could also survive in SCID pigs. Humanized SCID pig 
models could aid in the development and testing of vaccines, cancer immunotherapies, stem 
cell therapies, as well as other important biomedical advancements [53]. Development of 
such a humanized SCID pig requires clean housing and personnel protocols to ensure 
minimal exposure of these animals to pathogens. There are protocols  developed to raise 
SCID pigs in clean, positive-pressure bubble environments to limit disease and increase 
lifespan so these pigs can be used in long term studies [54], including development of 
methods to introduce and maintain a human immune system in SCID pigs.  
 As of this writing, very few studies have been conducted in relation to introducing 
human HSCs into non-murine models. Non-SCID lambs and piglets can support the 
development of human T, B, NK, and myeloid lineages when HSC cells were  injected in the 
fetal intraperitoneal space via in utero injections with human HSCs [55,56]. Additionally, the 
pig thymus can support the development of a wide range of human T cells [57,58]. The 
development of human immune cell subsets suggests that porcine cytokines can support the 
development of human immune cells. The differentiation of human cells in pig models  is 
consistent with existing literature that state porcine immune genes are highly similar to 
human [3,59]. In considering past studies, it is expected that human HSCs would engraft and 
differentiate in SCID pigs at least as well as they have in non-SCID pigs. Showing that porcine 
phagocytes tolerate human cells in vitro though the SIRPA-CD47 pathway is important 




Materials and Methods 
Generation of piglets and sample collections from pig, mouse and human subjects 
 Piglets were derived as described [8]. Piglets from all litters were co-housed with 
their littermates. All animal protocols and procedures were approved by Iowa State 
University’s Institutional Animal Care and Use Committee. Informed consent was obtained 
from human subjects and was approved by the Iowa State University’s Institutional Review 
Board.  Blood was collected into a heparinized vacutainer tube (BD, Franklin Lanes, NJ, USA). 
Peripheral blood mononuclear cells (PBMCs) were isolated as described [27]. 
Flow cytometry for hCD47 binding to PBMCs 
 PBMCs from pig and human were washed in Hanks Balanced Salt Solution (HBSS) to 
remove excess biotin from complete RPMI media (10% FBS, 2 mM glutamine, 50 µg/mL 
gentamicin, 10 mM HEPES) and incubated with biotinylated human CD47-Fc (hCD47-Fc) (BPS 
Biosciences, San Diego, CA, USA) followed by PE-Cy5 Streptavidin (BD Biosciences). Human 
cells were stained with anti-human SIRPA (R&D, Minneapolis, MN, USA, clone #602411), 
while porcine cells were stained with anti-pig monocyte/granulocyte (SWC3a/SIRPA) (BD 
Biosciences, clone 74-22-15A). A mouse IgG2b isotype control antibody (BD Biosciences) and 
goat anti-mouse IgG2b FITC (Southern Biotech, Birmingham, AL, USA) were used as controls. 
Human and porcine monocytes were singly stained with SIRPA and hCD47-Fc. We stained 
from the same stock of cells and gated monocytes the same way for each set of stained cells. 
In order to prevent non-specific Fc binding, Human TruStain FcX (BioLegend) and heat 
inactivated swine serum were also added to human and pig cells, respectively. Data was 




from a total of six pigs (3 SCID and 3 non-SCID) and four humans were used in three 
independent experiments. The three experimental groups contained piglets from two 
separate litters. 
Sequence alignment of SIRPA and CD47 
 
 Sequences of SIRPA from human (CAA71403.1, NP_542970), porcine 
(NP_001011508.1), BALB/C [20], C57BL/6 [28], and NOD [28] mouse, as well as CD47 from 
human (NP_001768.1), porcine (ABW24514.1), and mouse (BAA25401.1, XP_006521871.1) 
were  obtained from the NCBI database and aligned with Clustal Omega alignment tool [29]. 
BLASTP was used to determine percent identity for CD47 amino acid sequences between 
species [30]. 
Preparation of labeled red blood cells for phagocytosis assays 
 To serve as a source of cells in phagocytosis assays, red blood cells (RBCs) were 
isolated from pigs, humans, and mice. Whole blood was collected into a heparinized 
vacutainer tube (BD) and was diluted 1:100 into complete RPMI media and was used as a 
source of RBCs. The RBCs were then counted using BD counting beads and a flow cytometer. 
After counting, RBCs were stained with PKH67 fluorescent dye and counted again to verify 
positive PKH67 staining.  
Monocyte preparation for phagocytosis assays 
 PBMCs were plated into tissue culture treated flasks and monocytes were allowed to 
adhere overnight at 37°C. Non-adherent PBMCs were removed, and remaining monocytes 
were washed with HBSS. Monocytes were then trypsinized with 0.25% HyClone trypsin 




enumerated by flow cytometry with BD counting beads, and seeded at 105 cells per well in a 
24 well plate.  Monocytes were incubated over night at 37°C in complete RPMI to adhere. 
After incubation, additional fresh media was added to each well. 
 Labeled target RBCs were added to 105 monocytes at ratios of 1:20, 1:40, and 1:60 
and incubated at 37° C for 6 hours. Media with RBCs was removed, and remaining RBCs were 
lysed with ammonium chloride lysing solution; therefore removing any non-phagocytosed 
RBCs from the surface of the monocyte. Monocytes were trypsinized, fixed, and 
fluorescence was acquired on a BD Biosciences FACSCanto II flow cytometer to evaluate 
internalized RBCs. The percentage of PKH67 positive monocytes was determined for each 
sample. A total of six pigs (3 SCID and 3 non-SCID) and were used in two independent 
experiments. The two experimental groups contained piglets from three separate litters. 
CD47 blocking assay 
 PKH67-stained human RBCs were incubated with either 0.5 µg of anti-CD47 clone 
B6H12.2 (eBioscience, San Diego, CA, USA), anti-CD47 clone 2D3 (eBioscience), or mouse 
IgG1 isotype control antibody (eBioscience) per 106 RBCs for 30 minutes at room 
temperature. The B6H12 binds to human CD47 on an epitope which blocks its ability to bind 
to human SIRPA [31], while 2D3 binds to human CD47, but does not block the interaction 
with human SIRPA. The 2D3 antibody acts as an opsonization control to show that the 
presence of the antibody on the surface of the cell does not contribute increases in 
phagocytosis. After the incubation period, washed RBCs were then added to adhered 
monocytes at an effector to target ratio of 1:10. Similar binding between B6H12 and 2D3 




Figure 3.2). A total of seven pigs (2 SCID and 5 non-SCID) and two humans were used in 
three independent experiments. The three experimental groups contained piglets from two 
separate litters. 
Statistical Analysis 
 To compare levels of phagocytosis between RBCs from human, pig, and mouse 
(Figure 3.3) and to evaluate the ability of different monoclonal antibodies to human CD47 to 
inhibit phagocytosis of human RBCs (Figure 3.4 A, B), a multiple linear regression model was 
assessed. P values are reported from a type III analysis of variance (ANOVA) with fixed 
effects of target RBC species (Figure 3.3) or antibody treatment (Figure 3.4) using R [32]. 
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Figure 3.1. Multi-species alignment of SIRPA and CD47 
 
(A) Sequence alignment of human (NP_001768.1), porcine (ABW24514.1), and mouse 
(BAA25401.1, XP_006521871.1) CD47 IgSF domain. Blue highlighted residues indicate amino 
acids in human and mouse sequences that are different from pig. Green and red highlighted 
residues are amino acids that are different from pig in mouse and human sequences, 
respectively. (B) Sequence alignment of human (CAA71403.1, NP_542970), porcine 
(NP_001011508.1), BALB/c [20], C57BL/6 [28], and NOD [28] mouse SIRPA IgV domain. Green 
and yellow highlighted residues indicate amino acids on human SIRPA that are deemed 
critical for binding human CD47 through mutagenesis experiments [34,35,36] with green 
highlighted showing conserved and yellow showing species specific amino acids. Residues in 
blue are those that differ between C57BL/6 and NOD that both human, porcine, BALB/c 
(only H59 and T91) SIRPA contain. Most importantly the SE residues only present in BALB/c 





Figure 3.2. Porcine monocytes bind to recombinant hCD47 in vitro 
 (A) PBMCs from human subjects (H), non-SCID (NS), and SCID (S) pigs were isolated from 
whole blood and stained for SIRPA expression and hCD47-Fc binding. PBMCs were gated on 
monocyte populations and analyzed. Grey histograms show isotype or fluorophore controls. 
The top row shows samples with high binding to hCD47-Fc, and the bottom row shows low 
binding for each sample type. Three independent experiments were run (n= 3 S pigs, 3 NS 
pigs, 4 humans). Images were generated in FlowJo. (B) Percentage and MFI values for SIRPA 













Figure 3.3. Porcine monocytes phagocytose human and pig RBCs at low levels 
(A) Percent phagocytic monocytes from SCID (S) (open symbol) and non-SCID (NS) (filled 
symbol) pigs incubated with fluorescently labeled human (diamond), pig (square), and 
mouse (triangle) RBCs at ratios of 1:20, 1:40, and 1:60 are shown. The average phagocytosis 
for both SCID and non-SCID pigs are shown in grey. Results from two independent 
experiments are shown (n= 3 S pigs, 3 NS pigs). * p <0.001. (B) Fluorescence intensity within 
monocytes was assessed by flow cytometry as a measure for phagocytosis. Phagocytic 
monocytes were characterized by positive fluorescent signal by flow cytometry for each 
animal. Fluorescence intensity for monocytes not incubated with any RBC is shown as the 
black outlined histogram; the same control histogram is on all nine plots. Histograms shaded 
in grey are monocytes after exposure to the different species and amounts of RBC. Images 













Figure 3.4. Porcine monocyte phagocytosis of human red blood cells is inhibited by SIRPA-
CD47 interaction 
 
(A) Schematic of cells and antibodies used.  Phagocytosis was only induced between human 
RBC and porcine monocytes when human RBC were incubated with anti-human CD47 
blocking antibody B6H12, showing that human CD47 binds to porcine SIRPA to inhibit 
phagocytosis. (B) Human monocyte phagocytosis of human RBCs incubated with B6H12, 
2D3, or mouse IgG control antibodies (n=2). (C) Porcine monocyte phagocytosis of human 
RBCs (n=2 S pigs, 5 NS pigs) incubated with the same antibodies. Percent phagocytic 
monocytes are shown for both human and porcine monocytes. Results from four 













Figure 3.S1. Anti-Sirpa antibodies decrease hCD47-Fc binding 
Plots and statistics shown are gated on monocytes from either human or pig samples. (A) 
Human and porcine monocytes were incubate with either IgG2b isotype/fluorophore and 
PeCy5 fluorophore controls or species specific anti-SIRPA antibodies and hCD47-Fc. Isotype 
and fluorophore controls were used to gate for both species. For both porcine and human 
monocytes, the SIRPA+ population is also hCD47-Fc positive. However, when cells were 
stained with just hCD47-Fc alone, without the anti-SIRPA antibodies, the percentage of 
hCD47-Fc positive cells was increased. (B) MFI values for hCD47-Fc binding (or PeCy5 
controls) are shown. For the two pigs and three human samples tested, the MFI of hCD47-Fc 
was decreased when anti-SIRPA antibodies were present, indicating that the anti-SIRPA 





Figure 3.S2. B6H12 and 2D3 binding to human RBC. 
In order to verify that the same amount of B6H12 and 2D3 antibodies were bound on the 
surface of human RBC, 106 hRBCs were stained with 0.5 μg of each antibody. An IgG1 isotype 
control was also used, and is shown as a light grey histogram. The fluorescence intensity for 
B6H12 and 2D3 staining was highly similar, indicating similar levels of antibody on the 
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Abstract 
Swine are a commonly used animal model for biomedical research. One such 
research application for swine models is the study of human or pig cells injected in utero into 
the fetal liver (FL) or intraperitoneal space (IP). In utero injections can be accomplished via 
laparotomy procedures in pregnant swine. In this study we aimed to establish 
comprehensive laparotomy protocols for ultrasound guided injections into fetuses. Two 
pregnant gilts, with a total of sixteen fetuses, underwent laparotomy procedures at 41 and 
42 days of gestation. Half of the fetuses were injected in either the FL or IP space with saline 
and titanium wire for radiographic imaging after birth. After the laparotomy and fetal 
injections, both gilts maintained pregnancy through gestation and initiated labor at full term. 
Of the sixteen initial fetuses, twelve were liveborn, two were stillborn, and two were 




surgery between the two litters. After farrowing, piglets were radiographed, and six piglets 
were identified to have wire within the abdominal space. Livers were dissected, and 
additional radiographs were obtained, and it was determined that one piglet had wire within 
the liver, while the other five had wire within the IP space. In all, we describe in-depth 
laparotomy surgery protocols, ultrasound guided injection of saline and titanium wire into 
the FL or IP space, post-operative monitoring protocols, and information on radiographic 
detection of titanium wire after piglet birth. These protocols can be followed by other 
research groups intending to inject fetal piglets in either the IP space or FL with cells of 
interest. 
Introduction 
Swine are a popular animal model for biomedical research. Many research groups 
use pigs for cancer 16,17, cardiovascular 21, infectious disease research 10, and other areas. An 
application of swine models that is gaining interest is the ability to study human immune cell 
function and de novo development of human cells, also known as “humanization”, in pigs. 
Previous humanization studies in swine have been performed via in utero injection of human 
hematopoietic stem cells (HSC) into the fetal intraperitoneal space (IP) 4,9,12,13. Injections 
typically occur around 40 days of gestation, as this is the time period when hematopoiesis is 
occurring in the swine fetal liver 18.  
Fetal piglets can be injected in the IP space either through percutaneous (PC) 
injection through the dam’s abdomen into the uterus, or by laparotomy and injected 
through the uterine wall. Fujiki et al (2003) injected human HSC via ultrasound guided PC 




Fetuses from this study were also injected with small titanium wires so that injection site 
could be determined later by radiographic analysis 4. More recent human HSC injections in 
swine have utilized laparotomy procedures for ultrasound guided fetal IP injections 9,12,13. In 
addition, laparotomy techniques are utilized for the injection of human liver cells into swine 
fetal livers 3.  Laparotomy procedures allow for more precise aiming into the fetuses due to 
closer contact to the injection site.  
Recently, pigs with severe combined immunodeficiency (SCID) are an emerging 
animal model 6,7,14,19,20,23,24. SCID pigs are a particularly important biomedical model to 
develop due to their ability to accept human xenografts, including pluripotent stem cells 8 
and cancer cells 2. It is of interest to the biomedical field to generate humanized SCID pig 
models, as well as to produce SCID pig breeders by porcine HSC transplantation for the 
propagation of such animals. HSC transplantation can be performed by ultrasound guided 
injection into the fetal IP space or fetal liver (FL) for the engraftment of human or porcine 
HSC. In addition, an interesting question to address is if HSC engraftment levels differ if cells 
are injected into the fetal IP space or liver. Titanium wire injection into these locations can 
be utilized for radiographic identification after piglet birth as analysis of cell engraftment 
takes place.  
There are research studies that outline brief descriptions of swine laparotomies, 
however there are no publications dedicated solely to protocols for ultrasound guided fetal 
injections via midline laparotomies in mid-gestation swine. Here we detail safe and 
successful surgical procedures, post-operative monitoring protocols, attempted differential 




as a model for a cellular suspension, as well as titanium wire for radiographic analysis. These 
protocols will be of value for veterinary surgeons working with swine in biomedical settings 
to help minimize losses, morbidity, and animal numbers. With this work we aim to provide 
protocols that can be referenced for consistency across different groups performing swine 
laparotomies for the injection of cells of interest into fetal piglets.  
Results 
Ultrasound guided injection into intraperitoneal space and fetal liver 
 One goal we aimed to accomplish with injecting the fetuses was to determine the 
feasibility of specifically aiming in the fetal intraperitoneal space or liver. To achieve this 
goal, fetuses were injected with a titanium wire at the site of saline injection such that x-ray 
analysis could be performed later to determine injection location. We aimed for fetal IP 
space injections in gilt 31-7 and FL injections in 34-8. We decided to only inject half of each 
litter, as in case there was fetal death caused by injections, the pregnancy would likely be 
maintained by surviving (non-injected) piglets. All fetuses are listed in Table 4.2. 
 Gilt 31-7 had a total of ten fetuses, with four in the left horn and six in the right horn. 
A total of five piglets were attempted to be injected with wire and saline. Saline and wire 
were injected into fetuses A, C, E, G, and I. However, we observed the wire came out of fetus 
A externally from the uterus immediately after the injection, thus fetus A is reported as 
saline injected only. We did not attempt to inject another wire into fetus A. Of the other four 
fetuses, based on observations from ultrasound viewing at the time of injection, we 
anticipated that we injected wire within the IP space of three fetuses (C, G, and I), and one 




fetuses were injected with wire and saline. Of the three fetuses, we anticipated that we 
injected wire within the FL for two fetuses (L and N) and one in the IP space (P) (Table 4.2).  
Post-operative monitoring 
 Another important aspect to this surgery was to ensure that gilts did not succumb to 
infection or abort fetuses after the surgery was performed. Gilts were closely monitored for 
the 14 days following the surgery. Neither animal presented with a fever or vaginal discharge 
during this time period, nor for the rest of gestation. One gilt (34-8) showed moderate hind 
leg stiffness 2 days post-surgery. Meloxicam was continued an additional 2 days; no pain was 
observed following the additional meloxicam administration or the discontinuation of 
meloxicam. We observed no other signs of pain in the gilts; they presented with normal 
appetites, good locomotion, and attitudes. Bandages were replaced if coming loose or if 
incisional drainage was noted. Bandages were removed from both gilts one week after 
surgery.  Minimal redness and swelling were observed around the incision sites. Matrix was 
administered daily, in the morning, to help prevent abortions from occurring. Both animals 
were moved to a farrowing crate at gestational day 109 before going into labor at full term.  
Farrowing and radiographic identification of wire location post birth 
 It was also imperative to determine if injected fetuses could develop normally and to 
gestate to term after laparotomy procedures. Piglets IDs, as well as birthweights are listed in 
Table 4.3. The order of the piglets does not correspond to the order of the fetuses in Table 
4.2. As the piglets were farrowed, we did not have a way to determine piglet location in the 




Gilt 31-7 (litter 317) farrowed nine live and one fully developed stillborn piglet with 
no complications. Gilt 34-8 (litter 348) required a Cesarean section (C-section) after the first 
three piglets were manually assisted with delivery due to uterine inertia causing dystocia. 
The C-section took place approximately 5 hours after the previous piglet was delivered (24 
hours after first milk streaming was observed). The C-section was performed by euthanizing 
the gilt and exposing the uterus to retrieve any other piglets that were present. One fully 
developed stillborn (348-04) and one mummy (348-06) were found. The sixth known piglet 
(348-05) was not found within the uterus; mummy was designated for this pig. We do not 
suspect the uterine inertia was due to the laparotomy procedures, but rather due to piglet 
malposition in the birth canal and resultant unproductive contractions. Piglets from the 348 
litter were cross fostered on sow 31-7 for the duration of the study.  
 Piglets were euthanized at 2 (litter 317) or 3 (litter 348) days of age at which point 
they were radiographed for the detection of wires. From the surgeries, we expected that 
seven of the total sixteen piglets (Table 4.2) would have wires in either the liver or IP space. 
From initial lateral and abdominal x-rays, we found a total of six piglets with wires (Table 
4.3). It is likely that the wire from the seventh piglet was lost in the uterine wall during 
injections; we do not know specifically which fetus from gilt 31-7 wire was lost from. All 
wires appeared to be in the abdominal cavity of the piglets. Mummy 348-06 was also found 
to have a wire; although due to the small size it was difficult to distinguish where the wire 
was located, so the wire location was undetermined. Additionally, because we identified all 
three injected animals in the 348 litter by finding the three contained wires, mummy 348-05 




 After initial x-rays, livers were removed from all piglets and were x-rayed separately 
for wire detection. We found that one piglet (317-01) had a wire within the liver (Figure 4.2). 
All other piglets with a wire did not have a wire in the liver, which suggested that they 
contained wire within the intraperitoneal space. Examples of piglets with wire in liver (317-
01) and IP (317-08 and 348-03) are shown in Figure 4.3. Of the seven fetuses that were 
injected with wire, based on observations during surgery, we anticipated that three of these 
fetuses were injected in the liver. After radiographing, only one piglet was found to 
successfully have been injected in the liver, while all others with wire were injected IP.  
Discussion 
Previous work is reported on the use of laparotomies for injection of human stem 
cells and human liver cells into fetal piglets 3,4,9,12,13. However, a comprehensive and detailed 
account of surgical procedures, post-operative care, as well as FL and IP aiming has not been 
previously published. Here we report the successful injection of piglets within the IP space 
after laparotomy procedures on two pregnant gilts.  
Laparotomies as alternative to abdominal injections  
 There are two primary methods for the delivery of cells into fetal piglets. One 
method involves the insertion of a needle through the abdominal wall and uterus 1, while 
the other involves laparotomy procedures to directly inject through the uterine wall 3,9,12,13. 
Although injection through the skin is less invasive to the sow, manipulation of the uterus 
aids in aiming for specific locations within the fetus. Additionally, with such proximity when 
injecting through the uterine wall, vital fetal organs can be avoided during injection. 




needle, which may cause more trauma to the fetuses; a smaller gauge needle can be used in 
laparotomies.  
 These laparotomy procedures can also be approached by making a paramammary 
incision. We chose to perform our laparotomies with a ventral midline incision for a variety 
of reasons. Such incision location allows for better exposure to both horns of the uterus, as 
opposed to the paramammary approach, in which incision would be closer to one horn than 
the other. Also, the midline incision goes through the linea alba, which can promote better 
healing as opposed to going through muscle tissue.  By covering the incision with the Ioban 
bandage and housing the animals on solid flooring without bedding, the increased risk of 
contamination with a midline incision is mitigated. As gilts were used for the surgery, the 
mammary tissue that may present a problem for midline incisions in sows was not 
encountered.   
Methods for wire detection in the abdominal cavity 
In these procedures, it was important to establish methods for wire injections so that 
injection site could be determined. We designed a copper wire plunger system for our fetal 
injections that was used in a 22G needle with a 0.25 mm diameter titanium wire. A 22G 
spinal needle with a stylet could also be used for titanium wire injections.  
In our study, we radiographed piglets after they were born as opposed to 
radiographing the pregnant gilts immediately after surgery. There may be limitations in 
radiographing gilts or sows after surgery depending on equipment available at different 
facilities. We additionally decided to radiograph piglets after birth, as this would mimic the 




surgery and the end of gestation, a total of approximately 75 days elapsed, so it is possible 
that wires could move in the fetus to a different site. Radiographs or a computerized 
tomography image could be performed on the gilt or sow after surgery, but matching 
fetuses seen in utero with farrowed piglets may be difficult. If C-sections are performed, the 
position of piglets could be matched with the location of which fetuses were injected.  
Abortion and fetal death prevention 
 Matrix (Altrenogest) has historically been used to synchronize estrous in swine. 
During pregnancy, the body naturally produces progesterone. Altrenogest is a synthetic 
progestin and can therefore be used to help maintain pregnancies that may otherwise have 
been aborted due to stress of the procedure. Altrenogest has been used as a treatment in 
dolphins 15 and mares 11 to prevent abortions.   
 During surgery it is important to limit manipulation of the fetuses and uterus. 
Additionally, numerous needle punctures should be avoided on a single fetus as to reduce 
the likelihood of blunt trauma to any internal organs. Together, these practices can help 
reduce fetal and uterine stress. We demonstrated herein that a single injection using a 22G 
needle caused minimal trauma to the fetuses, as 5/6 titanium wire-injected identified piglets 
were fully developed at gestational end.  
Biomedical model development in swine 
 In all, we aimed to develop procedures that could be utilized for cell injections into 
fetal piglets. As swine models develop, whether immunocompetent or 
immunocompromised, they will continue to be used for translational research relevant to 




human HSCs into SCID pigs for the development of a humanized model. In order to 
accomplish this task, it is critical to develop protocols that would ensure for viability of all 
pregnant females and piglets during and after surgical procedures. The descriptions outlined 
here can be used as a guideline for future research requiring laparotomies and fetal 
injections in swine.  
Materials and Methods 
All protocols and methods were approved by Iowa State University’s (ISU) 
Institutional Animal Care and Use Committee. All protocols and procedures performed were 
in accordance with The Guide for the Care and Use of Laboratory Animals. 
Animals 
 Two commercial crossbred (Yorkshire and Duroc) gilts (referred to as 31-7 and 34-8 
herein) of approximately 1 year of age were bred at a university associated facility. Gilt 31-7 
weighed 167 kg and 34-8 weighed 182 kg at the time of surgery. Gilts were pregnancy 
checked 28 days after breeding and were tested for porcine reproductive and respiratory 
syndrome virus (PRRSv) and porcine circovirus type 2 (PCV2) before being transferred to the 
ISU Laboratory Animal Research (LAR) center at gestational day 40. Both gilts were negative 
for PRRSv and PCV2 by PCR. Gilt 31-7 underwent surgery at gestational day 41, while gilt 34-
8 underwent surgery at gestational day 42.  
Gilts were housed in clean conventional housing rooms at ISU LAR after surgery and 
through the rest of gestation. Specifically, the gilts were singly housed with nose-to-nose 
contact with each other on epoxy coated flooring and mats covering part of the floor. 




dried distiller’s grains (Heartland Co-op, Prairie City, IA) with chopped straw and timothy hay 
cubes added. Rooms were maintained between 68 and 72 F. At gestational day 109 gilts 
were moved to farrowing decks, with plastisol-coated metal grate flooring; room 
temperature was increased to 73-75 F. Diet was changed from gestation to lactation 
following farrowing. Heat lamps were placed on the sides of the farrowing crates to provide 
additional warmth for the piglets. All animals were checked every 12 hours. 
Laparotomy surgery protocol  
 Pregnant gilts undergoing laparotomy procedures were started on 15 mg of Matrix 
(Altrenogest) (Merck Animal Health, Madison, NJ) in morning feed starting 1 day before 
surgery (dosage independent of weight). Both gilts were maintained on Matrix through 
gestational day 113, which was given at approximately the same time every morning. Feed 
was withheld from both animals 12 hours prior to surgery. On the morning of surgery, 
Matrix was given orally, instead of in feed.   
Prior to anesthesia, gilts were given 0.01 mg/kg Glycopyrrolate (West-Ward 
Pharmaceuticals, Eatontown, NJ) by intramuscular injection. Gilts were then anesthetized 
with 5 mg/kg Telazol (Zoetis, Parsippany, NJ) and 2mg/kg Xylazine (Akorn, Lake Forest, IL) by 
intramuscular injection. After gilts were anesthetized, hair was clipped from the lower 
abdomen, surgical site was washed, and the gilts were moved to a surgical table and placed 
in dorsal recumbency. Gilts were then intubated and started on isofluorane (2-5%) and 
oxygen (2.5 L/min). A 20G IV catheter was placed in the ear vein. Lactated Ringer’s Solution 
(Hospira, Lake Forest, IL) was administered intravenously at a constant rate infusion for a 




administered intravenously via the catheter starting within 10 minutes of the initial incision. 
A pre-surgical scrub was performed with chlorohexidine (Phoenix, St. Joseph, MO, USA). 
Sterile material drapes and Ioban (3M, Maplewood, MN) were used to cover the surgical 
field.  
 A ventral midline incision from the caudal most nipple extending cranially to the 
caudal aspect of the umbilicus through the linea alba into the peritoneal cavity was made by 
sharp dissection. The left horn was exteriorized first, fetuses were visualized by ultrasound 
and a sterile gentian violet ink marker (Medline Industries, Dubuque, IA) was used to 
physically mark the outside of the uterus for each fetus (Figure 4.1A). Every other fetus in 
the horn was injected (See following section Ultrasound guidance of injection of saline and 
wire into intraperitoneal space or fetal liver for injection specifics). The left horn was then 
replaced into the abdominal cavity. The same procedure was then performed on the right 
horn.  
 Both uterine horns and abdominal cavity were lavaged with a total of 500 mL of 
Lactated Ringer’s Solution. The abdominal cavity was closed at the linea alba in a simple 
continuous pattern (1 Polydioxanone) with an additional overlying cruciate pattern (1 
Polydioxanone). The subcutaneous tissue was closed with a simple continuous pattern (0 
Polyglycolic Acid). The skin was closed in a buried subcuticular pattern (0 Polyglycolic Acid). 
The incision was then covered with sterile gauze and was held in place with an Ioban drape. 






Ultrasound guidance of injection of saline and wire into intraperitoneal space or fetal liver 
A ZONARE ultrasound system with a L14-5sp intraoperative linear array transducer 
(10 MHz) was used to identify fetuses and guide injections. A 2 mm long titanium wire (0.25 
mm diameter) was injected into the IP or FL space by use of 22G needle and a copper wire 
plunger made from multiple copper speaker wires. Copper wire plungers were preloaded 
into 22G needles and autoclaved in sterilized pouches along pre-cut titanium wires.  
 As described above, the uterine horns were imaged using ultrasound to identify the 
number of fetuses present and were marked. Every other fetus was injected in each horn 
(Figure 4.1B). Ultrasound guidance was used to identify either the fetal liver (Figure 4.1C) or 
intraperitoneal space. Once these areas were identified, titanium wire was loaded into the 
22G needle (Figure 4.1D) with sterilized needle nosed forceps. The needle was then aimed 
for either FL or IP by keeping the needle parallel to the ultrasound transducer to allow for 
visualization. Once the needle was inserted in the proper location, the copper wire plunger 
was moved forward to push the titanium wire out and into the fetus. The copper wire was 
then removed from the needle, while keeping the needle in the same place in the fetus. A 1 
mL syringe with 0.1 mL saline was inserted into the needle and this solution was injected 
into the fetus (Figure 4.1B).  
Post-operative care of pregnant females 
After the Ioban bandage was placed over the incision, animals received 0.18 mg/kg 
Buprenophine- Sustained Release (ZooPharm, Windsor, CO) subcutaneously (SQ). 
Buprenophine is shown to reach therapeutic levels in the serum 30 minutes after 




NJ) was administered through intramuscular injection. A dose of 0.3 mg/kg of meloxicam 
(Norbrook, Overland Park, KS) was given SQ. Gilts were then removed from the surgery table 
and placed in a recovery pen with warming blankets. Rectal temperatures were taken 
approximately every 30 minutes. A total of 2.5 L of Lactated Ringer’s Solution was given via 
IV until gilts began to wake.  
 Gilts were checked every 12 hours for the 14 days following the surgery. Animals 
were monitored for evidence of adequate pain control based on attitude, appetite, 
vocalization, and locomotion. Additionally, rectal temperatures, vaginal discharge, urination, 
and defecation were recorded over this time period. For the first three days following the 
surgery, gilts were given 0.25- 0.3 mg/kg Meloxicam (rounded to the nearest half 15 mg 
tablet; 45 mg) orally in the morning. Gilts were also given 15 mg of Matrix which was 
dressed over morning feed daily until gestational day 113. The Ioban bandage was removed 
one week after surgery.  
X-ray detection of injected wires 
 Piglets from both litters were delivered at full term. Piglets nursed until 2 or 3 days of 
age and were then euthanized humanely by intravenous pentobarbital sodium (Fatal-Plus; 
Vortech Pharmaceuticals, Dearborn, MI) injection (2-4 mL per piglet). Sows were also 
euthanized with 60 mL of pentobarbital sodium administered intravenously. Piglets were 
then brought to the ISU Small Animal Clinic where lateral and dorsoventral radiographs were 
acquired for both intact piglets as well as dissected livers.  
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Figure 4.1.  Exteriorization of uterine horns for ultrasound guided injection of wire and 
saline  
 
(A) During laparotomy procedures, each horn was exteriorized to ultrasound for fetuses. 
Fetuses were marked with a water-soluble marker. (B) Ultrasound was utilized to guide 
injection of wire and saline into fetuses. (C) An ultrasound image of fetal liver. (D) A 22G 
needle was preloaded with a long copper wire plunger. A 2 mm titanium wire was placed at 
the tip of the needle. The copper wire was then used as a plunger to push the titanium wire 







Figure 4.2. Liver x-rays for wire detection.  
 
After initial body x-rays were acquired, livers were removed and x-rayed separately for 
detection of wire. The top two rows (labeled 1-10) are from litter 317. The bottom row 
(labeled 1-4) are from litter 348. Only animal 317-01, shown on the top left, contained wire 







Figure 4.3. Titanium wire detection in liver and IP space of piglets.  
 
Radiographs were acquired from farrowed piglets. Examples of piglets with wires are shown. 
Piglet 317-01 had a wire within the liver, while piglet 317-08 and 348-03 had wires within the 








Table 4.1. Drug, medication, and equipment information
Product Dose Route Purpose Company
0 Polyglactin 910 with 
Irgacare MP
Suture Ethicon, Sommerville, NJ
1 Polydioxanone Suture Ethicon, Sommerville, NJ
Buprenophine, sustained 
release
0.18 mg/kg SQ Pain relief ZooPharm, Windsor, CO








Phoenix, St Joseph, MO
Copper wire (16-gauge 
speaker wire)
RCA, New York, NY
Ceftifur, crystalline free 
acid (Excede)
5 mg/kg IM Antibiotic Zoetis, Parsippany, NJ
380 mg/mL
60 mL per sow
2-4 mL per piglet







Ioban 2 3M, Maplewood, MN
Isofluorane To effect (3% to 5%) Inhalation Anesthetic Phoenix, St. Joseph, MO










Table 4.1 Cont. Drug, medication, and equipment information
Product Dose Route Purpose Company
Lactated Ringers solution
10 mL/kg during 
surgery
IV Hydration Hospira, Lake Forest, IL
 and recovery
Matrix (altrenogest)





Merck Animal Health, Madison, NJ
Meloxicam (injectable) 0.3 mg/kg SQ Pain relief Norbrook, Overland Park, KS
45 mg/gilt daily 
 for 3 d 
postoperatively
Skin marker (gentian 
violet ink)
Medline Industries, Dubuque, IA
0.9% Sodium chloride 
(saline)
0.1 mL per injection FL, IP Hospira, Lake Forest, IL
Tiletamine–zolazepam 
(Telazol)
5 mg/kg IM Anesthetic Zoetis, Parsippany, NJ
Titanium wire (diameter, 
0.25 mm)
FL, IP Sigma Aldrich, St Louis, MO




SQ: subcutanesous, IV:intravenous, IM: intramuscular, FL: Fetal liver, IP: intraperitoneal
Meloxicam (oral) Pain reliefOral









Uterine Horn Fetus Injection location notes Uterine Horn Fetus Injection location notes
Right 1
0.1 mL saline, IP. Wire 
came out
Right 1 Not injected
2 Not injected 2 0.1 mL saline and wire, FL
3 0.1 mL saline and wire, IP 3 Not injected
4 Not injected Left 4 0.1 mL saline and wire, FL
Left 5
0.1 mL saline and wire, 
potentially FL
5 Not injected
6 Not injected 6
0.1 mL saline and wire, 
potentially IP
7 0.1 mL saline and wire, IP
8 Not injected
9 0.1 mL saline and wire, IP
10 Not injected
31-7 34-8
Table 4.2  Ultrasonographic overview of anticipated  fetal injection locations during laparotomy procedures on 








Table 4.3 Overview of piglet birth status from gilts 31-7 and 34-8
Piglet ID Status Birth Weight (kg) Wire location Piglet ID Status Birth Weight (kg) Wire location
317-01 Live 1.3 Liver 348-01 Live 1.0 -
317-02 Live 1.4 - 348-02 Live 1.5 IP
317-03 Live 1.3 - 348-03 Live 1.5 IP
317-04 Live 1.1 - 348-04 Stillborn 1.2 -
317-05 Live 1.3 - 348-05 Mummy - -
317-06 Live 1.3 - 348-06 Mummy - Undetermined
317-07 Live 1.0 IP
317-08 Live 1.2 IP
317-09 Live 1.4 -
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Abstract 
 Pigs with severe combined immunodeficiency (SCID) are an emerging biomedical 
animal model. In this work we have generated T- B- NK- SCID pigs through site directed 
CRISPR/Cas9 mutagenesis of IL2RG within a naturally occurring DCLRE1C (Artemis)-/- genetic 
background. We confirmed that Art-/- IL2RG-/Y pigs lacked T, B, and NK cells in both blood and 
lymphoid tissues. We performed a bone marrow transplant on one Art-/- IL2RG-/Y SCID pig 
and were successful in reconstitution of porcine T and NK cells. Next, we performed in utero 
(IU) injections of cultured human CD34+ cord blood cells as a route to engraft cells within the 
fetal Art-/- IL2RG-/Y SCID pigs. At birth, human CD45+ CD3+ cells were in circulation of IU 
injected piglets. Human leukocytes were engrafted within the bone marrow, spleen, liver, 
thymus, and mesenteric lymph nodes of these animals. Together, we describe the first 
publication of initial development of an immunologically humanized SCID pig model.  
Introduction 
Animals with severe combined immunodeficiency (SCID) are invaluable to human 
biomedical researchers because they allow the engraftment and study of human cells in an 
in vivo environment.  In 2012, we discovered the first SCID pigs with natural mutations1,2 
within the Artemis gene causing T- B- NK+ SCID3,4. Since then, pigs with mutations in RAG15,6, 
RAG27,8, IL2RG9–11, and RAG2/IL2RG 12 have also been generated through different 
mutagenesis approaches.  Within the past few years, such SCID pigs are now being utilized 




facilities14, isolators 12 , and c-section15 techniques have been developed to deliver and raise 
SCID pigs in clean environments for longer term studies.  An important progressive step in 
developing the SCID pig model is to immunologically humanize these animals through the 
introduction of human CD34+ stem cells. Similarities between human and porcine immune 
genes16 suggests that human immune development would be supported in vivo within the 
pig17. Development of such a model could provide researchers with a larger humanized 
animal for use in a variety of different biomedical fields including cancer13,17, HIV, and 
vaccine development research.  
The first SCID mouse was described in 198318, and was shortly thereafter humanized 
by either injection of human peripheral blood leukocytes19 or implantation of human fetal 
liver, thymus and lymph node tissue20. Humanized mouse models are still being optimized 
and improved since their conception 35 years ago. Reconstitution of human immune cell 
subsets in SCID mice often requires addition of human cytokine genes, humanization of 
resident mouse immune genes, or administration of developmental cytokines to the mice 21–
24. Humanized mice have been utilized in a variety of different biomedical fields including 
cancer, infectious disease, transplantation, and drug testing25–27. However, there are 
limitations to mouse models such as size, differences in drug metabolism, and differences in 
disease pathology compared to humans 28,29. Thus, one major goal of the SCID pig 
community is to create an immunologically humanized SCID pig model, which could be used 
in conjunction with humanized SCID mouse models to test preclinical therapeutics.  
The most commonly used strain for humanization is the non-obese diabetic (NOD)-




SIRPA gene which allows it to bind to human CD47 to transduce a “don’t eat me” signal in 
mouse myeloid cells to inhibit phagocytosis31–33. We have demonstrated that porcine SIRPA 
also binds to human CD47 to inhibit phagocytosis of human cells34, indicating that pigs may 
be as permissive to human xenografts as NOD mice. In addition to the SIRPA polymorphism 
NSG mice also have a T- B- NK- cellular phenotype. This cellular phenotype can be generated 
through mutagenesis of required genes for VDJ recombination (Artemis or RAG1/2) as well 
as IL2RG. Previous reports show that mouse NK cells negatively impact the ability of human 
cell engraftment in SCID mice30. NK cells in Art-/- SCID pigs are functional in vitro 4, and thus 
we anticipate that swine NK cells could also negatively impact human cell engraftment. In 
order to deplete NK cells in our current Art-/- SCID pig model, we mutagenized IL2RG in an 
Art-/- mutant cell line. Together, the generated pigs are similar to NSG mice in cellular 
phenotype as well as in SIRPA/CD47  dependent phagocytic tolerance34.  
Here we describe the generation of Art-/- IL2RG-/Y SCID pigs that were derived by site- 
directed CRISPR/Cas9 mutagenesis of an Art-/- fetal fibroblast cell line. Modified Art-/- IL2RG-/Y 
embryos were implanted in gilts via surgical embryo transfer. Piglets were born at full term 
and were confirmed to have the expected T- B- NK- cellular phenotype based on flow 
cytometry and immunohistochemical (IHC) analysis of blood and lymphoid organs. We next 
asked if these double mutant pigs could be humanized via the introduction of human CD34+ 
stem cells. Gestational day 41 Art-/- IL2RG-/Y fetuses were injected with human CD34+ cells 
within the intraperitoneal space via ultrasound guidance. Piglets were born via Cesarean 
section delivery at gestational day 119.  Blood and lymphoid organs from delivered piglets 




consisting of CD3+ cells, were present in blood, spleen, bone marrow, liver, and thymic 
tissue. Thus, we describe here the first steps towards the generation of humanized SCID pigs.  
Results 
Generation of Art-/- IL2RG-/Y SCID pigs by site directed CRISPR/Cas9 mutagenesis of Art-/- fetal 
fibroblasts 
 We previously described the discovery of naturally occurring Art-/- SCID pigs3, which 
we have been able to raise and breed14,35 for research purposes. We started with this 
genetic background for IL2RG site-directed mutagenesis. One goal we have with producing 
Art-/- IL2RG-/Y SCID pigs is to generate a breeding colony such that IL2RG knockout piglets 
could be derived through natural birth rather than cloning procedures. In our breeding 
protocol, this would require bone marrow transplantation of a SCID boar such that he could 
be raised to sexual maturity and bred to an Art-/+ carrier female. Mutagenizing our existing 
Art-/- line would facilitate producing SCID pigs with matching SLA (swine leukocyte antigen) 
to carrier animals within our colony. Therefore, we decided to utilize cloned Art-/- fibroblasts 
for IL2RG mutagenesis for somatic cell nuclear transfer (SCNT) to generate pigs with these 
desired genetics. Figure 5.1A shows a schematic for the process of generating Art-/- IL2RG-/Y 
piglets. 
 Art-/- pFFs that would be mutagenized were derived from an Art-/- male and Art-/+ 
mating (see Materials and Methods for information on Artemis genotypes). Gestational day 
35 fibroblasts were collected and underwent SLA testing, as well as were genotyped for Art 
status. Genotyping revealed that two male and two female cell lines were Art-/- mutants, 




 To mutagenize IL2RG, a single guide RNA (sgRNA) was designed to target exon 5 of 
IL2RG (Figure 5.1B).  We selected a male Art-/- cell line (7707-FB1) with a matching SLA 
haplotype (26.6/68.19a) to a carrier fibroblast line (7709-FB6) to transfect with the sgRNA 
Table 5.S3). After transfection, a total of 202 individual clonal colonies from the 7707-FB1 
cell line were screened using PCR and Sanger sequencing. Five (2.5 %) clonal colonies were 
confirmed to be IL2RG-/Y (hemizygous) (Table 5.S4) with a 120 bp deletion in intron 4 and 
exon 5 of the IL2RG locus, which is expected to cause a frameshift leading to an early stop 
codon.  (Figure 5.1C).  A total of 920 IL2RG-/Y Art-/- and 512 non-modified SCNT (carrier) 
derived embryos (7709-FB6) were transferred surgically into seven different recipient gilts. 
Both cell lines shared the same SLA haplotype of 26.6/68.19a. Among those transferred, four 
gilts were confirmed pregnant and two carried the piglets to full term. These two surrogates 
produced five live male piglets via cesarean section that were reared in the SCID pig bubble14 
(Table 5.S5). All five piglets were confirmed to have the 120 bp loss in IL2RG  and the 
established mutation in exon 10 of Artemis3 (Art12 allele information found in Materials and 
Methods). None of the live born piglets were derived from non-modified, carrier embryos 
(7709-FB6) that would have been used as a bone marrow donor.   
Art-/- IL2RG-/Y SCID pigs lack T, B, and NK cells in blood and lymphoid organs 
 Once Art-/- IL2RG-/Y piglets were delivered, blood was collected and analyzed by flow 
cytometry to confirm the expected T- B- NK- cellular phenotype of these animals. Forward 
and side scatter plots (FSC/SSC) show the lack of a lymphocyte population in Art-/- IL2RG-/Y 
pigs compared to Art-/- and wild type pigs (Figure 5.2A).  Peripheral blood was stained for 




cells (CD172- CD3- CD8a+) were not in circulation of Art-/- IL2RG-/Y piglets (Figure 5.2B). We 
additionally stained for CD21 to confirm there were no B cells in circulation of the Art-/- 
IL2RG-/Y pigs (Figure 5.S1). Furthermore, Art-/- IL2RG-/Y lacked a thymus and lymphoid tissue 
in the intestines, as well as had a smaller spleen than wildtype pigs (Figure 5.S2).  
 We additionally confirmed that T and B cells were absent from lymphoid tissues. 
Lymph nodes and spleens were collected from wild type (18d), Art-/-(0d), Art-/- IL2RG-/Y(18d) 
pigs for IHC analysis. Lymph node tissue was stained for CD3 and CD79α to assess for the 
presence of T, and B cells, respectively. Both Art-/- and Art-/- IL2RG-/Y pigs lacked normal T and 
B cells in lymph nodes (Figure 5.2C).   
T and NK cell reconstitution in an Art-/- IL2RG-/Y SCID pig after pig bone marrow 
transplantation 
 An additional goal with the generation of Art-/- IL2RG-/Y SCID pigs was to establish a 
male breeding line.  Carrier Art-/+ females bred with an Art-/- IL2RG-/Y BMT SCID rescued boar 
could generate litters with a mix of males and females with different Art and IL2RG 
genotypes for future studies and breeding. The original intent with performing embryo 
transfers with non-modified carrier embryos was to act as a source of bone marrow for the 
Art-/- IL2RG-/Y pigs. In our full-term pregnancies, only Art-/- IL2RG-/Y piglets were born despite 
the fact that both Art-/- IL2RG-/Y and Art-/+ embryos were transferred into the surrogate 
female, and thus we needed an alternative source of bone marrow for a BMT.  
 We therefore performed a bone marrow transplantation on one Art-/- IL2RG-/Y male 
piglet with 100% SLA bone marrow match (haplotype 26.6/68.19a) from a 4 year old sow 




from the ribs and sternum were collected and administered to one Art-/- IL2RG-/Y SCID pig. 
The piglet was not conditioned prior to the BMT, as we have had success with porcine T and 
B cell reconstitution without conditioning in Art-/- SCID pigs35. 
 Blood was collected approximately once a month after the transplant and analyzed 
by either a complete blood count (CBC) or by flow cytometric analysis. Counts from CBC 
analysis showed that white blood cells and lymphocytes increased in number every month 
after the transplant, to near normal levels by 4 months after BMT (Figure 5.2D). PBMCs were 
stained for CD3, CD8α, and CD172 to assess cell populations. Circulating T and NK cells were 
detected in circulation at 4 months of age (Figure 5.2D). We assessed if B cells had 
developed in the transplanted boar by staining with CD21 and CD79α, and we observed very 
few circulating B cells (Figure 5.S3) within 6 months after the transplant. Similar B cell 
reconstitution issues have been reported in human BMT cases with mutations in Artemis 36–
38. This BMT Art-/- IL2RG-/Y  boar is sexually mature and healthy as of 9 months of age.  
Circulating human T cells in neonatal Art-/- IL2RG-/Y piglets after in utero injection of human 
hematopoietic stem cells 
 Once we confirmed the cellular phenotype of Art-/- IL2RG-/Y pigs, we next asked if 
these pigs were capable of engrafting human CD34+. We previously attempted intravenous 
and intraosseous injection of human CD34+ cells into single mutant Art-/- piglets (T- B- NK+) 
with various cell doses and busulfan conditioning (Table 5.S6) and we saw no evidence of 
engraftment within blood or lymphoid organs after a maximum of 15 weeks post cell 
inoculation. We thus utilized an alternative approach of in utero (IU) injection of human 




During mid-gestation, the fetal liver is a site for hematopoiesis39–42. Specifically, 
between 30-45 days of gestation, the hematopoiesis occurs within the liver of fetal swine43. 
Previous reports show that injection of human CD34+ cells into the intraperitoneal space of 
pre-immunocompetent piglets and sheep leads to the differentiation and engraftment of 
human immune cells44–47. However, such injections have not been reported in pigs with 
SCID. Approaches to inject fetal piglets require laparotomy procedures to expose the uterus 
to visualize fetuses via ultrasound imaging. Thus, we utilized laparotomy surgery with 
ultrasound guided injections of human CD34+ cells into the intraperitoneal space of Art-/- 
IL2RG-/Y fetuses (Figure 5.3A) (Boettcher et al.  Comparative Medicine, in press).  Human 
CD34+ cells derived from cord blood were cultured with thrombopoietin, FLT-3L, and stem 
cell factor for the seven days prior to injection to expand the cell populations for the 
appropriate cellular dose. After culturing, cells were either CD45+CD34+ (72-76%) or CD45+ 
CD34- (24-28%) (Figure 5.S4).   
To perform fetal injections, one surrogate gilt was transplanted with 320 Art-/-    
IL2RG-/Y mutant embryos (Table 5.S7). Pregnancy was confirmed at 28 days of gestation and 
laparotomy surgery for IU injection was performed on gestational day 41. We injected half of 
the fetuses (n=6 total; 3 injected) with 2 or 4 million cultured human CD34+ stem cells. The 
gilt fully recovered from the laparotomy surgery and piglets were delivered via Cesarean 
section at gestational day 119 and a total of three piglets were born (6901, 6902, and 6903). 
Cord blood was immediately collected from the three piglets to assess if human immune 
cells were in circulation. We have tested and created panels of anti-human antibodies that 




pig and human CD45, as well as human CD47. Two of the three pigs (6901 and 6903) were 
found to have human CD45+ (Figure 5.3B), as well as human CD47+ cells in cord blood (Figure 
5.3C).  
One piglet (6901) was euthanized on day 0 due to severe cleft palate. Peripheral 
blood was collected from 6901 at day 0, while peripheral blood was collected from 6902 and 
6903 at 1 day of age and stained for human T cells (CD3, CD4, and CD8) (Figure 5.3D), B cells 
(CD20) and (Figure 5.3E), and myeloid cells (CD33) (Figure 5.3F). Red blood cells were also 
stained for human CD47 (Figure 5.3G). Nearly all of the human CD45+ cells in 6901 and 6903 
consisted of human CD3+ cells. We then stained for human CD4 and CD8α to assess if human 
T helper and cytotoxic cells developed within these pigs. Both pigs had single positive CD4 
and CD8α populations of T cells in peripheral blood (Figure 5.3D).  
Human CD45+ cell engraftment in Art-/- IL2RG-/Y bone marrow, liver, spleen, and thymic tissue 
 Since we observed that human cells were in circulation, we next assessed if human 
immune cells engrafted within lymphoid organs. Interestingly, during necropsy, we observed 
grossly visible mesenteric lymph nodes in 6901 and 6903, but not 6902. Additionally, all 
three pigs had some remnant, immature thymic tissue present over the heart (Figure 5.S6), 
which was collected for analysis. Of the tissues collected, cells were isolated from bone 
marrow, liver, spleen, and thymic tissue for flow cytometric analysis. Whole cell suspensions 
were stained from bone marrow and thymus, while mononuclear cells were stained from 
liver and spleen. Human CD45+ cells were found in all four tissue types in 6901 and 6903, 




thymic tissue cells from these two animals were human cells. Animal 6902 did not have any 
human cells in any lymphoid organs.  
 Since a majority of the human cells we observed in these pigs were CD3+, we were 
interested in assessing the expression of CD4 and CD8α within the thymic tissue cells.  T cells 
that are early in their stage of development express both CD4 and CD8. In animal 6901, we 
observed that thymic hCD45+ hCD3+ cells were either CD4+ CD8α- or CD4- CD8α-, while in 
6903 they appeared to be CD4- CD8α- (Figure 5.4B).  
 In addition to flow cytometric analysis of cells within lymphoid tissues, we also 
analyzed tissues via IHC analysis. We collected lymphoid tissues and assessed for the 
presence of human T and B cells in the in utero injected piglets. Thymic tissue, spleen, ileum, 
and mesenteric lymph nodes from both 6901 and 6903 had CD3+ cells (Figure 5.5A). Spleens 
from both 6901 and 6903 also had punctate Pax5+ cells present. A mesenteric lymph node 
from 6901 also had Pax5+ cells (Figure 5.5B). Tissues from 6902 did not stain positively for 
either CD3 or Pax5. These histology results are consistent with the flow cytometric analyses 
in showing that human leukocytes engrafted within the Art-/- IL2RG-/Y SCID pig lymphoid 
tissues.  
Discussion 
 Herein we have described the first steps towards the development of 
immunologically humanized large animal SCID model. To create this model, we introduced a 
mutation into the IL2RG gene by CRISPR/Cas9 site directed mutagenesis into a naturally 
occurring Art-/- SCID background to generate Art-/- IL2RG-/Y pigs that lacked T, B, and NK cells. 




successful reconstitution of graft T and NK cells, but very few B cells.   Next, we utilized IU 
injection procedures to introduce human hematopoietic stem cells into the IP space of SCID 
pig fetuses. We observed that human CD3+ cells were present in bone marrow, spleen, liver, 
and thymic tissue in injected pigs after birth. Human Pax5+ cells were also present within the 
spleen and mesenteric lymph nodes of injected pigs. Protocols described here can be utilized 
to improve engraftment efficiency within SCID pig models in the future.  
Further human immune cell characterization of SCID pigs 
 Presently, there have been few studies that have probed for engraftment potential of 
human cells within pigs. Previous studies primarily utilized PCR to detect human cell types in 
circulation44,47. To probe for these human cell types by other methods (flow cytometry and 
immunohistochemistry), antibody-based tools need to be developed and validated to 
confirm the host species of cell type that is being detected. In developing this initial human 
immune engraftment model in SCID pigs, we have described a set of non-cross reactive 
antibodies that are specific for human antigens in flow cytometry (Table 5.1 and Figure 
5.S5).  
 An additional method for detecting human cells within the SCID pig lymphoid organs 
is immunohistochemistry. This method would allow us to have a secondary method for the 
detection of human cells, as well as give additional information on how the human cells are 
localized within the tissues. One of the issues that arises during IHC analysis is that during 
sample preparation of formalin fixed paraffin embedded tissues is that the antigen retrieval 
process can make antigens less specific when trying to stain for species specific antigens. 




on the specific marker) may recognize antigens that are present in both human and pig 
proteins, and thus results are not informative on human engraftment.  For example, human 
and pig share 62% identical amino acids in their CD3ε subunit. Therefore, a single antibody 
clone may bind to epitopes on both human and pig CD3ε after protein denaturation. 
Because we are working with SCID pigs, which lack porcine CD3+ cells, utilizing an antibody 
that cross reacts with human and porcine CD3+ lymphocytes may still be an option to use for 
interrogating the presence of human cells in SCID pigs. Hence, it is important to have both 
flow cytometry, as well as IHC data to show species specificity of the antigen being stained.   
 Outlooks on B cell reconstitution in Art-/- ILR2G-/Y SCID pigs 
 One issue that arose in both the pig to pig BMT, as well as IU injection of human 
HSCs, was the failure of pig and human B cells to robustly develop. Historically, some human 
SCID patients that have undergone BMT have also failed to develop graft derived B cells36. In 
some cases, significant B cell reconstitution in human BMT can take up to two years 48,49. 
One leading hypothesis as to why there are B cell development issues is due to lack of 
physical space in the B cell niche in the bone marrow. Single mutant IL2RG pigs develop B 
cells that are detected in circulation9,10, although they are non-functional due to the absence 
of T helper cells. Mutations in Artemis lead to a B cell block of differentiation at the pre-B cell 
phase 50. Together, an Art-/- Il2RG-/Y pig likely still has these premature B cells present in the 
bone marrow, which would prevent further engraftment and differentiation of graft stem 
cells in this niche. Conditioning before stem cell transplantation has helped improve B cell 
reconstitution in some cases51, although such conditioning procedures would be difficult for 




 Another important factor for B cell development is the microflora of the host 
organism. Recent research shows that the gut microflora contributes to the last phases of B 
cell development52. Our current SCID pig housing protocols require that pigs are raised in 
biocontainment facilities to reduce the incidence of pathogen exposure and disease. Such 
rearing conditions prevents the colonization of normal flora in these animals that may be 
required for B cell development. Further studies are needed to determine the specific 
microflora that Art-/- IL2RG-/Y SCID pigs may need for B cell development after either pig to 
pig BMT or transplantation of human stem cells.    
Improving human cell engraftment in SCID pigs  
 One surprising finding was that we did not find human myeloid cells, as has 
previously been reported in past IU injections in immunocompetent pig fetuses47. In this 
initial model, we only probed for myeloid cells during the first 7 days of life. In earlier studies 
44, myeloid lineage had been assessed at 40 days post injection (80 days of gestation). It may 
be possible that human myeloid cells are transient during gestation in this fetal injection 
model. Further investigation will be needed to improve human myeloid reconstitution in 
neonatal Art-/- IL2RG-/Y SCID pigs. 
 In the process of in vitro CD34+ cell culturing with SCF, TPO, and FLT-3L, some cells 
may lose their stemness, which could contribute to the lack of a variety of cells that 
differentiated within our SCID pig model. In mouse models, genetic modifications of CSF-1, 
IL-15, GM-CSF, Flt-3L, IL-3, and TPO and others have been required to attain human myeloid 
and NK cell engraftment21,23,53–56. Humanization of certain cytokine genes may be required in 




and porcine cytokines can be a first-line screen for assessing porcine cytokine cross 
reactivity.  
 Another potential method to increase engraftment is to condition the fetuses prior to 
human cell injection. Plerixafor, a drug that mobilizes stem cells out of the bone marrow57, 
has previously been utilized in IU injections of human cells into sheep fetuses to improve 
engraftment of human cells58. Plerixafor is an agonist for CXCL12 on stromal cells, which 
binds to CXCR4 on HSC57. Administration of plerixafor mobilizes sheep HSC out of the bone 
marrow such that there are more available niches to human HSC to engraft.  Goodrich et al. 
(2014) described that the administration of plerixafor along with administering a CD34+ 
CXCR4+ human stem cells and mesenchymal stem cells improved from 2.80% chimerism (in 
peripheral blood) to 8.77% chimerism 5 weeks after transplantation. Now that T- B- NK- SCID 
pigs and biocontainment facilities are available, a similar regimen could be administered to 
SCID pig fetuses prior to IU injection with human stem cells. In addition, the same human 
stem cell line could be re-injected into piglets after birth. 
Concluding remarks 
 As the field of biomedical SCID pig research expands, new techniques will arise to 
optimize human cell engraftment within this model. We can draw from previous large 
animal IU injection protocols44–47,58,59, as well as humanization techniques performed in 
immunocompromised mice 60,61. In this model we show that human T and B cells develop. If 
we can improve reconstitution of human cell subsets, the humanized SCID pig can be an 





Materials and Methods 
Ethics statement 
 All animal protocols were approved by Iowa State University’s Institutional Animal 
Care and Use Committee. All animals were utilized in accordance with the USDA guide to 
large animal requirements in the Animal Welfare Act.  All human sample collection protocols 
were approved by Iowa State University’s Institutional Review Board.  
Establishment of porcine fetal fibroblast cell lines with Art-/- genetic background 
 Our population of SCID pigs have two natural mutations in two separate Artemis 
alleles, termed Art12 and Art16. The Art12 allele contains a nonsense mutation in exon 10, 
and the Art16 allele contains a splice site mutation in intron 83.  Frozen semen from a bone 
marrow transplanted (BMT) rescued Art12/16 35 boar was utilized to artificially inseminate 
two Art carrier sows. The sows were sacrificed at day 35 of gestation and fetuses were 
collected in a sterile manner to obtain fetal fibroblasts (pFF) as described previously62. 
Briefly, minced tissue from each fetus was digested in 20 ml of digestion media (Dulbecco-
modified Eagle medium [DMEM] containing L-glutamine and 1 g/L D-glucose [Cellgro] 
supplemented with 200 units/ml collagenase and 25 Kunitz units/ml DNaseI) for 5 h at 
38.5℃. After digestion, pFF cells were washed in sterile PBS and cultured in DMEM 
supplemented with 15% fetal bovine serum (FBS) and 40 μg/ml gentamicin. Upon reaching 
100% confluence, the pFF cells were trypsinized, frozen in FBS with 10% dimethyl sulfoxide 
(DMSO) and stored long-term in liquid nitrogen. Simultaneously, cellular DNA was sent to 




SRY and Artemis primers (Table 5.S1) were utilized to identify pFF sex and Artemis 
genotype3.  
CRISPR/Cas plasmid and sgRNA product 
 Guide RNAs targeting exon 5 of IL2RG were designed utilizing software available from 
Zhang Lab (https://zlab.bio/guide-design-resources). The sequence of the designed sgRNA is:  
5’-GGCCACTATCTATTCTCTGAAGG-3’; the bold font identifies the PAM site. The sgRNA oligos 
were annealed and ligated into the human codon-optimized SpCas9 expression plasmid 
(pX330; Addgene plasmid # 42230) as described previously63. We only transfected male 
Art12/12 cell lines (herein referred to as Art-/-). 
Identification of off-target sequences 
 To identify putative off-target sequences for the CRISPR/Cas9 mutagenesis used in 
Art-/- IL2RG-/Y piglets, bioinformatics tools (http://www.rgenome.net/cas-offinder/) were 
used to identify potential off-target sequences. Ten potential off-target sites were identified, 
and primers for the off-target positions were designed. Genomic DNA was obtained from ear 
notches of Art-/- IL2RG-/Y pigs were used as template in a PCR amplifying the potential off-
target regions. Primers and gene information for this purpose are shown in Table 5.S2. DNA 
sequencing results revealed that no mutations occurred in any of the potential off-target 
positions. 
Establishment of transfected clonal colonies and identification of IL2RG mutagenesis 
 Male Art-/- pFFs were used for cell transfection in this study as described in Whitworth 
et al64. Briefly, pFFs were cultured in 75cm2 flasks to reach 90% confluency, trypsinized, and 




Opti-MEM and 75% cytosalts [120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4; pH 7.6, 5 mM 
MgCl2]) and were prepared for transfection. A mixture of 1μg sgRNA ligated vector and 200 
μL of cell suspension in electroporation buffer was then transferred into 2 mm gap cuvettes 
(Fisher Sci, 9104-6050), and exposed to three- 1 msec square-wave pulses at 250 V, using the 
BTX Electro Cell Manipulator (Harvard Apparatus). Transfected cells were then diluted, and 
80-200 cells were plated in 100 mm culture dishes to obtain distinct clonal cell colonies and 
maintained at 38.5oC in 5% CO2. After 10-12 days in culture, cell colonies were delineated 
using cloning cylinders and picked for clonal colony propagation and DNA sequencing. 
Primers (Table 5.S1) flanking the IL2RG exon 5 target region were utilized to test clonal 
colonies and PCR products thus obtained were purified by ExoSAP-IT PCR product Cleanup kit 
(Affymetrix Inc, Thermo Fisher Scientific). Mutant PCR products were cloned into PCR2.1 
vectors (Life Technologies) and transformed into E.coli DH5-α maximum competent cells (Life 
Technologies). Ten colonies were chosen and DNA from these samples were sent to the Iowa 
State University DNA Facility for sequencing. Sequences were aligned by Bio-Edit software 
(Ibis Biosciences, Carlsbad, CA, USA) for comparison with wild-type alleles, to identify cell 
lines with the appropriate mutations in IL2RG on the Art-/- background.  
Double mutant embryo production and surgical embryo transfer 
 Oocytes from sow source (DeSoto Biosciences, Inc.) or from gilt ovaries (Pineridge 
abattoir) were utilized for in vitro maturation (IVM) as previously described 65,66. Briefly, sow-
derived oocytes were shipped overnight in maturation medium (TCM-199 with 2.9 mM 
HEPES, 5μg/mL insulin, 10 ng/mL epidermal growth factor, 0.5μg/mL porcine follicle 




25 ng/mL gentamicin) and transferred into fresh medium after 22 h. Following IVM, cumulus-
oocyte-complexes (COC) were vortexed for 3 minutes in 0.1% hyaluronidase in TCM199 with 
HEPES to obtain denuded oocytes. Metaphase II (MII) oocytes, identified by the presence of 
an extruded polar body, were placed in manipulation medium (TCM199 with HEPES 
supplemented with 7 μg/mL cytochalasin B) and used thereafter for somatic cell nuclear 
transfer (SCNT). The extruded polar body along with a portion of the adjacent cytoplasm, 
presumably containing the MⅡ plate, was removed, and a donor nucleus of the appropriate 
Art-/- IL2RG-/Y genotype was placed in the perivitelline space by using a thin glass capillary. 
The reconstructed embryos were then placed in a fusion medium (0.3 M mannitol, 0.1 mM 
CaCl2, 0.1 mM MgCl2, and 0.5 mM HEPES) and exposed to two DC pulses (1-sec interval) at 
1.2 kV/cm for 30 μsec using a BTX Electro Cell Manipulator (Harvard Apparatus). After fusion, 
these embryos were activated in embryo activation medium (10 μg/mL cytochalasin B) for 4 
h. After chemical activation, cloned zygotes were treated with 500 mM Scriptaid for 12-14 h 
and then cultured in porcine zygote medium 3 (PZM-3) until embryo transfer. Embryos thus 
produced over two days were then surgically transferred into the ampullary-isthmic junction 
of the oviduct of the surrogate on day 1-2 post estrus. Pregnancies were confirmed by 
ultrasound 28-30 days following embryo transfer. 
 C-section and rearing of Art-/-IL2RG-/Y SCID pigs 
 At gestational day 119, pregnant gilts underwent Cesarean sections. Briefly, lidocaine 
patches were placed on both ears and the epidural site. Initial anesthesia was induced with 
either an epidural of propofol (0.83-1.66 mg/kg) or intramuscular injection of Ketamine (1-2 




An abdominal incision was made to expose and remove the uterus. After removal, the 
uterus was immediately rinsed in chlorohexidine and then surgically opened to remove the 
piglets. All piglets had their cords clamped before being immediately placed into sterile 
polystyrene boxes and delivered into biocontainment facilities14. All piglets were fed 250 mL 
of pasteurized porcine colostrum within the first 24 hours of life. Piglets derived from the gilt 
that underwent laparotomy procedures for human stem cell injection (see below) did not 
receive colostrum.  
Genotyping of neonatal Art-/- IL2RG-/Y pigs 
 After birth, DNA was isolated from ear notch tissues and was subjected to genotyping 
for Art and IL2RG status using primers and protocols described in Table 5.S1.  
Flow cytometry staining for Art-/- IL2RG-/Y pig characterization and bone marrow engraftment 
monitoring 
 Whole blood or cord blood from newborn Art-/- IL2RG-/Y was collected into an EDTA 
blood collection tube. Whole blood was stained for porcine CD3, CD8α, and CD172 to assess 
the presence of porcine T and NK cells. Cells were additionally stained for CD21 to assess the 
presence of B cells (Figure 5.S1). Blood from the Art-/- IL2RG-/Y BMT was also stained for CD79 
to assess B cell reconstitution (Figure 5.S3). Additional information about antibodies used 
can be found in Table 5.1.  
 Blood was collected from the bone marrow transplanted boar approximately once a 
month after the BMT. Blood was subjected to either a complete blood count (CBC) at Iowa 




antibodies as listed above. All samples were run on a custom BD LSR II and data was 
analyzed using Flowjo (Tree Star).  
Pig bone marrow isolation and bone marrow transplantation 
 A 100% SLA matched female sow of approximately 4 years of age was euthanized as 
a bone marrow donor for one Art-/- IL2RG-/Y piglet. Briefly, the sternum and ribs were 
collected from the animal and dipped in 70% ethanol. A sterilized Dremel tool was used to 
make holes halfway through the bone to loosen bone marrow. Sterilized Spratt Brun bone 
curettes were used to scrape marrow from the bone. HBSS (without phenol red) was used to 
flush the bone marrow to collect cells; any other loosened marrow was also placed in HBSS. 
After marrow isolation, the suspension was washed in HBSS. The cells were resuspended in 
ACK lysing solution (Lonza) for ten minutes at room temperature. The suspension was 
washed in HBSS and filtered through a 70 μm cell strainer. A total of 227.5 million 
unfractionated cells were isolated and resuspended in approximately 3 mL of HBSS for 
infusion.  
 To infuse marrow into the Art-/- IL2RG-/Y donor, the five-day old SCID piglet was 
anesthetized and maintained on isoflurane gas through the procedure. A catheter was 
placed in an ear vein and the cell suspension was infused. After infusion, personnel 
monitored the piglet until awake.   
Immunohistochemistry of human and porcine immune markers 
 Lymphoid organs were collected into 3.7% formaldehyde in 1X PBS for 24 hours. 
Tissues were then moved to 70% ethanol until processing. Immunohistochemical (IHC) 




performed in paraffin-embedded tissue thin sections at Kansas State Veterinary Diagnostic 
Laboratory (KSVDL). Briefly, deparaffinized slide-mounted thin sections were pre-treated for 
5 minutes with a peroxide block, followed by incubation with primary antibody. A mouse 
monoclonal anti-CD3 (clone LN10, Leica Biosystems) was used to stain for pig T cells, while a 
mouse monoclonal anti-CD79α (clone HM57, Abcam) was used to stain for B cells. Primary 
antibodies were incubated with PowerVision Poly-HRP anti-mouse IgG at room temperature 
for 25 minutes with DAB chromagen, and then counterstained with hematoxylin.  
 Lymphoid tissues from SCID pigs engrafted with human cells were treated similarly as 
above. Staining was performed at Michigan State University’s Department of Pathobiology 
and Diagnostic Investigation.  Tissues were stained for anti-CD3 (Dako #A0452) and anti-Pax5 
(Ventana clone 24) to assess for the presence of human T and B cells, respectively. Briefly, 
CD3 staining was performed by antigen retrieval with standard ER1 retrieval for 20 minutes, 
and tissues were analyzed on a BondMax for the detection of DAB chromagen. For Pax5 
staining, antigen retrieval was performed with standard CC1 retrieval for 64 minutes, and 
tissues were analyzed on a Discovery Ultra AP for ultrared detection.  
Human hematopoietic stem cell isolation from cord blood 
 Human cord blood was collected at Mary Greeley Hospital into 50 mL conical tubes 
containing 8 mL of anticoagulant citrate dextrose solution (38 mM citric acid, 85.25 mM 
sodium citrate, 136 mM dextrose). Mononuclear cells (MNCs) were isolated from cord blood 
by diluting blood 1:2 in HBSS and then layering over Ficoll-Paque. Buffy coats were collected 
and washed in HBSS. Prior to stem cell isolation, MNCs were resuspended in an isolation 




To isolate human CD34+ cells, we used a CD34 MicroBead kit from Miltenyi Biotech. 
Briefly, MNCs were incubated in iHBSS with CD34 microbeads and FcR blocking reagent for 
30 minutes at 4˚ C on a rocker. After incubation period, cells were washed in iHBSS. Cells 
were then passed through an LS column in a Miltenyi magnet to capture human CD34+ cells. 
The column was then removed from the magnet and cells were flushed. Cells were washed 
once more in HBSS. Cells were frozen in 10% DMSO and 90% FBS at -80˚ C until use. 
Human HSC thawing, culturing, and preparation for fetal injection 
 Human CD34+ cells were thawed by diluting into complete RPMI media (10% FBS, 2 
mM glutamine, 50μg/mL gentamicin, and 10 mM HEPES).  Cells were cultured in Miltenyi 
StemMACS media containing Thrombopoietin (TPO), Stem Cell Factor (SCF), and Flt3-Ligand 
(FLT-3L) at starting concentrations of 38-42 x 103 cells/mL. Cells were left in culture for 7 
days to expand. After culturing, cells were prepared for injection by washing three times in 
phosphate buffered saline. After washing, stem cells were resuspended at a concentration of 
26.6 x 106 cells/mL. A total of 150 μl of cell suspension with either 2 or 4 x 106 cells were 
administered to the fetuses in 0.9% saline. 
Laparotomy procedure for fetal injection of human stem cells 
 Laparotomy procedures were performed as described in Boettcher et al. (2019, 
Comparative Med, In press).  Briefly, the gilt was started on 15 mg of Matrix orally one day 
before surgery; she was maintained on Matrix until gestational day 118. Immediately prior 
to sedation, the gilt was given 0.01 mg/kg Glycopyrrolate by intramuscular injection. The gilt 
was anesthetized with 2 mg/kg Xylazine and 5 mg/kg Telazol by intramuscular injection. The 




oxygen (2.5 L/min). Lactated Ringer’s solution was given in an ear catheter at a constant rate 
infusion within 10 minutes of the first incision. The abdominal area was scrubbed with 
chlorohexidine and the surgical field was covered with sterile drapes and Ioban drapes.  
 A ventral midline incision was made from the caudal most nipple extending to the 
caudal aspect of the umbilicus through the linea alba into the peritoneal cavity. The left 
uterine horn was removed and was visualized with a ZONARE ultrasound with an L14-5sp 
intraoperative linear array transducer (10 MHz). Two live and one nonviable fetus were 
visualized in the left horn; one was injected with 4 million cultured human stem cells in a 
volume of 0.15 mL within the intraperitoneal space. The left horn was placed back into the 
abdominal cavity, and the right horn was removed. The right horn was visualized, and three 
fetuses were observed. One was injected with 2 million human stem cells, while one other 
was injected with 4 million human cells within the intraperitoneal space. In total, three out 
of the five viable fetuses were injected. The abdominal cavity was lavaged with 500 mL of 
Lactated Ringer’s solution prior to being sutured closed. The gilt then received 0.18 mg/kg 
Buprenophine- Sustained Release subcutaneously, 5 mg/kg Ceftiofur Crystalline Free Acid 
(Excede), and 0.3 mg/kg of meloxicam. The gilt was monitored by personnel until recovered 
from anesthesia. The gilt recovered from the laparotomy surgery with no issues. The gilt 
underwent a Cesarean section at day 119 of gestation (see above).  
 At the time of Cesarean section, we observed that there were two live piglets within 
the left horn and one live piglet in the right horn of the uterus. During the laparotomy, we 
observed two viable fetuses in the left horn; one was injected, and one was not, and relative 




identify the two developed piglets in the left horn as injected (6901) and non-injected 
(6902). In the right horn, there were originally three viable fetuses, but only one piglet 
survived to term. After flow cytometric analysis, we confirmed that there were human cells 
present and that this piglet was injected (6903).  
Flow cytometry analysis for human cells in Art-/- IL2RG-/Y pig blood 
 Peripheral or cord blood was collected from piglets into EDTA blood containers.  
Whole blood was stained with antibodies against human and pig cell subset markers (Table 
5.1). Each staining step was incubated for 15 minutes at 4˚C and washed with 1X PBS with 
0.1% sodium azide. Red blood cells were lysed with ammonium chloride lysing solution. Cells 
were fixed in 2% formaldehyde in 1X PBS and data was acquired on a FACs Canto II flow 
cytometer and data was analyzed using FlowJo (Treestar). 
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Figure 5.1. Use of CRISPR/Cas9 system to generate Art-/- IL2RG-/Y SCID pigs.  
 
(A) Semen from an Art-/- boar was used to inseminate Art-/+ carrier sows. Two pregnant sows 
were euthanized at 35 days of gestation and fetal fibroblasts were collected. Collected Art-/- 
fetal fibroblasts were electroporated with PX330 plasmid with sgRNA against IL2RG target 
site, generating Art-/-IL2RG-/Y mutant fetal fibroblasts (pFF). Once the mutant pFFs lines were 
established, somatic cell nuclear transfer was performed, and embryos were transferred into 
surrogate gilts. Piglets born from these litters were delivered via Cesarean section at 
gestational day 119 and were delivered into biocontainment facilities.  (B) SgRNA design to 
target IL2RG exon 3. Sequence in blue indicates designed gRNA, letters in red reflect PAM 
sequence (NGG), and arrows indicate the location of primers used to genotype embryos and 
piglets. (C) Genotype of IL2RG mutation in pFF and cloned pig.  Blue letters indicate deleted 
nucleotide sequence in pFF and cloned pig. Red dashes indicate deletion of nucleotides. 











Figure 5.2. Art-/- IL2RG-/Y SCID pigs lack T, B, and NK cells in peripheral blood and lymphoid 
organs and T cells can be reconstituted after pig to pig bone marrow transplantation  
(A) Flow cytometric analysis of major leukocyte populations in wildtype, Art-/-, and Art-/- 
IL2RG-/Y pigs. Percentages for granulocytes (G), monocytes (M), and lymphocytes (L) are 
shown for each type of pig. (B)  Mononuclear populations were gated from each sample and 
assessed for presence of monocytes (CD172+ CD3- CD8-), T cells (CD172- CD3+ CD8-/+), and NK 
cells (CD172-CD3- CD8+). CD172 expression was assessed first, then CD172- populations were 
assessed for expression of CD3 and CD8.  Art-/- IL2RG -/Y pigs lack T and NK cells. (C) Lymph 
nodes were collected and assessed for T cells (CD3) and B cells (CD79α). (D) One Art-/- IL2RG-
/Y SCID piglet underwent a bone marrow transplant. At 4 months post transplantation, MNC 
were stained for CD172, CD3, and CD8 to assess for donor T and NK cells (left). Complete 
blood counts were also performed throughout a four month period (right). White blood cell 











Figure 5.3. Human leukocytes in Art-/- IL2RG-/Y SCID pig cord and peripheral blood after in 
utero injection of human cells. 
(A) Art-/- IL2RG-/Y embryos were surgically transferred into a surrogate gilt. At gestational day 
41, the pregnant gilt underwent a laparotomy procedure to expose the uterus. Ultrasound 
guidance was utilized to inject human CD34+ stem cells into the intraperitoneal space of fetal 
piglets. After surgery, gilts underwent C-section at gestational day 119 and piglets were 
delivered into biocontainment facilities. (B) Blood was collected from a human and three 
neonatal (6901, 6902, and 6903) SCID pigs and stained for human and pig CD45, as well as 
human CD47. All cells in circulation were gated from SCID pigs. Pigs 6901 and 6903 both had 
human cells in cord blood, as shown by presence of hCD45+ and hCD47+ cells. (C, D, E, F) 
Peripheral blood was collected from 6901 (day 0), 6902, and 6903 (Day 1) and stained for 
various human immune cell markers. Whole human blood was stained as a control to show 
gating strategy. All cells in circulation were gated from SCID pigs, while only lymphocytes and 
monocytes were gated from the human sample, for the analysis of T, B, and myeloid cells. 
RBC were also stained separately for human CD47.  (C) Presence of human T cells were 
assessed by staining for human CD45, CD3, CD4, and CD8. CD3+ cells (left) were then 
assessed for CD4 and CD8α expression (right). Human T cells were present in both 6901 and 
6903. Single positive CD4+ and CD8+ cells were also present. (D) Human B cells were assessed 
by staining for hCD45 and CD20. B cells were not present in any pigs (E) Human myeloid cells 
were assessed by staining for hCD45 and hCD33. Myeloid cells were not present in any pigs. 
(F) RBCs were stained for CD47 expression to determine if human erythroid lineage 






















Figure 5.4. Human leukocyte engraftment in bone marrow, liver, spleen, and thymic tissue 
of in utero injected Art -/- IL2RG -/Y SCID pigs. 
(A) Lymphoid organs from 0 day old (6901) or 7 day old (6902 and 6903) SCID pigs were 
analyzed for the presence of human leukocytes by staining with human and pig CD45. Bone 
marrow liver, spleen, and thymic tissue from 6901 and 6903 both contained human CD45+ 
cells. All cells from isolated bone marrow and thymic tissue were stained, while 
mononuclear cells from spleen and liver were stained.  (B) Human CD45+ cells in isolated 
cells from thymic tissue expressed human CD3. Black histogram is gated on hCD45+ cells, 
while grey is hCD45- cells. Human CD4 and CD8α expression was assessed on human CD3+ 













Figure 5.5. Human CD3+ and Pax5+ cells in lymphoid organs of in utero injected Art -/- IL2RG 
-/Y SCID pigs 
Lymphoid tissues were collected and stained for (A) CD3 and (B) Pax5. (A) Thymic tissues 
from 6901 and 6903 were robustly populated with CD3+ cells, and CD3+ cells were also 
present in periarteriolar sheaths within the spleen. The ileum tissue from both animals had 
punctate CD3+ cells (black arrows); CD3+ cells were also present within mesenteric lymph 
nodes (LN). Lymphoid tissues from 6902 did not contain CD3+ cells. (B) Spleen from both 
6901 and 6903 had punctate Pax5+ cells. Only the mesenteric LN in 6901 had Pax5+ cells. No 






Purpose Marker Clone Fluorophore Company
pCD3 BB23-8E6-8C8 PE-Cy7 BD Bioscience
pCD8α 76-2-11 PE BD Bioscience
pCD172 72-22-15A FITC BioRad
pCD16 G7 x BioRad
anti ms IgG1 RMG-1-1 BV421 BioLegend
pCD21 BB6-11C9.6 Alexa Fluor 647 Southern Biotech
hCD79α HM47 PE Invitrogen
pCD45 LS-C127705 FITC LSBio
hCD45-biotin HI30 x eBioscience
SA-PeCy5 x PE-Cy5 BD Bioscience
hCD20 2H7 PE BioLegend
hCD3 UCHT1 X BioLegend
Anti ms IgG1/IgG2a BV421 BD Bioscience
hCD56 B159 PE-Cy7 BD Bioscience
hCD33 WM53 PE BioLegend
hCD11b ICRF44 PE-Cy7 BioLegend
hCD4 RPA-T4 PE-Cy7 BioLegend
hCD8a HIT8a PE BioLegend
hCD15 H198 PE Invitrogen
hCD34 AC136 APC Miltenyi
hCD47 B6H12 x eBioscience

















































Figure 5.S1. B cells are absent in Art-/- IL2RG-/Y pigs.  
Whole blood was stained for CD3 and CD21 from a wildtype, Art-/- and Art-/- IL2RG-/Y pigs.   
Art-/- pigs lack B cells, although they have a “leaky” T cell phenotype. Art-/- IL2RG-/Y pigs do 

















Figure 5.S2. Lymphoid organs from wildtype and Art-/- IL2RG-/Y pigs. 
 Art-/- IL2RG-/Y pigs lack a thymus, have an atrophied spleen, as well as lack mesenteric lymph 















Figure 5.S3. Decreased engraftment and differentiation of B cells in an Art-/- IL2RG-/Y SCID 
pig 5 months post bone marrow transplant. 
 
Whole blood was collected from a wildtype and BMT Art-/- IL2RG-/Y SCID pig and stained for 
CD3, CD79α, and CD21. Lymphocytes were gated and first assessed for expression of CD3. 
The CD3 negative population was then assessed for expression of CD21 and CD79α. The BMT 











Figure 5.S4. Human CD45 and CD34 expression on IU injected stem cells.  
Human CD34+ stem cells were isolated from cord blood and cultured for 7 days prior to in 
utero injections with FLT-3L, stem cell factor, and thrombopoietin. Piglet 6901 was injected 
with cultured stem cells from Cord 1, while piglet 6903 was injected with stem cells from 















Figure 5.S5. Species specific antibodies utilized to detect human cells in IU injected SCID 
pigs.   
 
Whole blood was collected from a human and a wild type pig and stained for a variety of 
markers found in lymphoid, myeloid, and granulocytes. Markers and clones are labeled 
above; specific antibody information can be found in Table 5.1. All cells were gated for the 
analysis of pCD45, hCD45, and hCD47. Only monocytes were gated for the analysis of hCD33 
and hCD11b. Only granulocytes were gated for the analysis of hCD15. Only lymphocytes 












Figure 5.S6. Gross visualization of mesentery and remnant thymic tissue of 
Art-/- IL2RG-/Y pigs that underwent IU injection of human cells.  
 
Pigs 6901 and 6903 were found to have circulating human leukocytes, while 6902 did not. 
Some remnant thymic tissue is present on all pigs; 6903 appears to have slightly more. Pigs 
6901 and 6903 have lymph node structures present in the mesentery, while 6902 does not. 



















94˚C for 5 min, 30 cycles of 94˚ for 30s, 
60˚C for 30 s, and 72˚C for 35 s, followed 
by 72˚C for 5 minutes
95˚C for 5 min, 38 cycles of 94˚ for 30s, 
58˚C for 30 s, and 72˚C for 30 s, followed 
by 72˚C for 5 minutes
Figure 5.S1 Primers used for genotyping fetal fibroblast lines and cloned piglets
95˚C for 2 min, 38 cycles of 94˚ for 30s, 
54˚C for 30 s, and 72˚C for 30 s, followed 
by 72˚C for 5 minutes
95˚C for 2 min, 38 cycles of 94˚ for 30s, 
54˚C for 30 s, and 72˚C for 30 s, followed 













Table 5.S2. Primers used to test potential off-target mutagenesis
Potential 
target 












































































































Table 5.S3. Artemis genotype and MHC information  for pFF cell lines
Fibroblast ID Sex Genotype MHC Additional Information
7709-FB1 M 16/+ 26.6/68.19a
7709-FB2 M 12/+ 35.12a/68.19a
7709-FB3 F 12/+ 26.6/68.19a
7709-FB4 F 12/12 26.6/35.12a
7709-FB5 F 12/12 26.6/35.12a
7709-FB6 M 16/+ 26.6/68.19a Anticipated SLA donor
7709-FB7 F 12/+ 26.6/68.19a
7707-FB1 M 12/12 26.6/68.19a Mutagenized line
7707-FB2 M 12/16 26.6/68.19a
7707-FB3 F 12/+ 35.12a/68.19a
7707-FB4 M 12/+ 35.12a/68.19a
7707-FB5 M 12/+ 35.12a/35.12a



















 (Mutated colony/tested colonies)
Art
 -/- Male 5/202 (2.5%)
Cell Genotype Sex
Table 5.S4. The efficiency of CRISPR/Cas9-mediated IL2RG 
































at day 30 
No. (%) of 
term 
pregnancies








Table 5.S5. Somatic cell nuclear transfer results in embryos for transfer to fertile recipients





























conditioning Time on trial
202-05 IV 217,000
2 doses of 2mg 
Busulfan (2.3 kg)
10 weeks
202-06 IV 271,000 x 10 weeks
202-07 IV 304,000 x 14 weeks
203-01 IV 105,000 x 10 weeks
203-02 IV 105,000
2 doses of 4 mg 
Busulfan (4.7 kg)
15 weeks
203-05 IV 216,000 x 15 weeks
202-09 IV 111,111 x 14 weeks
226-07 IO 9,180,000 x 7 weeks
227-05 IV 17,870,000 x 9 weeks
227-07 IO 5,900,000 x 9 weeks
Table 5.S6. Humanization attempts in single mutant Art -/- pigs by 






















No. of ET 
recipients
No. of term 
pregnancies
















-/Y 320 1 1 (100%) 6 3 3 2
 
Table 5.S7. Somatic cell nuclear transfer embryos for transfer into fertile recipients for in 
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Abstract 
 Ovarian cancer (OvCa) is the most lethal gynecologic malignancy, with two-thirds of 
patients having late-stage disease (II-IV) at diagnosis. Improved diagnosis and therapies are 
needed, yet preclinical animal models for ovarian cancer research have primarily been 
restricted to rodents, for data on which can fail to translate to the clinic. Thus, there is 




being more similar to humans in terms of anatomy and physiology, would be a viable 
preclinical animal model for OvCa. We injected human OSPC-ARK1 cells, a chemotherapy-
resistant primary ovarian serous papillary carcinoma cell line, into the neck muscle and ear 
tissue of four severe combined immune deficient (SCID) and two non-SCID pigs housed in 
novel biocontainment facilities to study the ability of human OvCa cells to form tumors in a 
xenotransplantation model. Tumors developed in ear tissue of three SCID pigs, while two 
SCID pigs developed tumors in neck tissue; no tumors were detected in non-SCID control 
pigs. All tumor masses were confirmed microscopically as ovarian carcinomas. The 
carcinomas in SCID pigs were morphologically similar to the original human ovarian 
carcinoma and had the same immunohistochemical phenotype based on expression of 
Claudin 3, Claudin 4, Cytokeratin 7, p16, and EMA. Confirmation that OSPC-ARK1 cells form 
carcinomas in SCID pigs substantiates further development of orthotopic models of OvCa in 
pigs. 
Introduction 
 Ovarian cancer (OvCa) is the most lethal among gynecologic malignancies, taking an 
estimated 14,000 lives in the United States in 2018 (1). OvCa often goes undetected until 
late stages due to non-specificity of its early symptoms, hence 2/3 of patients have late-state 
disease (stage III- IV) at diagnosis. The current standard of care is debulking surgery to 
remove tumor masses followed by first-line platinum and Taxol chemotherapy (2). Debulking 
is critical to successful chemotherapy, and so prior identification of tumor masses by 
diagnostic imaging often plays a key role in pre-surgical planning. X-ray computer 




spread in OvCa for presurgical planning, yet there are well acknowledged “blind-spots” 
where tumor spread simply cannot be seen as the contrast between normal tissue and 
tumors is insufficient to discriminate one tissue type from another. Thus, tumors can be 
missed, leading to incomplete tumor resection. Methods to enhance tumor detection are 
being developed for a variety of imaging modalities, including magnetic resonance imaging 
(MRI) and positron emission tomography (PET), making use of various targeting mechanisms 
to specifically target ovarian cancers. For example, small peptides and molecules including 
OTL38 (4), GE11 (5), and CPE (6–9), which bind to folate receptor, EGFR, and claudins, 
respectively, have been successfully tested in preclinical mouse trials. Clinical trials for use of 
OTL38 are already beginning to recruit patients with folate receptor positive ovarian cancer 
for the use of this fluorescent molecule during cytoreduction or debulking surgeries (10).  
 Current research to improve imaging technologies and methodologies uses either 
human volunteers or rodent models. Imaging research involving human OvCa patients is 
challenging for a variety of reasons. For imaging modalities which involve significant 
radiation, such as CT, extensive research cannot be performed due to radiation dose. 
Second, it is challenging to perform serial imaging research on OvCa patients due to ongoing 
treatment regimens and patient morbidity. Such serial scans could be useful in developing 
predictive imaging capability derived from a multiparametric data set (11). Development of 
imaging strategies on rodents poorly informs how one approaches the clinical scenario. This 
is due to the size of the animal and the tumors, as well as the equipment that are used in 
animal imaging experiments. Small tumors exhibit different perfusion (12) and water 




and exhibit vastly different pharmacology of administered drugs (14), while humans and pigs 
have similar liver content of cytochrome proteins (15,16). All of these characteristics, and 
many more, influence imaging results.  
It is not always practical to use human OvCa patients for developing or validating new 
imaging techniques, and rodents are inadequate for developing clinically relevant imaging 
protocols. Recently there is a new hybrid field of molecular imaging and surgery called 
optical surgical navigation (17). This field couples fluorescence imaging with surgery to 
enhance surgical removal of tumors by way of fluorescent marker uptake. The translational 
value of new fluorescent tracers, either targeted or untargeted, can only be meaningfully 
evaluated in the context of a research subject that has appropriate size and physiology to 
OvCa patients.  A pig model of OvCa could fill this crucial gap.  
Human cancer xenotransplantation studies have not been possible in pigs until the 
recent identification (18) or creation (19–22) of severe combined immunodeficient (SCID) 
pigs (23) . SCID pigs have previously been reported to accept grafts of human melanoma 
(A375SM) and pancreatic carcinoma (PANC-1) cancer cell lines (24), as well as human 
induced pluripotent stem cells (25). In addition to xenotransplantation methods of studying 
cancer, genetic models of porcine cancer have also been developed. Inducible and germline 
mutations of TP53R167H (26,27) and KRASG12D (28,29) have been introduced into pigs, which 
are useful in studying lymphomas, osteogenic tumors, renal tumors, and others. These 
neoplasms were detected with computed tomography (CT), magnetic resonance imaging 
(MRI), and ultrasound imaging systems (27), exemplifying the pig’s utility as an imaging 




 To initiate the development of a large animal model of ovarian cancer, we tested 
whether human ovarian cancer cells could survive and develop ectopic tumors in SCID pigs. 
OSPC-ARK1 cells, derived from an ovarian serous papillary carcinoma (OSPC), were injected 
into male and female SCID pigs and were monitored for tumor development for this first 
stage screen. We demonstrate that OSPC-ARK1 derived carcinomas developed in three of 
four SCID pigs tested. Additionally, we verified an immunophenotype comparable to human 
patient OSPC samples based on the expression of Claudin 3, Claudin 4, Cytokeratin 7, p16, 
and EMA in SCID pig carcinomas. In summary, we demonstrate that SCID pigs can 
successfully develop OSPC-ARK1 carcinomas, which warrants further development of an 
orthotopic SCID pig model of ovarian cancer. 
Results 
OSPC-ARK1 cells injected into SCID pigs develop carcinomas 
 To assess if human ovarian carcinomas could develop in SCID pigs, a total of four SCID 
(S1, S2, S3, and S4) and two non-SCID (NS1 and NS2) pigs were injected with OSPC-ARK1 
cells. Due to limited female SCID availability, we injected two female and two male SCID pigs 
in this initial study to answer our question of if OSPC-ARK1 cells were capable of developing 
tumors ectopically in immunocompromised pigs. Four sites were injected in each pig; one 
subcutaneous on each ear, and one intramuscular on each side of the neck. We decided to 
inject in these superficial sites such that we could easily and noninvasively monitor tumor 
growth over time. Evidence of growth in these sites would warrant injection into a more 




 Palpable tumors were observed on the ears of three SCID pigs prior to euthanasia. S1 
and S2 were euthanized at 13 and 30 days after neoplastic cell inoculation and no grossly 
visible tumors were observed on the neck sites of injection. S3 was euthanized 11 days after 
injection and tumors were observed on the left and right ears. S4 was euthanized 7 days 
after injection, at which point a tumor was detected on the right ear (Figure 6.1).  Wild-type 
animals, NS1 and NS2, did not have visible tumors at 30 days post injection. Table 6.1 shows 
an overview of locations of carcinoma development in the six pigs.  
 At euthanasia, samples from each injection site were collected and fixed, and H&E 
staining and analysis was used to determine if tumor architecture was present. Of the four 
SCID pigs injected, ovarian carcinomas were present in three animals in at least one injection 
site. S1 and S3 (Figure 6.1) developed carcinomas in the neck. S1, S3, and S4 all developed 
carcinomas within the ear tissue. S3 had carcinoma present in all four injection locations. In 
all cases neoplastic cells incited and were surrounded by an extensive scirrhous response. 
Most commonly, neoplastic cells formed small nests, solid cords or elongated cleft like 
glandular structures that were lined by anaplastic neoplastic cells. There was marked 
anisocytosis and anisokaryosis and the degree of cellular pleomorphism and the remarkable 
scirrhous response are characteristic findings of high grade serous ovarian carcinomas. In 
summary, we were able to demonstrate that OSPC-ARK1 cells were able to successfully form 






OSPC-ARK1 carcinomas in SCID pigs maintain expression of common ovarian carcinoma 
diagnostic markers 
 We next wanted to determine if ovarian carcinoma protein marker expression were 
retained in the pig xenotransplants. OSPC-ARK1 cells, the original human carcinoma 
(neoplasm from which the OSPC-ARK1 cell line was derived), and OSPC-ARK1 derived 
carcinomas in SCID pigs and SCID mice were subjected to immunohistochemical analysis 
(Figure 6.2). S1 (female) is shown in Figure 6.2. We assessed the expression of p16, epithelial 
membrane antigen (EMA), cytokeratin 7 (CK7), which have previously been used in 
diagnostic panels (31); we also assessed expression of Claudin 3 and 4 in all samples. 
Expression of CK7, p16, and EMA were all highly similar in tissue samples from all three 
species, as well as in the pellets generated from the OSPC-ARK1 cell line. Importantly, 
Claudin 3 and 4 expression in SCID pig carcinomas was also highly similar to the observed 
expression pattern in the original human carcinoma. In summary, OSPC-ARK1 carcinomas in 
SCID pigs have the same immunophenotype as the original ovarian carcinoma from a human 
patient. 
Discussion 
 We have described the successful development of human OSPC-ARK1 carcinomas in 
SCID pigs. Injected sites were verified histopathologically as true carcinomas. We additionally 
showed that tumors in SCID pigs phenotypically resembled human ovarian carcinomas 
through assessing the expression of OvCa protein markers CK7, p16, and EMA (31). 




Claudin 4, which we have previously used as an imaging and therapeutic target in mouse 
models (6–8).  
 The ability of human ovarian tumors to grow in SCID pigs warrants further 
development of an orthotopic model of this cancer. The capability to study a human tumor 
in a non-rodent species is critically important as it would allow researchers and medical 
practitioners to utilize imaging modalities that are used in clinical settings. Additionally, 
there are many cases where progression from early-stage to late-stage occurs rapidly and 
can often happen within the span of a few months. We have raised SCID pigs for up to 6 
months (unpublished results) in biocontainment facilities (30), which would allow long term 
trials that are required for studying spread and metastasis to be performed.  The SCID pigs 
used in this study have natural mutations in Artemis (18), which is a critical component of 
the VDJ recombination pathway required for TCR and BCR development, and thus have a T- 
B- NK+ cellular phenotype. NK cells are functional in our SCID model in in vitro assays (32), 
which could have anti-tumor activity on human cancer cells as evidenced by the absence of 
tumor development in S2. Thus, use of a T- B- NK- SCID pig may better facilitate human 
ovarian tumor growth.  
Pigs and humans share more similar reproductive tract sizes and structures than 
mice. In this initial trial, tumor growth from the OSPC-ARK1 cell line was not dependent on 
the sex of the animal. However, as we develop this model further, we would inject OSPC-
ARK1 cells into the peritoneum or ovarian bursa in female SCID pigs. Such orthotopic tumor 
sites would allow for new imaging research to be initiated in SCID pigs. Studies involving 




Moving forward, it will be an important step to test human specific imaging targets (CPE, 
folate, GE11) and systems (PET, MRI) in SCID pigs xenografted with human tumors.  
We have previously utilized the CPE peptide to either label tumors with a fluorescent 
marker (8) or deliver a suicide gene (9)  to the site of ovarian tumors mice. Inoculation of 
OSPC-ARK1 cells into SCID pigs would allow for methods, dosages, efficacy, and safety of the 
CPE peptide to be established. Additionally, injection of fluorescently labeled CPE would 
allow for surgical practices to be performed for use of this peptide in marking smaller tumors 
that are difficult to detect by commonly used imaging practices. The pigs would be of 
comparable size to humans, so dosages of the peptide would be relevant as well. In all, 
confirming that human ovarian carcinomas can successfully develop in SCID pigs provides a 
basis for further development of an orthotopic OvCa model in pigs. 
Materials and Methods 
Generation and care of piglets 
 Wildtype and Art-/- piglets were generated as described (18) and were housed in 
positive pressure biocontainment bubble facilities (30).  All animal protocols and procedures 
were approved by Iowa State University’s Institutional Animal Care and Use Committee 
(IACUC).  
Human tissue collection 
 Informed consent was obtained from human subjects and was approved by the Yale 
Institutional Review Board. The OSPC-ARK1 primary ovarian cell line used in this study was 
established from samples collected at the time of tumor recurrence from a patient harboring 




Cell preparation and injections 
 SCID pigs: OSPC-ARK1 cells were grown in complete RPMI media (10% FBS, 50μg/mL 
gentamycin, 10 mM HEPES) until 80-100% confluent. Cells were trypsinized and washed five 
times in sterile phosphate buffered saline (PBS). Cells were then counted with a 
hemocytometer and were brought to a concentration of 50 x 106 cells/mL. 
 Animals were anesthetized with isoflurane. A total of six pigs were used in two 
independent experiments. Injection sites were marked, and all animals were injected 
subcutaneously in the right and left ear and intramuscularly into the right and left side of the 
neck. In the first trial, four 43 day old pigs (S1, S2, NS1, and NS2) were injected with 5 million 
cells in a 100 μL PBS cell suspension. In the second trial, two 18 day old SCID pigs (S3 and S4) 
were injected with the same number and volume of cells in the same locations. The SCIDs in 
trial 1 were female, while the SCIDs in trial 2 were male.  Table 7.1 shows an overview of 
piglet ID, sex, trial, genotype, age at trial end, and locations of carcinoma formation.  
 SCID mice: C.B-17/SCID female mice 5–7 weeks old were purchased from Harlan 
Sprague-Dawley (Indianapolis, IN) and housed in a pathogen-free environment. They were 
given basal diet and water ad libitum. All animal protocols and procedures were approved by 
Yale University’s IACUC. OPSC-ARK1, a chemotherapy-resistant primary ovarian serous 
papillary carcinoma cell line, was used to develop a xenograft model. OPSC-ARK1 cancer cell 
line was injected IP at a dose of 7 million cells.  
Tissue collection and processing 
 Tissues were collected at the marked injection sites and fixed in 10% neutral buffered 




routine processing, tissues were embedded into paraffin and serial sections were cut at 5 µm 
thickness. Slides were either stained with hematoxylin and eosin or used for 
immunohistochemical labeling. In addition, OPSC-ARK1 cells were harvested and fixed in 
10% neutral buffered formalin for 24 hours and transferred to 60% alcohol. Following 
centrifugation, cell pellets were harvested and suspended in liquid histogel (Thermo Fisher 
Scientific, Ann Arbor, MI, USA). After the histogel had solidified, samples were transferred to 
60% alcohol followed by routine tissue processing and embedding into paraffin. Serial 
sections were cut at 5 µm thickness and processed in parallel to the tissue samples. 
Immunohistochemistry 
Serial sections of the pig tumors and the cell line were routinely labeled with 
immunohistochemistry for Claudin 3, Claudin 4 (both Thermo Fisher Scientific, Ann Arbor, 
MI, USA), Cytokeratin 7 (Agilent, Santa Clara, CA, USA), p16 (BD Biosciences, Franklin lakes, 
NJ, USA), and EMA (LifeSpan BioSciences, Seattle, WA, USA). In addition, OPSC-ARK1 
xenotransplant tumors from mice and sections of the original biopsy of this neoplasm that 
had been processed in a similar manner as the pig tissues were run as controls. 
Immunohistochemistry was performed on the Dako link 48 Automated Staining System 
(Agilent Technologies, Santa Clara, CA, USA) using the peroxidase conjugated EnVision 
Polymer Detection System (Agilent Technologies, Santa Clara, CA, USA) for all antibodies. 
Briefly, endogenous peroxidases were neutralized with 3% hydrogen peroxide for 5 minutes. 
Antigen retrieval was achieved by incubating slides in either low pH (Claudin 3, Claudin 4 and 
EMA) or a high pH (EMA) retrieval solution for 20 mins on the Dako PT link (Agilent 




proteinase K (Cytokeratin 7). Non-specific immunoglobulin binding was blocked by 
incubation of slides for 10 min with a protein-blocking agent (Agilent Technologies, Santa 
Clara, CA, USA). Using the Dako autostainer, slides were incubated for 30 minutes with a 
rabbit polyclonal anti-human Claudin 3 antibody (#34-1700), a mouse monoclonal anti-
human Claudin 4 antibody (clone 3E2C1), a mouse monoclonal anti-human Cytokeratin 7 
antibody (clone OV-TL 12/30), a rabbit polyclonal anti-human EMA antibody (#LS-C30532) 
and a mouse monoclonal anti-human p16 antibody (clone G175-405) at dilutions of 1:100, 
1:250, 1:75, 1:500 and 1:100, respectively. The immunoreactions were visualized with 3,3-
diaminobenzidine substrate (Dako, Carpinteria, CA). Sections were counterstained with 
Mayer’s haematoxylin.  
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Figure 6.1. OSPC-ARK1 cells develop into carcinomas after subcutaneous and intramuscular 
injection in SCID pigs 
 
SCID pigs were injected with OSPC-ARK1 cells subcutaneously in the ear and intramuscularly 
in the neck. Of the four SCID pigs, three developed carcinomas in the ear, and two 
developed carcinomas in the neck. S3 developed a palpable tumor on the ear 11 days after 
inoculation. H&E staining of carcinomas from the ear of S4 and neck of S3 are shown. 
Elongated cleft like glandular structures lined by anaplastic neoplastic cells and surrounded 
by a scirrhous response are a characteristic finding of high grade serous ovarian carcinomas 
and are easily recognizable in both the original human patient carcinoma and the carcinoma 














Figure 6.2. OSPC-ARK1 carcinomas in SCID pigs resemble the human ovarian serous 
papillary carcinoma morphologically and demonstrate the same immunophenotype.  
 
OSPC human patient ovarian carcinoma, OSPC-ARK1 carcinoma from S1, OSPC-ARK1 
carcinoma from a SCID mouse, and OSPC-ARK1 neoplastic cells were stained with H&E and 







Table 6.1. SCID and non-SCID pig descriptions and tumor growth locations
Pig ID Sex Days on trial Age at end of trial R Ear L Ear R Neck L Neck
S1 F 13 56 d + - + -
S2 F 30 73 d - - - -
S3 M 11 29 d + + + +
S4 M 7 25 d - + - -
NS1 M 30 73 d - - - -




















MUTATIONS IN ARTEMIS CAN LEAD TO LEAKY CD3ε+ CELL DEVELOPMENT IN SWINE WITH 
SEVERE COMBINED IMMUNODEFICIENCY 
 
Prepared for submission to PLOS ONE. 
 
Adeline N. Boettcher1, A. Giselle Cino-Ozuna2, Yash Solanki1, Ellis J. Powell1, Jeana L. Owens2, 
Sara A Crane1, Amanda Ahrens3, Crystal L. Loving4, Joan. E. Cunnick1, Raymond R.R. 
Rowland5, Sara E. Charley1, Jack C.M. Dekkers1, Christopher K. Tuggle1 
 
 
1Iowa State University, Department of Animal Science, Ames, IA, USA 
2Kansas State University, Veterinary Diagnostic Laboratory, Manhattan, KS, USA 
3Iowa State University, Laboratory Animal Research, Ames, IA, USA 
4US Department of Agriculture, Agricultural Research Service, National Animal Disease 
Center, Food Safety and Enteric Pathogen Unit, Ames, IA, USA 




ANB designed experiments, ran flow cytometry, and wrote manuscript. AGCO and JLO 
performed immunohistochemistry on tissues. EJP performed flow cytometry experiments. 
YS and SAC performed TCR PCR analysis on lymph node tissues. AA performed necropsies on 
animals and collected tissue and blood samples. CLL, JEC, RRRR, and JCMD were involved in 
experiment planning. SEC was involved with SCID pig care, genotyping, and tissue collection. 




 Severe combined immunodeficiency (SCID) is described as the lack of functional T 
and B cells. In some cases, mutant genes encoding proteins involved in the process of VDJ 
recombination retain partial activity and are classified as hypomorphs. Such hypomorphic 
activity can allow for the development of a leaky T and B cell phenotype in patients and 
animals afflicted with SCID. We previously described two natural single nucleotide variants in 
Artemis (DCLR1EC) in a line of Yorkshire pigs. One of these alleles contains a splice site 




exon 10 that results in a premature stop codon (Art12). Art16/16, Art12/16, and Art12/12 
SCID pigs develop small populations of CD3ε+, but in most cases not CD79α+, cells in 
circulation and in lymph nodes. Neonatal pigs (0 days of age) have CD3ε+ cells within lymph 
nodes prior to any environmental antigen stimulation. CD3ε+ cells in SCID pigs appear to 
have a skewed CD4α+CD8α+ T helper memory phenotype in most animals. We additionally 
confirmed that, in some pigs, functional VDJ joints can be found in lymph nodes as probed 
by PCR amplification of TCRδ V5 and J1, as well as TCRβ V20 and J1.2, providing evidence of 
residual activity of Artemis activity.  This is the first description of a natural leaky T cell 
phenotype in SCID pigs. Documentation of this phenotype is important for SCID pig 
biomedical researchers, as well as potentially using this system as a model for human SCID 
patients.  
Introduction 
 We have identified and described two natural mutations within the Artemis gene in 
two separate alleles (termed Art16 and Art12) in a line of Yorkshire pigs, which leads to SCID 
in a homozygous or heterozygous state.1 The Art16 allele contains a splice site mutation 
within intron 8 of Artemis and all transcripts in homozygous Art16/16 fibroblasts are missing 
exon 8. The Art12 allele contains a nonsense mutation in exon 10 that leads to a premature 
stop codon and many of the transcripts in Art12/12 fibroblasts are missing large portions of 
all exons.1 Upon the discovery of the Art SCID pigs, bone marrow transplantation (BMT) was 
performed to further study these animals. Among the SCID pigs that underwent BMT, two 
Art16/16 pigs developed host derived CD3+ T cell lymphomas.2 This led us to hypothesize 




mutations have been reported in RAG3 and Artemis4,5 in human patients, and can lead to 
complications such as cancer5,6 and Omenn’s syndrome.7 We describe here the development 
of leaky CD3ε+ cells in pigs with Artemis deficient SCID phenotype. 
Results 
Circulating CD16- CD3ε+ cells in SCID pigs raised in conventional housing 
Our initial discovery of circulating CD3ε+ cells in SCID pigs occurred during a routine 
engraftment check on a SCID pig that had previously received a bone marrow 
transplantation. During this engraftment check, peripheral blood mononuclear cells (PBMCs) 
from a carrier, the putative BMT, and negative control SCID animals were assessed for CD3ε 
expression. Flow cytometry analysis revealed that the control SCID pig tested had a small 
population of CD3ε+ cells within the blood lymphocyte population (data not shown). Blood 
was tested again from a carrier (Pig 1; p1), Art12/16 (p2), and Art16/16 (p3) littermate pigs, 
all of which were 7 weeks of age and raised in conventional (non-biocontainment) rooms. NK 
cells in our Art model are present and functional in vitro9, and thus PBMCs from these 
animals were stained for CD3ε and CD16 to help identify if the cells observed were NKT cells. 
CD3ε+ cells in SCID pigs were observed again, confirming the earlier observation of “leaky” 
SCID. All SCID pig CD3ε+ populations were CD16-, suggesting that they were not of NK cell 
origin (Figure 7.1A). 
SCID pigs in biocontainment facilities develop CD3ε+, but not CD79α+ cells 
 We next sought to determine when these CD3ε+ cells develop and if raising the pigs 
in clean biocontainment facilities8 would reduce the prevalence of CD3ε+ cellular 




housing settings8. PBMCs were analyzed from four pigs born and raised in biocontainment 
facilities over a 3 to 4 month period. PBMCs were stained for CD3ε and CD79α to access for 
leaky T and B cells. Carrier animals were stained along with SCID samples, and consistently 
had 70-90% CD3ε+ cells and 5-15% CD79α+ cells (data not shown) within the lymphocyte 
population. PBMCs from SCID pigs were gated on mononuclear cells (lymphocytes and 
monocytes) due to difficulties in distinguishing the two populations by FSC and SSC. 
Art16/16 (p4 and p5) animals had low to no circulating CD3ε+ cells, while the Art12/12 (p6) 
and Art12/16 (p7) and pigs showed variable amounts of CD3ε+ cells (Figure 7.1B). 
Interestingly, upon necropsy at 4 months of age, p4 had thymic tissue (Figure 7.S1A) which 
stained profusely positively for CD3ε+ cells, despite having low levels of circulating CD3ε+ 
cells (Figure 7.S1B). None of the animals had circulating CD79α+ cells during the 3-4 month 
period (Figure 7.1C). 
 We next wanted to determine the cellular phenotypes of the CD3ε+ cells in the SCID 
pigs. To assess the cellular phenotypes, PBMCs were stained for SWC6, CD4α, CD8α, and 
CD8β. SWC6 is expressed on a subset of γδ T cells found within the blood10,11. PBMCs from 
p7 (Art12/16), p6 (Art12/12), and p8 (carrier) were analyzed for these T cell markers at 3 
months of age. Cells were gated on lymphocytes for both animals for analysis. Both animals 
appeared to have a very small population of CD3ε+ SWC6+ cells (Figure 7.1D). The CD3ε+ 
SWC6- population in both p6 and p7 were primarily CD8α+ CD8β+CD4α- and CD8α+ CD8β- 
CD4α+. T helper memory cells in swine have previously been described to have a CD8α+ 





CD3ε+ cells in the lymph nodes of neonatal SCID pigs 
 Since we found that CD3ε+ cells circulate in older animals, we next asked if these cells 
were present in neonatal SCID pigs. Lymph nodes were collected from 0 day old SCID pigs 
with Art16/16 (p9 and p10), Art12/16 (p11 and p12), Art12/12 (p13 and p14), and carrier 
(p15) genotypes and assessed for the presence of CD3ε+ and CD79α+ cells by 
immunohistochemistry (IHC). Two animals for each genotype were assessed; representative 
histology images are shown in Figure 7.2A.  All SCID genotypes had some level of CD3ε+ cells 
present. P13 and p14 (Art12/12) lymph nodes had fewer CD3ε+ cells, which were punctate 
within the lymph node. Lymph node architecture in all SCID animals was abnormal compared 
to wild type tissues. CD79α+ cells were only found in p10 (Art16/16). These results indicate 
that leaky CD3ε+ cells, and in rare cases CD79α+ cells, initiate development in utero. 
CD3ε+ cells in 5 and 6 month old SCID pigs  
 We additionally collected lymph nodes from Art16/16 SCID pigs that were 5 and 6 
months of age. P16 was originally raised in biocontainment facilities and was later moved to 
conventional housing at approximately 3 months of age. At 6 months of age, she developed 
severe skin lesions due to an allergic or hypersensitivity response. At the time of euthanasia, 
a blood sample was collected from this animal, and 33% of lymphocytes were found to be 
CD3ε+ (Figure 7.2B). Other T cell markers were not assessed at this time. Lymph nodes were 
also collected, and CD3ε+, but not CD79α+, cells were present (Figure 7.2C) 
 Another older animal, p17, was also raised to 5 and a half months of age in 
biocontainment facilities. He succumbed to an E. coli bacterial infection and was euthanized 




flow cytometry and histological analysis  (Figure 7.2D, E). Mononuclear cells (MNCs) from a 
popliteal lymph node were isolated and analyzed by flow cytometry. Of gated MNCs, 64% of 
cells were CD3ε+. A small portion of the CD3ε+ cells were also SWC6+.  CD3ε+ cells in p17 
lymph nodes consisted of CD8α+ CD4α- and CD8α+ CD4α+. Expression of CD8β was not 
assessed at this time.  IHC staining of the same lymph nodes showed presence of large 
number of CD3ε+ cells throughout the entire lymph node. CD79α+ cells were not present in 
lymph nodes.  
SCID pigs have the potential to produce cells with TCR rearrangements  
 CD3ε is a coreceptor for the T cell receptor (TCR), and thus we wanted to determine 
if VDJ recombination was occurring at TCR loci. PCR analysis was performed using primers 
that were specific for TCRδV5 and TCRδJ1 , as well as TCRβV20 and TCRβJ1.2 13 (Figure 7.2F). 
The TCRβJ1.2 gene is 87 base pairs away from the TCRβJ1.1 gene segment, so we were able 
to capture TCRβJ1.1 rearrangement with this primer, as well.   
 SCID pigs of all three genotypes (p6, p16-25) were assessed. At least one pig from 
each SCID genotype had recombination between the V and J segments for both TCR 
complexes, although not every animal showed evidence of recombination. PCR products 
(with asterisks) were sequenced to confirm amplificons contained V and J gene segments 
(Figure 7.S2, 7.S3). Two SCID pigs (p20 and p24) had amplicons that sequenced through the 
VDJ joint, indicating that the there was only a single clone for the V and J gene segments 
tested (Figure 7.S4). Wildtype TCRδV5- J1.1 amplicons only sequenced to the end of the V5 




these results show that VDJ recombination can occur in SCID pigs, although the repertoire is 
not expansive.  
Discussion 
 Here we report the description of a leaky T cell phenotype in SCID pigs with naturally 
occurring mutations in Artemis. We first observed that CD3ε+ cells were capable of 
developing in these SCID pigs when two Art16/16 bone marrow transplanted pigs developed 
host derived T cell lymphoma2. We followed these findings by next asking if CD3ε+ cells were 
found in circulation of pigs housed in conventional settings and biocontainment. We found 
that SCID pigs raised in either setting and across all three SCID genotypes (Art16/16, 
Art12/16, and Art12/12) had a leaky T cell phenotype. We next assessed if neonatal SCID 
pigs had CD3ε+ cells in lymph nodes to gain insight on when these cells could be developing. 
We found CD3ε+ cells in lymph nodes of all SCID genotypes, although Art12/12 SCID pigs had 
fewer cells in those that we analyzed. Lastly, we assessed for VDJ recombination by 
amplifying TCRβ and δ with V and J specific primers and found that all three SCID genotypes 
are capable of VDJ recombination. We suspect the TCR repertoire is limited in these SCIDs, 
as not all SCID pigs had recombination, and in some animals, there appears to be a clonal 
repertoire for the recombination events tested.  
 Hypomorphic mutations are reported in human patients within RAG114, Artemis15, 
and IL2RG16 genes. Such mutations can lead to Omenn’s syndrome7 or cancer 
development4,6. Omenn’s syndrome is characterized by the development and expansion of a 
population of self-reactive T cells. Symptoms of Omenn’s syndrome include diarrhea, 




recombination errors made during VDJ recombination.5 Identifying that SCID pigs with Art16 
and Art12 alleles are capable of producing CD3ε+ cells suggests that such complications 
could arise in SCID pigs. We have previously had SCID pigs with severe rashes, diarrhea, as 
well as masses of lymphoid tissue that may be explained as Omenn’s syndrome or cancer 
(unpublished observation). The characterization of CD3ε+ cell development in our SCID pigs 
suggest that these ailments could occur in our Art SCID model. Other SCID pig models exist 
with mutations in RAG1/2 and IL2RG in which similar diseases could occur. Researchers and 
veterinarians working with SCID pigs need to be aware of the potential of leaky T cell 
development.  Presence of these cells could affect the health and potential use of these 
animals in different biomedical models.  
Materials and Methods 
Ethics statement 
 All animal procedures and protocols were approved by Iowa State University’s 
Institutional Animal Care and Use Committee.   
Generation of piglets and rearing 
 SCID pigs were generated as previously described1 and were housed in either clean 
conventional rooms or in biocontainment facilities8. All pigs, genotypes, housing conditions, 
age, CD3ε result summaries, analysis methods and figure references are in Table 7.1.   
Flow cytometry of PBMCs and MNCs 
 PBMCs were isolated as previously described9. To collect MNCs, lymph node tissue 
was first placed in HBSS with 10μg/mL gentamicin. Tissues were minced in a digestion 




as d-HBSS). The tissue and d-HBSS mixture was left to incubate for one hour at 37˚C with 
vortexing every 15 minutes. The suspension was then strained over a 100 μm cell strainer. 
Cells were washed once more in d-HBSS. Isolated PBMCs and MNCs were counted by flow 
cytometry using a BD cell counting kit.  
 PBMCs were stained with anti-pig CD16 (G7; Bio-Rad) with a goat anti-mouse IgG1 
secondary antibody, anti-pig CD3ε (BB23-8E6-8C8), and anti- human CD79α (HM47) for 
preliminary analysis. An intracellular staining kit was used to stain the cells for CD79α (BD 
Biosciences). To analyze CD3ε+ cells in blood and tissues, PBMCs and MNCs were stained 
with anti-pig CD8β (PPT23), anti-pig CD8α (76-2-11), anti-pig SWC6 (MAC320), anti-pig CD4α 
(74-12-4), and anti-pig SWC6 (MAC320). SWC6 is an uncharacterized membrane marker 
found to identify a population of γδ TCR+ T cells that are CD2- CD8α-, known as null γδ T cells, 
which are the predominate γδ T cell subset found in the blood10,11. Cells were fixed in 2% PBS 
formaldehyde and data was acquired in a FACs Canto II. Data was analyzed using FlowJo.  
Immunohistochemistry of collected lymphoid tissues 
 Tissues were collected and placed into 3.7% formaldehyde in 1X phosphate buffered 
saline for 24 hours. Tissues were then moved to 70% ethanol until processing. 
Immunohistochemical (IHC) staining for T and B lymphocyte markers was performed in 
paraffin-embedded tissue thin sections at Kansas State Veterinary Diagnostic Laboratory 
(KSVDL). Briefly, deparaffinized slide-mounted thin sections were pre-treated for 5 minutes 
with a peroxide block, followed by incubation with primary antibody. Primary antibodies 
included mouse monoclonal anti-CD3ε (clone LN10, Leica Biosystems) and mouse 




min with PowerVision Poly-HRP anti-mouse IgG at room temperature, with DAB chromagen, 
and counterstained with hematoxylin. 
 PCR of lymph node DNA for TCRβ and TCRγ V and J rearrangements 
 PCR analysis was performed on lymph node tissue collected from SCID and carrier 
pigs. Zymo Research Genomic-DNA™ Tissue Miniprep Kit was used to extract the genomic 
DNA from the tissue. A 40µl PCR reaction volume was used. 160 nanograms of Genomic DNA 
was used as a template, and amplification was carried out using Promega GoTaq® Green 
Master Mix. TCRβ recombination was assessed by using primers designed for TCRβV20 (5’ 
GATGTCATGGACATCATTTGCCATC 3’)13 and TCRβJ1.2 (5’ GGGCCGAAGTTATAGTCATA 3’). 
TCRδ recombination was assessed by using primers designed for TCRδV5 (5’ 
TTCAGACACGTGACCTTCAG 3’)13 and TCRδJ1 (5’ GTTCCACAACCAGCTGAGTC 3’)13. Germline 
sequence of TCRβV20 was amplified as a positive control using the TCRβV20 primer listed 
above with a reverse primer (5’ GCTGAGATTCTGGGATTCAC 3’)13. All samples used the same 
thermal cycling parameters: 94°C for 10 minutes, followed by 39 cycles of 95°C for 30 s, 62°C 
for 30 s, 72°C for 1 min 30 s, followed by a final step of 72°C for 10 min. 
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Figure 7.1. SCID pigs have CD3ε+ cells in circulation, but not CD79α+ cells 
(A) PBMCs from a carrier and SCID pigs housed in conventional clean rooms were stained for 
CD16 and CD3ε. All CD3ε+ cells in SCID pigs were CD16-. (B) Four SCID pigs (p4- Art16/16, p5- 
Art16/16, p6-Art12/16, and p7- Art12/12) were monitored over a three to four month period 
for circulating CD3ε+ and CD79α+ cells. P6 and p7 had variable levels of CD3ε+ cells 
throughout this period. CD79α+ cells were not detected in any of the four SCID pigs. (C) 
CD3ε+ cells from p6 and p7 were assed for expression of SWC6, CD4α, CD8α, and CD8β. 
CD3ε+ cells within the SCID pigs were primarily CD8α+ CD8β+ CD4α- and CD4α+ CD8α+ CD8β- 




























Figure 7.2. CD3ε+ cells are present in SCID lymph nodes at various ages.  
(A) Lymph nodes were collected from 0 day old SCID pigs (p15- carrier, p10-Art16/16, p11; 
Art12/16, p14- Art12/12) and were stained for CD3ε and CD79α. All genotypes had CD3ε+ 
cells present; cells were punctate within SCID pigs with the Art12/12 genetic background. 
Only one SCID pig (p10) had CD79α+ cells present. (B) PBMCs (gated on lymphocytes) were 
stained for CD3ε expression from a 6 month old Art16/16 SCID (p16). (C) Lymph nodes were 
stained for CD3ε and CD79α expression from p16. (D) Mononuclear cells were isolated from 
a popliteal lymph node from p17 and stained for CD3ε, SWC6, CD4, and CD8α. A small 
population of CD3ε+ SWC6+ cells were present. A majority of the CD3+ SWC6- population 
were CD4α+ CD8α+. (E) Lymph nodes were stained for CD3 and CD79α expression from p17. 
(F) DNA from lymph node was amplified with primers specific for TCRδV5 – TCRδJ1, as well 
as TCRβ V20- TCRβ J1.2 from SCID pigs with all genotypes. P18 is a carrier. P19, p20, p21, and 
p17 are Art16/16. P22, p23, and p24 are Art12/16. P25 and p6 are Art12/12. Bands with 
asterisks were sequenced to confirm presence of V gene segment within the amplificon 















Pig # Genotype Housing Age Immunophenotype Analysis Figure ref.
1 ART12/+ C 7 W Control animal F 1A




 cells in PB F 1A




 cells in PB F 1A
4 ART16/16 B 4 M
Low levels of CD3ε
+
 cells in PB; thymic 
tissue with CD3ε+ cells present; LN with 
CD3ε+ cells present
F, IHC 1B-C; S1
5 ART16/16 B 4 M Low levels of CD3ε+ cells in PB F 1B-C, 1C
6 ART12/12 B 3 M CD3ε
+ cells present in PB F, PCR 1B-D, 2F
7 ART12/16 B 3 M CD3ε+ cells present in PB F 1B-D
8 ART12/+ B 4 M Control animal F 1D
9 ART16/16 N/A 0 D No CD3ε+ or CD79α+ cells in LN IHC N/A
10 ART16/16 N/A 0 D CD3ε+ and CD79α+ cells present in LN IHC 2A
11 ART12/16 N/A 0 D
CD3ε+ cells present, and no CD79α+ cells 
presnt in LN IHC 2A
12 ART12/16 N/A 0 D
Punctate CD3ε+ cells present, and no 
CD79α+ cells present in LN IHC N/A
13 ART12/12 N/A 0 D
Punctate CD3ε+ cells present, and no 
CD79α+ cells present in LN IHC N/A






Pig # Genotype Housing Age Immunophenotype Analysis Figure ref.
14 ART12/12 N/A 0 D
Punctate CD3ε+ cells present, and no 
CD79α+ cells present in LN IHC 2A
15 ART12/+ N/A 0 D Control animal IHC 2A
16 ART16/16 B/C 6 M
CD3ε
+
 cells present in PB; CD3ε
+
 cells 
present, and no CD79α
+
 cells present in 
LN
F, IHC 2B-C
17 ART16/16 C 5.5 M
CD3ε+ cells present, and no CD79α+ cells 
present in LN.  SWC6+ cells present in 
LN;  TCRβ recombination
F, IHC, PCR 2D-F
18 ART16/+ C 6 W Control animal PCR 2F
19 ART16/16 C 6 W No TCRδ or TCRβ rearrangement PCR 2F
20 ART16/16 C 6 W TCRδ rearrangement PCR 2F
21 ART16/16 C 6 W TCRδ rearrangement PCR 2F
22 ART12/16 C 6 W No TCRδ or TCRβ rearrangement PCR 2F
23 ART12/16 B 11 W TCRδ rearrangement PCR 2F
24 ART12/16 B 4 W TCRδ and TCRβ rearrangement PCR 2F
25 ART12/12 B 10 W No TCRδ or TCRβ rearrangement PCR 2F
C: Conventional housing, B: Biocontainment, PB: peripheral blood, LN: lymph node, F: Flow 
cytometry, IHC: immunohistochemistry, PCR: polymerase chain reaction, TCR δ: Recombination 
between V5 and J1, TCR β: Recombination between V20 and J1.2 
Table 7.1 Cont. Overview of SCID pigs, genotypes, and description of CD3ε and CD79α cells found in 







Figure 7.S1. Thymic and lymph node tissue from an Art16/16 SCID pig (p4) stained 
positively for CD3ε 
 
(A) P4 (Art16/16) had thymic tissue present at 4 months of age. (B) Thymic tissue and (C) 
lymph node tissue were stained for CD3ε. (B) Thymic tissue stained robustly positive for 
CD3ε. (C) CD3ε+ cells were present within the lymph node as well. Interestingly, this animal 











Reference_V5              ACCTGAAAGGAAAAGAAAATGATTCTTGTGGGCTTTGGCCTTTTGTTTTTCTGTAAGTAC  
213_04_Carrier_Pig18      ACCTGAAAGGAAAAGAAAATGATTCTTGTGGGCTTTGGCCTTTTGTTTTTCTGTAAGTAC 
213_07_1616_Pig20         ACCTGAAAGGAAAAGAAAATGATTCTTGTGGGCTTTGGCCTTTTGTTTTTCTGTAAGTAC  
213_10_1616_Pig21         CCTGGAAAAGAAAAGAAAATGATTCCTCTGCACTCTCCCCATGTCTGTTTCTCTACTTGC  
217_05_1216_Pig23         ACCTGAAATGAAAAGAAACTGATTCTTGTGTGCTTTAGCCTTTTGTTTTTCTGTAAGTAC  
222_04_1216_Pig24         ACCTGAAAGGAAAAGAAAATGATTCTTGTGGGCTTTGGCCTTTTGTTTTTCTGTAAGTAC  
223_07_1212_Pig6          CCCTGAATGGAAAAAAAAATGATTCTTGTGGGCTTNANCCTTTTGTTTTTCTGTAAGTAC  
Reference_J1              ------------------------------------------------------------ 
                                                                                       
Reference_V5              ATTTGTTCTCACGTCCCACTTGTTCTACCGCCCTGATTCCCTTTTTCTGACTTTCTTAAG  
213_04_Carrier_Pig18      ATTTGTTCTCACGTCCCACTTGTTCTACCGCCCTGATTCCCTTTTTCTGACTTTCTTAAG  
213_07_1616_Pig20         ATTTGTTCTCACGTCCCACTTGTTCTACCGCCCTGATTCCCTTTTTCTGACTTTCTTAAG  
213_10_1616_Pig21         ATTTGTTCACACGTCCCACTTGTTCTACCGCCCTGATTCCCTTTTTCTGACTTTCTTAAC  
217_05_1216_Pig23         ATTTGTTCTCACGTCCCACTTGTTCTACCGCCCTGATTCCCTTTTTCTGACTTTCTTAAG  
222_04_1216_Pig24         ATTTGTTCTCACGTCCCACTTGTTCTACCGCCCTGATTCCCTTTTTCTGACTTTCTTAAG  
223_07_1212_Pig6          ATTTGTTCTCACGTCCCACTTGTTCTACCGCCCTGATTCCCTTTTTCTGACTTTCTTAAG  
Reference_J1              ------------------------------------------------------------ 
                                                                                       
Reference_V5              GCTTGGTTTCTTTTTCATTCACTTGGCTTTGCAGTGATTTTCTGCCTTTATTTTTCATCT 
213_04_Carrier_Pig18      GCTTGGTTTCTTTTTCATTCACTTGGCTTTGCAGTGATTTTCTGCCTTTATTTTTCATCT  
213_07_1616_Pig20         GCTTGGTTTCTTTTTCATTCACTTGGCTTTGCAGTGATTTTCTGCCTTTATTTTTCATCT  
213_10_1616_Pig21         GCTTGGTTTCTTTTTCATTCACTTGGCTTTGCAGTGATTTTCTGCCTTTATTTTTCATCT  
217_05_1216_Pig23         GCTTGGTTTCTTTTTCATTCACTTGGCTTTGCAGTGATTTTCTGCCTTTATTTTTCATCT  
222_04_1216_Pig24         GCTTGGTTTCTTTTTCATTCACTTGGCTTTGCAGTGATTTTCTGCCTTTATTTTTCATCT  
223_07_1212_Pig6          GCTTGGTTTCTTTTTCATTCACTTGGCTTTGCAGTGATTTTCTGCCTTTATTTTTCATCT  
Reference_J1              ------------------------------------------------------------                                                                                      
 
Reference_V5              GTGTGTCCCTCCCCTGCCTCTGCCCATTGAGTTCCCTCAGGGTGGGCTTGTGCTGGACCC 
213_04_Carrier_Pig18      GTGTGTCCCTCCCCTGCCTCTGCCCATTGAGTTCCCTCAGGGTGGGCTTGTGCTGGACCC  
213_07_1616_Pig20         GTGTGTCCCTCCCCTGCCTCTGCCCATTGAGTTCCCTCAGGGTGGGCTTGTGCTGGACCC  
213_10_1616_Pig21         GTGTGTCCCTCCCCTGCCTCTGCCCATTGAGTTCCCTCAGGGTGGGCTTGTGCTGGACCC  
217_05_1216_Pig23         GTGTGTCCCTCCCCTGCCTCTGCCCATTGAGTTCCCTCAGGGTGGGCTTGTGCTGGACCC  
222_04_1216_Pig24         GTGTGTCCCTCCCCTGCCTCTGCCCATTGAGTTCCCTCAGGGTGGGCTTGTGCTGGACCC  
223_07_1212_Pig6          GTGTGTCCCTCCCCTGCCTCTGCCCATTGAGTTCCCTCAGGGTGGGCTTGTGCTGGACCC  
Reference_J1              ------------------------------------------------------------                                                                                       
 
Reference_V5              CGTGCCTGTGGAGTGCAGGACTTATACCTTCCTTATTTCCTGTTTCCTTATTTCTTCTCT  
213_04_Carrier_Pig18      CGTGCCTGTGGAGTGCAGGACTTATACCTTCCTTATTTCCTGTTTCCTTATTTCTTCTCT  
213_07_1616_Pig20         CGTGCCTGTGGAGTGCAGGACTTATGTCTTCCTTATTTCCTGTTTCCTTATTTCTTCTCT  
213_10_1616_Pig21         CGCGCCTGTGGAGTGCAGGACTTATACCTTCCTTATTTCCTGTTTCCTTATTTCTTCTCT  
217_05_1216_Pig23         CGTGCCTGTGGAGTGCAGGACTTATACCTTCCTTATTTCCTGTTTCCTTATTTCTTCTCT  
222_04_1216_Pig24         CGTGCCTGTGGAGTGCAGGACTTATACCTTCCTTATTTCCTGTTTCCTTATTTCTTCTCT  
223_07_1212_Pig6          CGTGCCTGTGGAGTGCAGGACTTATACCTTCCTTATTTCCTGTTTCCTTATTTCTTCTCT  
Reference_J1              ------------------------------------------------------------ 
                                                                                       
Reference_V5              TCACAGACAAGGGTGTGCTGTGTAACAAAGTGACCCAGACTTCCCTGGAAGAGGTGGTGG  
213_04_Carrier_Pig18      TCACAGACAAGGGTGTGCTGTGTAACAAAGTGACCCAGACTTCCCTGGAAGAGGTGGTGG  
213_07_1616_Pig20         TCACAGACAAGGGTGTGCTGTGTAACAAAGTGACCCAGACTTCCCTGGAAGAGGTGGTGG  
213_10_1616_Pig21         TCACAGACAAGGGTGTGCTGTGTAACAAAGTGACCCAGACTTCCCTGGAAGAGGTGGTGG  
217_05_1216_Pig23         TCACAGACAAGGGTGTGCTGTGTAACAAAGTGACCCAGACTTCCCTGGAAGAGGTGGTGG  
222_04_1216_Pig24         TCACAGACAAGGGTGTGCTGTGTAACAAAGTGACCCAGACTTCCCTGGAAGAGGTGGTGG  
223_07_1212_Pig6          TCACAGACAAGGGTGTGCTGTGTAACAAAGTGACCCAGACTTCCCTGGAAGAGGTGGAGG  
Reference_J1              ------------------------------------------------------------                                                                             
 
Reference_V5              TGAGTGGCAGTAAGGTGACACTGCCCTGCACTTTTGAAACCTCACACTCAGATCCAGACC  
213_04_Carrier_Pig18      TGAGTGGCAGTAAGGTGACACTGCCCTGCACTTTTGAAACCTCACACTCAGATCCAGACC  
213_07_1616_Pig20         TGAGTGGCAGTAAGGTGACACTGCCCTGCACTTTTGAAACCTCACACTCAAATCCAGACC  
213_10_1616_Pig21         TGAGTGGCAGTAAAGTGACACTGCCCTGCACTTTTGAAACCTCACACTCAAATCCAGACC  
217_05_1216_Pig23         TGAGTGGCAGTAAGGTGACACTGCCCTGCACTTTTGAAACCTCACACTCAGATCCAGACC  
222_04_1216_Pig24         TGAGTGGCAGTAAGGTGACACTGCCCTGCACTTTTGAAACCTCACACTCAGATCCAGACC  
223_07_1212_Pig6          TGAGTGGCAGTAAGGTGACACTGCCCTGCACTTTTGAAACCTCACACTCAGATCCAGACC  










Reference_V5              TCTACTGGTACCGAATACGTCCAGATCGTACCTTCCAGCTTGTCTTGTACAGGGATAATA  
213_04_Carrier_Pig18      TCTACTGGTACCGAATACGTCCAGATCGTACCTTCCAGCTTGTCTTGTACAGGGATAATA  
213_07_1616_Pig20         TCTACTGGTACCGAATACGTCCAGATCGTACCTTCCAGTTTGTCTTGTACAGGAATAATA  
213_10_1616_Pig21         TCTACTGGTACCGAATACGTCCTGATCGTACCTTCCAGATTGNCTTGTACACGGATCATA 
217_05_1216_Pig23         TCTACTGGTACCGAATACGTCCAGATCGTACCTTCCAGCTTGTCTTGTACAGGGATAATA  
222_04_1216_Pig24         TCTACTGGTACCGAATACGTCCAGATCGTACCTTCCAGCTTGTCTTGTACAGGGATAATA  
223_07_1212_Pig6          TCTACTGGCACCGAATACGTCCAGATCGCACCTTCCAGCTTGTCTTGTACAGGGATAATA  
Reference_J1              ------------------------------------------------------------                                                                                       
 
Reference_V5              CTAGGTCCTACGATGCT-GATTTTGCTCGGGGTAGATTTTC-TGTGCAGCACAGTCTGG  
213_04_Carrier_Pig18      CTAGGTCCTACGATGCT-GATTTTGCTCGGGGTAGATTTTC-TGTGCAGCACAGTCTGG  
213_07_1616_Pig20         CTAGGTCCTACGATGCT-GATTTTGCTCGGGGTAGATTTTC-TGTGCAGCACAGTCTGG  
213_10_1616_Pig21         CTAGGTCCTACGATGCTTGATTTTGCTCTGGTTATATTTTCCTGTGCTTCACAGTCTGG  
217_05_1216_Pig23         CTAGGTCCTACGATGCT-GATTTTGCTCGGGGTAGATTTTC-TGTGCAGCACAGTCTGG  
222_04_1216_Pig24         CTAGGTCCTACGATGCT-GATTTTGCTCGGGGTAGATTTTC-TGTGCAGCACAGTCTGG  
223_07_1212_Pig6          CTAGGTCCTACGATGCT-GATTTTGCTCGGGGTAGATTTTC-TGTGCAGCACAGTCTGG  
Reference_J1              -----------------------------------------------------------                                                                                       
 
Reference_V5              CCCACAAAACCTTTCACTTGGTGATCTCCTCAGTGACAACTAAAGACACTGCCACTTACT  
213_04_Carrier_Pig18      CCCACAAAACCTTTCACTTGGTGATCTCCTCAGTGACAACTAAAGACACTGCCACTTACT 
213_07_1616_Pig20         CCCACAAAACCTTTCACTTGGTGATCTCCTCAGTGACAACTAAAGACACTGCCACTTACT  
213_10_1616_Pig21         CCCACAAAACCTATCACTTGGTGAGCTCCTCATTGACAACTAAAGACACTGCCACTTTAC  
217_05_1216_Pig23         CCCACAAAACCTTTCACTTGGTGATCTCCTCAGTGACAACTAAAGACACTGCCACTTACT  
222_04_1216_Pig24         CCCACAAAACCTTTCACTTGGTGATCTCCTCAGTGACAACTAAAGACACTGCCACTTACT  
223_07_1212_Pig6          CCCACATAACCTTTCACTTGGTGATCTCCTCAGTGACAACTAAAGACACTGCCACTTACT  
Reference_J1              ------------------------------------------------------------                                                                                       
 
Reference_V5              ACTGTGCCTT-GGACTCC------------------------------------------  
213_04_Carrier_Pig18      ACTGTGCCTT-GGACTCC------------------------------------------  
213_07_1616_Pig20         ACTGTGCCTT-GGACTC------------CGGAGATAAACTCATCTTTGGA-AAAGGGAC  
213_10_1616_Pig21         TACTTTGCCCTTGNNNNGTCACCTACCTTCCGTAGTATACTACATCTATCAGAAAGGGTC  
217_05_1216_Pig23         ACTGTGCCTT-GGACTCCGGAGTCGATATACTCG-T------------------------  
222_04_1216_Pig24         ACTGTGCCTT-GACGAGATCTCGTACCTCCGGAGGTAAACTCATCTTTGGA-AAAGGGAC  
223_07_1212_Pig6          ACTGCGCCTT-GGAATCNGCATGTNNNGCTACGGNTCANCTAGTTGTNGGA-CANNTGCG  
Reference_J1              -------------------------ATGATACAGATAAACTCATCTTTGGA-AAAGGGAC                                                                                       
 
Reference_V5              ----------------- 
213_04_Carrier_Pig18      ----------------- 
213_07_1616_Pig20         TCAGCTGGTTGTGGAAC 
213_10_1616_Pig21         ACTCAAACTTCTTT--- 
217_05_1216_Pig23         ----------------- 
222_04_1216_Pig24         TCAGCTGGTTGTGGAAC 
223_07_1212_Pig6          TCAATAGCCTCTGCAAC  
Reference_J1              TCAGCTGGTTGTGGAAC 
 
 
Figure 7.S2. Sequence alignment of TCRδ V5 and J1 products from carrier and SCID pigs.  
 
DNA from lymph node tissue was amplified with primers specific for TCRδ V5 and J1 of TCR 
delta (shown in yellow). Sequences above were acquired by sequencing with the forward 
(first) primer. Reference sequences TCR_DeltaV5 and TCR_DeltaJ1 were derived from 
sequence accession number AB182371.1 from NCBI. Red indicate the V5 sequence, while 








                                                                                 
TCR_BetaV20 GATGTCATGGACATCATTTGCCATCATAGACGACGACCACTAGGGGGCGGAGTAGTGAG-CAGGATTAGTAGGCAGCCAA 
Pig17_1616 GTTGTTAAGGACAGCAATGGGCATCATAGAGGACGTCCACTAGGGGGGGGAGTAGTGAGGCAGGATTAGCAGGCAGGCAA 
Pig24_1216  ---GTTATGGACATCATTTGCCTTCATAGACGACNNCCCCTTGGGGGCGGAGTAGTGAG-CAGGATTAGTAGGCAGCCAA 
                            
TCR_BetaV20      CCGGCCTTCTATGGGTG-GAGAACAGAAGATTGGGGGGCAAGGTCGCACCTTCCTTCAGAGAGGTGTGGTGCCAGGCCAG 
Pig17_1616       CTCGTCTTCCAAGGGTGGAGAGCAAGTAGACTGGGGGGCAAGGTCGCACCGTCCTTCAGAGAGGTGCGGNGCCAGGGAAG 
Pig24_1216       CCAGCCTTCCATGGGTG-GAGAACAGAAGATTGGGGGGCAAGGTCGCACCTTCTTTCAGAGAGGTGTGGTGCGAGGCCAG 
 
TCR_BetaV20      CAGCTGAAGATGCTGGTGCTTCTGCTGCTTCTGGGACCCAGTAAGAGCCTTATTACCTGAGTAGCTTGGGCGAGTATGCG 
Pig17_1616       CAGCTGAAGATGCAGGTGCATGTGCGGCTTCTGCGACCCAGTGAGAGCGTTATGGCCTGAGTAGGTTGGGCGAGTATGCG 
Pig24_1216       CAGATGAAGATGCTGGTGCTTCTGCTGCTTCTGGGACTCAGTAAGAGCGTTATTACCTGAGTAGCTTGGGCGAGTATGCG                 
 
TCR_BetaV20      TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTGGCGTGAGTCGGGTGGGAGCCGGGGATTGTGGATTCTTTAGT 
Pig17_1616       TGTG------------------------TGTGAGTGTTGGCGTGAGTTGGGTGGGAGCCGGGGATTGTGGAATCTTTAGG 
Pig24_1216       GGTGTGTGTGT-------TGTGTGTGTGTGTGTGTGTTGGCGTGAGTTGGGTGGGAGCCGGGGATTGTGGATTCTTTAGG 
  
TCR_BetaV20      CTGATCAAAACAAGAGGGGACCTCCACGCTTTCTGGAGGTGGAAAGGGTAAAGCGAGAAGCCACCAGTCGTGGGGGGAGT 
Pig17_1616       GTGATTAAAACNNGAGGGGACGTCCACGATGTGTGGAGGTGGAAAGGGTAAAGCGAGAAGCCGTCAGTCGCGGGGGA-GT 
Pig24_1216       CTGATCAAAACAAGAGGGGACCTCCTCGCTCTCTGGAGGTGGAAAGGGTAAAGCGAGAAGCCACCTGTCGTGGGGGT-GT 
                     
TCR_BetaV20      GAGGGTTAT-GACCCTAAGAAGTAGGACAGAGAGACTTCGGAAAGCCAATGGGATTCCCTGGGAGCTGTGAGAAAGGGAA 
Pig17_1616       GAGGGCTAT-GACCCTAAGAAGTGGGACAGAGAGACTTCGGAAAGCCAGTGGGATTCCCTGGGAGATGTGAGAAAGGGAA 
Pig24_1216       GAGGGTTATGGACCCTAAGAAGTAGGACAGTGAGACTTCAGAAAGCCAATGGGATTCCCTGGGAGCTGTGAGAAAGGGAA
  
TCR_BetaV20      GGGAGCCAGGCTGATTTTCTGCCCATGGTCAGGTCCGCCTGGTCCTGCCGGCTGCTCATCTCTTTGACCTCTGTCTCAGC 
Pig17_1616       GGGAGCCAGGCTGATCTTCTGCCCATGGTCAGGTCCGCATGGTCGTGCCGGATGCTCATCTCTTTGACCTCTGTCTCAGC 
Pig24_1216       GGGAGCCAGGCTGATTTTCTGTCCATGGTCGGGTCCGCCTGGTCCTGCCGGCTGCTCATCTCTTTGACCTCTGTCTCAGC 
  
TCR_BetaV20      AGGCTACGGGTTTGGCGCCCTCGTCTCTCAACATCCCGGCAGGGCCATCTGTAAGAGTGGTGCCTCTGTGACCATCCAGT 
Pig17_1616       AGGCTACGNNTATGGCGCCCTGGTGTNNCCACATCCCAGCAGGGCCATCTGTAAGAGCGGTGCCTCTGTGTCCATCCAGT 
Pig24_1216       AGGGTACGGGTTTGGCGCCCTCGTCTCTCAACATCCCGGCAGGGCCATCTGTAAGAGCGGTGCCTCTGTGACCATCCAGT 
  
TCR_BetaV20      GCCGTACAGTGGACCTTCAAGCCACAACTATGTTCTGGTATCATCAGTTCCCAGA-ACAG-GGCCCCCTGCTGATAGCAA 
Pig17_1616       GCCGTTCAGTGGACTTTCAAACCACATCAATGTTATGATATCATCAGGTGC-ACAGAACAGGTGCTCCTGCCAGCAGCAA 
Pig24_1216       GCCGTACAGTGGACCTTCAAGCCATAACTATGTTCTGGTATCATCAGTTCCCAGA-ACAG-GGCCCCCTGCTGATAGCAA 
  
TCR_BetaV20      CTTCTAACATGGGCTCT-AATGCCACCTACGAAAAAGGTTATAACAGCGCCAAGTTTCTCATC--AGCCACCCAAACCA- 
Pig17_1616       CTTCTCACGTGGGAAATCAAG-GCCACCGAGGAGTATGGTTTCAAGGAGGCCGCAGTNTGATGTCATGGACATCATGCGC 
Pig24_1216       CTTCTGACGTGGGCTCT-AATGCCACCTACGAAAAAGGTTATAACAGCGCCAAGTTTCTCATC--AGCCACCCAGACCA- 
  
TCR_BetaV20      -AAGGTTTTCATCTCTGGTGGTGAGAAGCGTGCATCCTGCCGACAGCAGCCTCTACTTTTGTGGTGCTAGTGA 
Pig17_1616       CATCTCTCTGTTCANNTGTGGGCCGAAGTTATAGTCATACAGAG-------TGTAAATTGGAGGTCCAAGGAC  
Pig24_1216       -AACGTTTTCATCTCTGGTGGTGAGAAGCGTGCATCCTGCCGACAGCAGCCTCTACCTTTGTTGAGATGGAGG  





Figure 7.S3. Sequence alignment of TCRβ V20 and J1.2 products from carrier and SCID 
pigs. 
 
DNA from lymph node tissue was amplified with primers specific for TCRβ V20 and J1.2. The 
SCID animals were sequenced with the reverse primer and then aligned with TCRβV20 
(derived from accession number AB476299.1 from NCBI). Red indicate the TCRβV20 








Figure 7.S4. Chromatograms of V-D-J joins in TCRβ (V20 and J1.2) and TCRδ (V5 and J1) 
show evidence of single TCR clones 
 
Chromatograms are shown for TCRδ (top) and TCRβ (bottom) amplicons from lymph nodes 
of SCID pigs p20 (Art16/16) and p24 (Art12/16). Clean sequences were obtained through 
the VDJ joint for TCRδ, indicating that the repertoire for the TCRδV5 and TCRδJ1 is clonal in 
these two SCID pigs (top). Slightly more variability was observed in TCRβV20- TCRβJ1.1 









DISSERTATION SUMMARY  
 Within this work I have described the initiation of three potential biomedical models 
within the SCID pig: (1) an immunologically humanized SCID pig model, (2) an ovarian cancer 
model, and (3) leaky T cell development in SCID pigs.  
  In Chapters 3-5 I describe the beginning stages of developing a humanized SCID pig. I 
described in Chapter 3 that porcine SIRPA recognizes and binds to human CD47 to prevent 
subsequent phagocytosis of human cells. This was an important question to investigate 
because it allowed us to answer that SIRPA-CD47 dependent phagocytosis of human cells by 
porcine monocytes in an in vivo environment should not occur. Such phagocytosis would 
inhibit the ability for human hematopoietic stem cells (HSCs) to engraft. Next, in Chapter 4, I 
describe laparotomy surgery protocols that were developed to allow for the injection 
human HSCs into the fetal liver and intraperitoneal space. In Chapter 5 we were able to 
bring together elements of Chapter 3 and 4 to utilize laparotomy procedures to inject 
human HSCs into Art-/- IL2RG-/Y SCID pig fetuses. The phenotype of the Art-/- IL2RG-/Y pigs 
were T- B- NK-. In mouse models, SCID mice lacking NK cells have higher levels of human 
immune cell engraftment. Thus, the generation of the Art-/- IL2RG-/Y SCID pig provided an 
improved alternative to our original T- B- NK+ Art-/- model. In our first attempt at 
humanization, we observed that human T cells developed and engrafted within lymphoid 
organs after in utero injections. Analysis for other human cell types (B cells and 
hematopoietic stem cells) within lymphoid tissues is ongoing. 
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 In Chapter 6 I describe the early stages of a model of ovarian cancer in SCID pigs. I 
describe that SCID pigs can successfully develop ovarian carcinomas when injected with 
ovarian cancer cell line OSPC-ARK1. In our initial trials, we injected cancer cells in an ectopic 
site (ear and neck). Since we were able to show that carcinomas developed, the next step 
will be to inject the cells into the ovaries of SCID pigs. In conjunction with this orthotopic 
model, targeted imaging techniques could also be tested. 
 Lastly, in Chapter 7, I describe leaky T cell development in SCID pigs. Human patients 
afflicted with certain mutations within Artemis or RAG1/2 genes can sometimes develop 
leaky T cells that can cause issues such as Omenn’s syndrome or lymphoma development. I 
describe the basic characterization of the T cells in the SCID pigs. Further investigation into 
the leaky nature of the T cells in the SCID pigs may warrant their use to better understand 
hypomorphic mutations and their negative impacts on human health.  
 Together, the chapters in this dissertation provide a basis for the continual 
development of cancer and immunological biomedical models within the SCID pig. 
GENERAL DISCUSSION 
Improvement of BMT in SCID pigs 
 The SCID pig holds potential to be utilized as a bone marrow transplantation (BMT) 
model that could bear relevant information for human patients afflicted with SCID. 
Specifically, we have utilized BMT to rescue SCID pigs in the past. In some of these BMT 
cases (in Art-/- and Art-/-IL2RG-/Y SCID pigs), B cell reconstitution did not occur, or was very 
slow.  One example of this was shown in Chapter 5 with the Art-/- IL2RG-/Y SCID pig that had 
low levels of B cells six months after a 100% SLA matched BMT. One interesting report in an 
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Artemis null human SCID patient described that after an BMT from an HLA identical sibling, 
T cells developed, but not B cells1. This patient underwent a second BMT from the same 
donor approximately 2.5 years after the first transplant. During this second transplant 
procedure, the patient was conditioned with busulfan. Within 1 month post-BMT, the 
patient had detectable circulating B cells 1. The SCID pig could prove to be a useful large 
animal model for investigating how to improve cellular reconstitution after BMT.  
  One leading hypothesis as to why B cells fail to develop after BMT in some SCID 
patients is that that available B cell niche is occupied by host non-developing pre-B cells 2. 
Conditioning with busulfan and cyclophosphamide prior to BMT has been associated with 
increased engraftment after BMT3. An interesting experiment that could be performed 
within SCID pigs is how different drug conditioning regimens impact the premature B cell 
populations in the bone marrow. This would allow researchers and other medical 
professionals to determine exactly how these different drugs could impact the B cell niche 
within the bone marrow. These investigations could lead to insight on optimal conditioning 
regimens for individuals undergoing BMT, whether for human or pigs with SCID.  
 Additionally, tools required for CD34+ stem cell isolation from pigs could be 
improved so they can be utilized in BMT procedures. Currently, there are no published 
methods to isolate CD34+ cells from bone marrow or cord blood in pigs. In our current BMT 
protocols, we use a whole-unfractionated bone marrow suspension for infusion into BMT 
recipients. As such, this protocol requires that our BMT donors are a 100% SLA (swine 
leukocyte antigen) match to the recipients because we do not deplete donor T cells. Finding 
100% SLA matched pigs can be difficult at times due to limited pig availability. Development 
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of protocols to specifically isolate CD34+ cells would facilitate finding donors for the SCID 
pigs because a 100% SLA match would not be required for BMT.  
 One method for pig CD34+ cell isolation is through sorting bone marrow or cord 
blood by labeling with anti-pig CD34 antibodies. R&D Systems has a commercially available 
anti-pig CD3+ antibody (Cat # AF3890) that works in direct ELISAs and Western blots. This 
antibody could be tested with porcine cord blood or bone marrow for reactivity in a whole 
cell suspension for flow cytometry. Additionally, Layton et al (2007)4 generated an anti-
porcine CD34 antibody for flow cytometry analysis. They found that approximately 4% of 
porcine bone marrow cells express CD34 in the femurs of one week old pigs4. Both 
antibodies could be tested first with flow cytometry, and then with Protein G Magnetic 
Sepharose beads for the magnetic isolation of porcine CD34+ cells. 
 Culturing kits are commercially available for the expansion of human CD34+ cells.  
These kits include a cocktail of cytokines including human FLT-3L, stem cell factor (SCF), and 
thrombopoietin (TPO). In Chapter 2, I show that porcine and human FLT-3L, SCF, and TPO 
cytokines share relatively high amino acid homology (85%, 74%, and 90%, respectively), 
suggesting that porcine cytokine receptors may functionally recognize porcine cytokines, 
and vice versa. An experimental question that could be addressed is if porcine CD34+ cells 
(whether isolated or in a mixture with other cell types) can proliferate and expand in culture 
with these human cytokines. If these human cytokines are functional on porcine 
hematopoietic stem cells, banks of porcine stem cells could be expanded and frozen for 




Future improvements for in utero humanization of SCID pigs 
 One major accomplishment described in this dissertation work was showing that 
human T and B cells can differentiate and engraft in Art-/- IL2RG-/Y SCID pigs after in utero 
injection. These first “humanized” pigs had human T cells in circulation, spleen, ileum, and 
mesenteric lymph nodes. A few Pax5+ cells were found in mesenteric lymph nodes and 
spleen (preliminary data not shown in Chapter 5). These pigs did not show evidence of 
engraftment of human RBC, NK, or myeloid lineage cells. In future humanization attempts, 
we need to develop methods to increase the total number of cells that engraft, as well as 
begin to understand why certain cell subsets failed to develop.  There are a few major steps 
that can be done to understand human engraftment within SCID pigs, as well as protocol 
modifications to improve reconstitution: (1) determine cross reactivity of porcine cytokines 
on human cells, (2) understand normal immune cell differentiation and homing in a 
developing immunocompetent fetal pig, (3) inject human CD34+ cells at an earlier time point 
in gestation, (4) inject a higher dosage of human CD34+ cells within SCID pig fetuses (5) 
administer an in utero conditioning regimen, and (6) stimulate the immune system in IU 
injected neonatal SCID pigs. Table 8.1 provides an overview of our current protocols and 
how they can be modified in the future.  
 Firstly, in continuing the development of this model, it will be necessary to 
understand how porcine cytokines interact with developing human immune cells. 
Engraftment of human hematopoietic stem cells will initially depend on cytokine signaling 
from porcine cells. Cytokines important for growth, proliferation, maintenance of 
hematopoietic stem cells (CD34+) are FLT-3L, SCF, and TPO5–8. These three swine cytokines 
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are commercially available (Abcam, Kingfisher Biotech, Cloud-Clone) and could be tested in 
vitro for activity with both human and porcine stem cells (description on porcine CD34+ 
isolation is described above).  Similar approaches can be utilized for cytokines responsible 
for driving myelopoiesis (IL-3, GM-CSF, M-CSF), lymphopoiesis (IL-17), B cell development 
(IL-4, IL-7), NK cell development (IL-15), RBC development (EPO), and others. These in vitro 
tests will give insight as to when in vivo development of human immune cells may be halted 
due to incompatibilities between human receptors and porcine cytokines.   
 A second necessary step in understanding why certain lineages of human cells may 
not have developed (or developed at low frequencies) in our initial attempt, is to appreciate 
hematopoiesis within fetal swine. Figure 8.1 shows an overview of hematopoietic events in 
fetal swine, as well as an overview on past in utero injections.  At gestational day 20 (DG) 
fetal Ig VDJ recombination occurs within the yolk sac9,10. B cell development then transitions 
to the fetal liver at approximately 30 DG, and then to the bone marrow at 45 DG 9,10.  B cells 
are the first lymphocytes that are found in the periphery of fetal piglets11. T cell 
development coincides with these events, with the first lymphopoiesis occurring in the fetal 
liver between DG 20-60, peaking at DG 4011. Thymocytes are first detected in the fetal 
thymus at around 38 days of gestation11,12. Myelopoiesis in swine is not as well documented 
as T and B cell development. 
 In Chapter 5 we injected Art-/- IL2RG-/Y SCID pigs at 41 DG. We chose this day 
because it had been previously published that administration of human cells at this time 
point in pre-immune, normal animals, resulted in differentiation of small populations of 
human T, B, myeloid and NK cells 13–16. In our SCID trial, we showed that human T and B 
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cells developed and engrafted within the lymphoid organs such as the thymus (T cells), 
spleen and mesenteric lymph nodes (T and B cells). One explanation for the lack of robust B 
cell development was that we injected stem cells at a point in gestation where B cell 
development is transitioning from the fetal liver to the bone marrow9,10. As such, expression 
of cytokines required for B cell development may be downregulated in the fetal liver during 
this period. Injection of human CD34+ cells at an earlier timepoint, between 30-35 DG, may 
provide a richer fetal liver environment to enhance human B cell development. Analysis of 
cytokine expression levels within the swine fetal liver at different time points in gestation 
(ie. DG 30, 35, 40, 45) would be insightful for identifying when the fetal liver has the highest 
hematopoietic potential.   
 Taking the above into consideration, the third step to potentially improving 
engraftment is to inject human stem cells into the SCID fetuses at an earlier point in 
gestation. In the first description of IU injections into pig fetuses, Fujiki et al. (2003)13 
attempted injections at an earlier timepoint of 33 DG and were successful in observing 
engraftment. There are technical difficulties with injecting at an earlier gestational time 
point because the fetuses are smaller and potentially more difficult to aim for via 
ultrasound guidance. However, injecting into the fetus at an earlier time point may increase 
engraftment potential given that the human cell number (per fetus) could remain the same 
(4 million) or more. This would increase the dosage per fetus (per kg), as well as potentially 
allow more dispersion of cells within the injection site, and therefore within the developing 
piglet. Additionally, the fetal liver may provide a more robust environment for 
hematopoiesis, as described in the paragraph above.  
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 A fourth step in progressing this model is to administer a higher dose of human 
hematopoietic stem cells within the SCID pig fetuses. In our initial trial of IU injections, 
human CD34+ stem cells were cultured in the presence of thrombopoietin, stem cell factor, 
and FLT-3L to expand the cells for the proper dosage of 2-4 million cells per fetus. After 
initial magnetic isolation of CD34+ cells from cord blood, purity ranges from 70-95%. After 
seven days in culture, approximately 20-25% of the human cells maintained expression of 
CD34. Taking CD34+ cell proportion into account, a total cell dosage of 2-4 million cultured 
cells would only equate to 0.25-1 million CD34+ cells per fetus.  Culturing within these three 
cytokines promotes differentiation in vitro5–8 and may restrict the differentiation within the 
SCID pig. For example, engraftment of human lymphoid cells within the SCID pig would be 
restricted since these culturing methods promote the differentiation of myeloid lineage in 
vitro. In future trials, CD34+ expression should be closely monitored during the culturing 
period; this would ensure that the cellular dose administered to the fetuses contains 4 
million CD34+ cells. Since we were able to show that a dosage of 4 million cells was safe, we 
could attempt to double this dosage to 8 million cells in future trials. An additional CD34+ 
magnetic purification could also be performed immediately prior to in utero injections to 
ensure a pure stem cell suspension would be injected into the fetuses.  
 A fifth consideration that could be made for improving this model is IU plerixafor 
conditioning, as well as co-injection with human mesenchymal stem cells. There are not 
many publications describing these techniques in large animals, however Goodrich et al 
(2014)17 established these techniques in sheep, which we can adapt for our swine system. 
Plerixafor disrupts the interaction between CXCL4 on hematopoietic stem cells and SDF1 
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(CXCR12) on stromal cells. This disruption leads to the mobilization of hematopoietic stem 
cells out of the bone marrow (and presumably the fetal liver), which vacates the stem cell 
niche. Goodrich et al. (2014)17 administered a combination of isolated human CD34+ derived 
stem cells, bone marrow derived mesenchymal stem cells (MSC), and plerixafor. They 
performed two sets of injections (DG 59 and DG 66) via injection through the abdominal 
skin into the uterus. The condition that led to the highest levels of human engraftment (20% 
human cells in peripheral blood 11 weeks post transplantation) was the following: Injection 
of 1 x 106 human MSC and 50,000 human CD34+ cells on DG 59 and injection of 80,000 
CD34+ cells (same cord blood unit) at DG 66. These protocols could be adapted for use in 
SCID pig fetuses. Currently we utilize laparotomy procedures, so we would be limited in 
performing two surgeries within this time period. However, administration of human CD34+ 
cells and MSC with plerixafor could be injected at a single timepoint around 30-35 DG. 
These conditions could even be tested first in immunocompetent swine since this regimen 
has not yet been established in swine. 
 Lastly, a sixth consideration for increasing differentiation and mobilization of human 
cells within the SCID pig would be to stimulate the immune system through vaccination. 
Assuming that human CD34+ cells remain engrafted within the SCID pig bone marrow at 
birth, these two methods could be potential routes to promote human immune 
development. One preliminary study showed that vaccination with Ovalbumin with L121 
adjuvant led to an increase in the amount of Lin- Sca1- c-kit+ (LSK) progenitor cells in the 
bone marrow. Additionally, there was an increase in CD4+ and CD8+ single positive 
populations in the thymus of these animals18. Another study assessed the differences of 
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vaccination in mice with either acellular or whole cell vaccines of Bordetella pertussis 19. The 
researchers found that whole cell vaccinations led to a higher number of LSK population 
within the bone marrow.  Additionally, there was a higher proportion of hematopoietic 
multipotent progenitor cells within the bone marrow. They hypothesize that the whole cell 
vaccination induces a more robust interferon response19. IFNα is reported to activate 
hematopoietic stem cells through phosphorylation of STAT1 and PKB/AKT20.  
 Together, a vaccination regimen with a strong adjuvant could be administered to the 
pigs to enhance differentiation of human cells. A potential experimental question could be 
to ask which regimens are most effective in the development of a humanized SCID pig 
model. In addition, such vaccination studies could provide answers to basic science 
questions about how vaccination impacts certain cell populations throughout the body.  
Future outlooks for the development and distribution of new SCID pig biomedical models 
 The current SCID pig models that we have developed now could be utilized in cancer 
and stem cell therapy preclinical trials that involve adaptive immune system independent 
questions. The immunologically humanized SCID pig model requires optimization before it 
could be practically used in trials (improvements listed in above section). The SCID models 
that we have now (Art-/- and Art-/-IL2RG-/Y) have the potential to grow and engraft a 
multitude of human cell types, presumably within their respective orthotopic locations.  
 The SCID pig would prove to be an innovative in vivo drug testing model. Small 
molecule inhibitors that target altered metabolic pathways in cancer cells21 could be tested 
in tumor bearing SCID pigs. Methods could be developed to monitor tumor growth in the 
animals with different imaging techniques, while also testing the potential toxicity or side 
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effects of the drugs within human-sized pigs22. The benefit of utilizing SCID pigs over other 
rodent models is that tumors in these animals could be allowed to grow to sizes comparable 
to those found in humans. Thus, results obtained from such studies (dosage and potential 
toxicity) would be translatable to the human patient.  
 Additionally, the SCID pig holds promise as an imaging and tumor resection model. 
In Chapter 6 I describe that OSPC-ARK1 cells successfully develop tumors within the SCID 
pig. A goal with developing the orthotopic model of ovarian cancer would be to utilize the 
described CPE peptide23,24 to fluorescently label the primary tumor and metastasized 
secondary tumors. There are a multitude peptide targeting techniques that are being 
developed 25,26 that could be tested within swine models.  
 One major hurdle that may exist for certain biomedical questions in the SCID pig is 
equipment and tissue accessibility. More advanced studies in SCID pigs, potentially involving 
surgical or imaging equipment may be difficult as the SCID pig requires housing in 
biocontainment. As interest in the SCID pig model expands, it will be necessary to expand 
biocontainment facilities to other clinical research facilities so that this animal model can be 
used more practically. Availability of this animal model near clinical research institutions 
would facilitate studies that would require the injection or implantation of patient derived 
tissues, such as patient derived xenograft cancer co-clinical trials that are often performed 
in mice models27. In addition, collaborations with pharmaceutical companies may expand 






 The major theme of all the work described in this dissertation is the development of 
new toolboxes to further utilize the SCID pig in biomedical research. As swine are becoming 
a more popular animal model to use, it will be imperative that new tools are developed 
such that this model can be utilized to its maximum potential. By continual improvement 
and model development, the SCID pig could prove to be a new alternative animal model in 
the fields of cancer, transplantation, and regenerative medicine.  
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Figure 8.1. Hematopoiesis in the swine fetal liver and performed IU injections 
Major lymphopoiesis events in fetal swine during gestation, as well as previously performed 














Table 8.1. Modifications to improve human immune cell engraftment in SCID pigs
First humanization 
attempt Potential future attempts
Injection DG 41 30-35
Cell dosage 2-4 million 4-8 million
%CD34+ in dose 25% 80-100%
Genetic background ART  -/-  IL2RG  -/Y ART  -/-  IL2RG  -/Y , ART -/- , WT (for comparison)
Conditioning regimen none Plerixafor (5mg/kg) in fetus
Support cell co-injection none Bone marrow derived mesenchymal stem cells



















Standard operating procedures for SCID pig characterization work 
Isolation of peripheral blood mononuclear cells (PBMCs) from blood 
Supplies: 
• 15 mL conical tubes 
• 50 mL conical tubes 
• HEPES (1M) 
• Hanks Balanced Salt Solution (room temperature) 
• Ficoll-Paque PLUS (room temperature) 
• Sterile transfer pipettes 
• 10 mL transfer pipettes 
 
Protocol: 
1. Prepare HBSS-HEPES: Add 12.5 mL of 1M HEPES to 500 mL of HBSS for a total 
concentration of 25 mM HEPES. 
2. Collect blood into heparin or EDTA tube 
3. Move collected blood into a 50 mL conical tube (25 mL of blood per tube maximum) 
4. Dilute blood in equal volume of HBSS (HEPES) up to an increment of 10 mL. Set 
aside. 
5. In 15 mL conical tubes, add 3 mL of Ficoll-Paque PLUS.  
6. Layer 10 mL of HBSS (HEPES) and blood mixture on top of the 3 mL of Ficoll. Be sure 
to layer slowly as to not disrupt the Ficoll layer. Disruption of this layer will not allow 
for proper cell separation. 
7. Centrifuge at room temperature for 15-20 minutes at medium to high speed. 
8. Once finished, remove upper layer (contains serum and HBSS) and discard with a 
transfer pipette 
9. Remove buffy coat containing PBMCs with transfer pipette and move to clean 15 mL 
tube 
10. Wash with 6-8 mL of HBSS and centrifuge. 
11. Resuspend cells in desired volume.  










Isolation of cells from lymphoid organs 
Supplies: 
• 50 mL conical tubes 
• 15 mL conical tubes 
• HEPES (1M) 
• Gentamicin 
• Hanks Balanced Salt Solution (room temperature) 
• Collagenase IV (powder) 
• 70% Ethanol 
• Scissors and forceps 
• Petri dish 
• 37 ˚C water bath or incubator 
• Vortex 
• Ficoll-Paque PLUS (room temperature) [optional] 
• Sterile transfer pipettes 
• 5, 10, and 25 mL transfer pipettes 




1. Prepare concentrated Collagenase IV: Add 150 mg of collagenase to 10 mL of HBSS. 
Mix well. Filter sterilize through 0.45 μm filter. 
2. Prepare HBSS-HEPES-Collagenase IV: Add 10 mL of the filtered 15 mg/mL 
collagenase to 500 mL HBSS (final concentration 300 mg/L). Add 12.5 mL of 1M 
HEPES to 500 mL of HBSS for a total concentration of 25 mM HEPES. 
3. Prepare HBSS-Gentamicin: Add 500 μl of 10mg/mL of Gentamicin (final 
concentration 10 μg/mL) to 500 mL of HBSS 
4. In 50 mL conical tubes, pipette 20 mL of HBSS-Gentamicin. These will be used as 
collection tubes for pieces of tissue collected. 
5. Collect tissue during necropsy. Place in HBSS-Gentamicin tubes. Place tubes on ice 
until ready to use in the lab.  
6. Once ready to work with tissues, remove one half of a sterile petri dish and pipette 
5-10 mL of HBSS-HEPES-Collagenase IV buffer. 
7. Remove tissue from HBSS-Gentamicin and place into petri dish. 
8. Cut tissue into small pieces with scissors. Wash tools with ethanol between samples 
9. Once tissues are cut, use a transfer pipette (cut thin end off, so the opening is larger) 
to move tissue and HBSS buffer to a new 50 mL tube. 
10. Add HBSS-HEPES-Collagenase buffer up to 20 mL. 
11. Vortex for 10-20 seconds. 
12. Place into 37˚C for 15 minutes. Vortex 10-20 seconds.  
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13. Repeat for up to 60 minutes. 
14. Once incubation period is over, filter tissue/cell suspension through a cell filter into a 
new 50 mL conical tube. Add HBSS-HEPES up to 10 mL. Centrifuge 
15. Remove supernatant and wash once more 
16. Resuspend cells to desired volume. 
17. OPTIONAL: If only interested in lymphocytes and monocytes, cells can be spun over 
Ficoll for isolation (As described in PBMC isolation protocol) 





















Counting cells with flow cytometry 
Supplies: 
• BD counting kit (beads, propidium iodide, thiazole orange) 
• Flow tubes (round bottom, 5 mL)  
• Cellular suspension 




1. In a 5 mL flow tube, add the following: 
▪ 200 μl PBS  
▪ 25 μl beads (1,000 beads / μl) 
▪ 25 μl cellular suspension 
▪ 1 μl propidium iodide 
▪ 1 μl thiazole Orange 
2. Run on flow cytometer 
 
The flow facility will run 1,000 beads. For the number of cellular events counted for every 
1,000 beads, multiply by 1,000. For example, if 1,000 beads and 2,500 cell events are 













Flow cytometry of isolated cells and whole blood  
This is a general protocol that can be modified for project specific needs.  
3. For phenotyping cells, stain between 100,000-300,000 cells in total. 
4. To start, pipette 100 μl phosphate buffered saline with 0.1% Azide (PBS-Az) into a 
flow tube 
5. Add cells. Typically want to add a volume of cells between 50-100 μl (concentrate 
cell stock if necessary) 
6. Add first set of antibodies (titer antibodies beforehand). Let incubate at 4˚C in fridge 
for 15 minutes. 
7. Add 2 mL PBS-Az to wash 
8. Centrifuge for 5 minutes to pellet 
9. Remove supernatant 
10. Repeat antibody steps as necessary with given protocol. 
11. After staining is complete, fix cells with 2% formaldehyde in PBS. Need at least 300 
μl volume in flow tube for acquisition on flow cytometer 
















Anticoagulant for cord blood collection 
Supplies 
• Citric acid (powder)  
• Sodium citrate (powder)  
• Dextrose (powder)  
• DI water 
• 0.22 μm filter 
• 2 clean and sterilized 500 ml bottles 
Protocol 
1. Add 300 mL of nanopure water to one 500 mL bottle 
2. Add 3.65 g of citric acid [final concentration 38 mM] 
3. Add 12.25 g of dextrose [final concentration 136 mM] 
4. Add 11 g of sodium citrate [final concentration 85.25 mM] 
5. Mix 
6. Bring water up to 500 mL 
7. Filter sterilize with 0.22 μm filter into a new bottle 
8. Put 8 mL of anticoagulant into a 50 mL tube. This amount of anticoagulant will be 
enough for a full tube of blood (~40 mL) 
9. Keep cold until use 













Isolation of human CD34+ cells from cord blood, freezing, thawing, and culturing 
Supplies 
• Hanks balanced salt solution (HBSS) 
• 50 mL conical tubes 
• Ficoll-Paque PLUS 
• Miltenyi Biotech LS column 
• Miltenyi Biotech human CD34 microbeads 
• Miltenyi Biotech magnet 
• HBSS stem cell buffer (HBSS-SCB) (0.5% FBS and 2 mM EDTA) 
• Anti-human CD34 antibody 
• Mouse IgG1 isotype antibody (optional) 
• Freezing cryo media (90% FBS 10% DMSO) 
• 37˚ incubator/water bath 
• Complete RPMI (10% FBS, 2 mM glutamine, 50μg/mL gentamicin, 10 mM HEPES) 
• Miltenyi StemMACS HSC expansion media 
• Miltenyi StemMACS HSC expansion cocktail 
• Cell culture flasks 
 
Protocol 
Mononuclear cell isolation from cord blood: 
1. Receive blood from hospital 
2. Dilute blood in same volume of HBSS (for ease of layering on Ficoll later, add 20 mL 
blood + 20 mL HBSS in a 50 mL conical tube for blood dilution) 
3. Add 8 mL Ficoll to separate set of 50 mL conical tubes 
4. Layer 40 mL of blood+ HBSS mixture over 8 mL Ficoll 
5. Centrifuge at 1400 rpm for 15-20 minutes at room temperature (room temperature) 
6. Once spin is complete, remove supernatant into waste bleach container 
7. Place buffy coat layer into a new 50 mL conical tube with a transfer pipette (can 
consolidate cells from multiple buffy coats in the same new tube) 
8. Wash buffy coat cells with HBSS 
9. Centrifuge 5-7 minutes 
10. Remove supernatant 
11. Wash cells again in HBSS-SCB 
12. Remove supernatant 
13. Resuspend cells in ~300 ul of HBSS-SCB (Add larger volume if there is a large cell 
pellet) 
Preparation of MNC suspension for column separation 
1. Add 100 ul* of FcR blocking reagent to MNC suspension 
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2. Add 100 ul* of CD34 microbeads to MNC suspension 
**If original cord blood volume was MORE than 75 mL, add 100 ul of 
each. If original cord blood volume was LESS than 75 mL, add 50 ul of 
each.  
3. Mix well. Place a tube roller/shaker in a fridge and place tubes on it. Let incubate in 
fridge for 30-60 minutes 
4. After incubation, wash cells by adding 10 ml of HBCC-SCB 
5. Centrifuge 5-7 minutes 
6. Remove supernatant 
7. Resuspend cells in 1 mL of HBSS-SCF 
CD34+ cell isolation through column 
1. Place LS column within the magnet 
2. Rinse column with 3 mL of HBSS 
3. Add cell suspension to column- collect flow through (this is the NEGATIVE fraction, 
while the column is in the magnet) 
4. Wash column with HSSS (3 x 3 mL) and collect flow through (NEGATIVE) 
5. Remove column from magnet and place over a NEW 15 mL conical tube 
6. Flush column with 5 mL of HBSS by SLOWLY pushing plunger into the column 
(POSITIVE fraction) 
7. Centrifuge cells and resuspend in 500 ul 
Analysis 
• Use anti human CD34 antibody on 10-15 ul of the 500 ul suspension to assess purity 
of isolated cells 
Freezing 
• To a freezing vial, add 500 ul cells and 500 ul of freezing media (90% FBS 10% DMSO) 
• Place tubes in -20C in Styrofoam and foil overnight 
• Move Styrofoam to -80C freezer overnight 
• Place tubes into boxes in -80C for long term storage 
 
Thawing 
• Before removing tube from freezer, put 1 mL of complete RPMI media into a 15 mL 
conical tube 
• Remove tube of frozen cells from -80 and place tube into 37˚C water (make sure 
tube is sealed) 
• Monitor until thawed 
• Use 1 mL pipette to transfer cell suspension to the 1 mL of RPMI in the 15 mL conical 
tube 
• Add 1 mL at a time with mixing in between each addition up to 5 mL 
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• Add 5 mL more of RPMI, mix 
• Add 5 mL more of RPMI, mix 
• Centrifuge for ~5 minutes to pellet cells 
• Remove supernatant, wash with 10 mL RPMI once more 
• Centrifuge to pellet 
• Remove supernatant and resuspend at desired volume 
• Count cells and check viability  
Culturing 
• Prepare Miltenyi media according to manufacturer’s directions 
• Briefly, resuspend expansion cocktail (consisting of Stem Cell Factor, 
Thrombopoietin, FLT-3L) in 100 μl of sterile phosphate buffered saline. This is a 100X 
solution. Store in aliquots of 10μl 
• For every 10 mL of StemMACS HSC media, add 10μl of StemMACS HSC cocktail 
• Aliquot 5 mL of StemMACS HSC media/cocktail into cell culture flasks 
• Aliquot thawed stem cells at a concentration of 30-40,000 cells/mL in the media 
• Monitor CD34+ expression during culturing period; culture for up to 7 days 
• After 7 days, collected non-adherent cells for injection into fetuses 















List of antibodies used for flow cytometric analysis of human and pig cell subsets 
Marker Clone Company Reference # Notes
Anti-human CD3ε UCHT1 Biolegend 300401 human specific
Anti-pig CD3ε BB23-8E6-8C8 BD Biosciences 561477
Anti-human CD4α RPA-T4 BioLegend 300511 human specific
Anti-pig CD4α 74-12-4 BD Biosciences 561474
Anti-human CD8α HIT8a BioLegend 300907 human specific
Anti-pig CD8β PPT23 BioRad MCA5954F
Anti-pig CD8α 76-2-11 BD Biosciences 559584
Anti-human CD11b ICRF44 BioLegend 301322 human specific
Anti-human CD15 H198 eBioscience 11-0159-41 human specific
Anti-pig CD16 G7 Biorad MCA127GA
Anti-human CD20 2H7 BD Biosciences 560960 human specific
Anti-pig CD21 BB6-11C9.6 Southern Biotech 4530-31
Anti-human CD27 LG.7F9 Invitrogen 11-0271-81 human specific
Anti-human CD27 323 Invitrogen 11-0279-41 human specific
Anti-human CD28 CD28.2 Invitrogen 11-0699-41 human specific
Anti-human CD33 WM53 BioLegend 303403 human specific
APC anti-human CD34 AC136 Miltenyi 130-098139
Anti-human CD34 4H11 Invitrogen 11-0349-41 human specific
Anti-human CD45-biotin H130 ebioscience 13-0459 human specific
Anti-human CD47 B6H12 eBioscience 14-0479-82 human specific
Anti-human CD47 2D3 eBioscience 14-0478-82 human specific
Anti-human CD79α HM47 Invitrogen 12-0792-42 labels human and pig cells
Anti-pig CD172 74-22-15A BD Biosciences 553640
Anti-human CD235 4720-4957 BioRad 4720-4957 human specific
Anti-pig SWC6 MAC320 BD Biosciences 561482
Pe-Cy5 streptavidin x Biolegend 405205
BV421 anti-mouse IgG1 RMG1-1 Biolegend 406615
PE anti-mouse IgG1 Southern Biotech 1072-09
BV421 anti-rat IgG1/IgG2a G28-5 BD Biosciences 743849  
 
 
 
